

Medizinische Fakultät der Charité – Universitätsmedizin Berlin  
Campus Benjamin Franklin  
aus der AG Eikosanoid & Lipidforschung  
des Frauen, Kinder und Perinatalzentrum  
Direktor: Prof. Dr. Achim Schneider

Host-pathogen interaction in vulvovaginal candidiasis:  
Regulation of COX-2 and iPLA<sub>2</sub> genes in host cell survival and  
apoptosis in *Candida albicans*-infected HeLa cells.

Inaugural-Dissertation  
zur Erlangung des Grades  
***Doctor rerum medicarum***  
der Charite-Universitätsmedizin Berlin  
Campus Benjamin Franklin

Vorgelegt: Ganchimeg Ishdorj  
Aus: Ulaanbaatar, Mongolia

Referent: Prof. Dr. A. Schneider

Korreferent: Priv.-Doz. Dr. Chr. Harteneck

Gedruckt mit Genehmigung der Charite-Universitätsmedizin Berlin  
Campus Benjamin Franklin

Promoviert am: 06.12.2005.

## ACKNOWLEDGEMENTS

I am deeply indebted to Dr.med. Dr.rer.nat. Dr. (h.c.) Santosh Nigam, EO Professor (RSA), Eicosanoid- & Lipid Research Division and Centre for Experimental Gynecology & Breast Research, University Medical Center Berlin, Charite-Campus Benjamin Franklin, for giving me the opportunity to accomplish this dissertation work in his laboratory and for his supervision and guidance throughout the study. I also wish to express my appreciation for his generosity and hospitality during the stay in Berlin with my family.

I wish to thank all fellow PhD students in Dr. Nigam's laboratory, past and present, for their help and friendship during my stay in Berlin. I am grateful to Dr. Rupal Deva and Dr. Roberto Ciccoli for their useful discussion and their help in solving all instrumental and analytical problems.

My special thanks also go to other collaborators and colleagues in the neighboring labs. I especially acknowledge Dr. Jürgen Eberle, Dermatology Department UKBF, for allowing me to use instruments in his laboratory and Prof. Reinhold Kreutz, Department of Clinical Pharmacology UKBF, for helpful discussion and providing every support to conduct the real-time PCR analysis. I also express my sincere thanks to Dr. Nina Agabian (UCSF, CA, USA) for supplying *C. albicans* knock-out strains.

My sincere gratitude goes also to Prof. Bertram Wiedenmann and other members of the Graduate College 276 "Signalerkennung und umsetzung" for helpful discussion and for all support and organizing interesting seminars. I also wish to thank all those colleagues and friends who were involved and collaborated in so many ways to conduct these studies.

I also wish to express my deep appreciation to Mrs. Renate Nigam for her kindness, generosity and hospitality.

Finally, my deepest gratitude goes to my husband Zorigoo and my little daughter Uranbileg. Without their inspiration and constant encouragement and prayers the completion of this dissertation would never ever have been possible. My cordial thanks also go to my parents to whom I owe everything in my life. This work is dedicated to them.

I am grateful to the "Deutsche Forschungsgemeinschaft, Bonn" (Ni242-33/1) Schwerpunkt "Pilzinfektion" and Mongolian Academy of Sciences for their financial support. I also acknowledge the immense financial supports from UKBF-Forschungsförderung, VW-Stiftung, Hannover, Schering AG, Berlin and from Funds of the Chemical Industry, Germany.

**SUMMARY**

*Candida albicans* is generally found as a commensal colonizer of the mucocutaneous surfaces of the oral cavity, gastrointestinal tract and lower female reproductive tracts of humans. Normally, not pathogenic and causing no damage to host in its commensal state, *Candida* can become pathogenic usually in association with host immunosuppression, such as organ transplantation and chemotherapy and is responsible for recurrent vulvovaginal candidiasis. Upon infection with *C. albicans*, several signal transduction pathways are triggered in host cells. In HeLa cells, maximum expression of COX-2 mRNA was observed after 6 hours of infection with *C. albicans*. In addition, initial increase in PGE<sub>2</sub> production, which decreased as infection progressed, was observed. Since infection describes an oxidative stress phenomenon NAC, a potent free radical scavenger, was found to prevent COX-2 upregulation and PGE<sub>2</sub> biosynthesis, suggesting an involvement of ROS and NF-κB. Infection with *C. albicans* triggered NF-κB-dependent transcription. Regulation of NF-κB transactivation function is controlled at several levels, including interaction with coactivator proteins. In the present study, we showed that the transactivation function of NF-κB is also regulated through interaction of p65 subunit of NF-κB with HDAC-1 corepressor protein. Our data indicated that HDAC-1 recruits directly p65 subunit of NF-κB and likely exerts its corepressor function. Strikingly, we found that the expression of Gam-1, an early gene product of the avian adenovirus CELO, which is essential for viral replication, increased the level of COX-2 transcription through the NF-κB in a similar way, as with the HDAC inhibitor TSA. We also showed that Gam-1 can effectively inhibit histone deacetylation by HDAC-1, and that it binds to HDAC-1 both *in vitro* and *in vivo*. The effect of Gam-1, having the specific function of binding and inactivating HDAC-1, suggests that these deacetylase complexes play an important role in limiting the early gene expression as a result of invading microorganisms. In support of this, we showed that transient transfection of HDAC-1 is able to repress *C. albicans*-induced NF-κB-mediated COX-2 gene activation. Moreover, TSA treatment drastically increased the hyperacetylation of the *C. albicans*-induced histone H3. We observed these changes in nuclear transcription, thereby demonstrating that the fungal infection can induce *in vivo* chromatin remodeling events to stimulate the inflammatory genes.

Furthermore, *C. albicans* infection induced activation of the defence mechanism of the host. Thus, the host cells activate PLA<sub>2</sub> enzymes which lead to the production of AA. AA is converted

by eicosanoid-converting enzymes to eicosanoids that mediate the inflammation. We have shown that *C. albicans* possesses a potent active calcium-independent PLA<sub>2</sub> enzyme, which in cooperation with cPLA<sub>2</sub>, is capable of releasing AA from membrane phospholipids of the host cell. This AA is subsequently converted by COX-2 to PGE<sub>2</sub>. Seemingly, PLA<sub>2</sub> activity of *C. albicans* and not of host cell PLA<sub>2</sub> causes the initial cleavage of AA from membrane lipids of host cell. This process then leads to activation of host cell PLA<sub>2</sub>. Confirmation of this pathway was obtained when inhibition of iPLA<sub>2</sub> enzyme by BEL or MAFP was performed. A complete inhibition of *C. albicans*-mediated NF-κB-regulated COX-2 activation, and PGE<sub>2</sub> production in HeLa cells was achieved. The inhibition of iPLA<sub>2</sub> also caused the marked decline of PKCα in HeLa cells infected by *C. albicans*. These findings imply that iPLA<sub>2</sub> not only plays a crucial role in the phospholipid remodeling, but also a key role in the signaling for AA release and PGE<sub>2</sub> production in *C. albicans*-infected HeLa cells.

ROS, including superoxide anion, hydroxyl radical, and hydrogen peroxide, have been known to trigger a variety of biological responses within cells. The cleavage of IκBα requires an oxidizing milieu and appears to be one of the mechanisms by which ROS activate NF-κB. ROS have been shown to potentiate the iPLA<sub>2</sub> activity. It was reported that, in uterine stromal cells, H<sub>2</sub>O<sub>2</sub> caused a significant release of AA and iPLA<sub>2</sub> activity, which is independent of intracellular Ca<sup>2+</sup> concentration. Both AA and PLA<sub>2</sub> activity could be inhibited almost completely by BEL. We also found similar results demonstrating a significant inhibition of iPLA<sub>2</sub> by the free radical scavenger PDTC or by antioxidant NAC in HeLa cells infected by *C. albicans*. In order to obtain support for the observation regarding ROS-iPLA<sub>2</sub>-NF-κB regulation, we investigated whether iPLA<sub>2</sub> and the NF-κB p65 subunit react not only functionally but also physically in *Candida*-infected HeLa cells. The coimmunoprecipitation experiments with monoclonal antibodies against iPLA<sub>2</sub> and NF-κB p65 subunit in untreated and *Candida*-infected HeLa cells showed that iPLA<sub>2</sub> may undergo a physical binding with the whole complex IκBα-p50/c-Rel-p65.

Next, we investigated the *C. albicans*-induced apoptosis of host cells. Several pathogens are known to interfere with host cell apoptotic control. Intracellular pathogens have evolved diverse strategies to induce or inhibit host cell apoptosis, aiding dissemination within the host or facilitating intracellular survival. Macrophages undergo apoptotic cell death after infection with *C. albicans* strains capable of hyphal formation. Activation of caspase-3 has been observed after endocytosis of *C. albicans* by neutrophils. In this study, we report that *C. albicans*-infected HeLa

cells undergo apoptosis under strict regulation of cellular iPLA<sub>2</sub> and TLR2. The caspase-3 activation, which mediates the cleavage of multiple substrates to cause characteristic alteration that occur during apoptosis, was maximally elevated almost 6 hours before the onset of apoptosis. Moreover, caspase-3-mediated apoptosis of HeLa cells followed the classical death receptor pathway in which TLR2 triggers the signaling by recruitment of FADD containing protein and caspase-8. Dissection of early and late responses to *Candida albicans* infection revealed that cellular iPLA<sub>2</sub>-mRNA expression first increased for 6 hours, but subsequently declined until 18 hours and finally disappeared. Concomitantly, the onset of apoptosis was detected at 12 hours, and continued until 30 hours and then decreased. To confirm the role of iPLA<sub>2</sub>, we transfected an iPLA<sub>2</sub> containing plasmid in HeLa cells and infected with *C. albicans*. No apoptosis was observed in cells overexpressing iPLA<sub>2</sub> until 24 hours. Conversely, when HeLa cells pretreated with iPLA<sub>2</sub> inhibitor BEL were challenged with *C. albicans*, an earlier onset of apoptosis after 8 hours was observed. Moreover, BEL caused upregulation of TLR2 mRNA and increased apoptosis in infected cells. We therefore conclude that iPLA<sub>2</sub> functions as a key regulator for tuning of TLR2-mediated apoptosis in *Candida*-infected HeLa cells.

## CONTENTS

	<b>Page</b>
<b>ACKNOWLEDGEMENTS</b>	<b>i</b>
<b>SUMMARY</b>	<b>ii</b>
<b>CONTENTS</b>	<b>v</b>
<b>LIST OF FIGURES</b>	<b>ix</b>
<b>LIST OF ABBREVIATIONS</b>	<b>xi</b>
<b>1. INTRODUCTION</b>	<b>1</b>
1.1 <i>Candida albicans</i> and its pathogenesis	1
1.1.2 Lipid and fatty acid metabolism in <i>Candida albicans</i>	2
1.2 Host cell response to fungal infection	4
1.2.1 Adherence as an initial step of host-pathogen interaction	5
1.2.2 Toll-like receptors and innate antifungal responses	5
1.3 Host cell survival	7
1.3.1 Phospholipase A <sub>2</sub> (PLA <sub>2</sub> ) enzymes	8
1.3.1.1 Function of PLA <sub>2</sub> in AA release and phospholipid remodeling	8
1.3.2 Cyclooxygenases and its transcriptional regulation	11
1.3.3 Nuclear factor- $\kappa$ B and its activation	12
1.3.4 Chromatin modification	14
1.4 Earlier study regarding host factors affecting the pathogenicity of <i>C. albicans</i>	15
1.5 Host cell apoptosis	17
<b>2 AIMS AND OBJECTIVES</b>	<b>19</b>
<b>3 MATERIALS AND METHODS</b>	<b>20</b>
3.1 Materials	20
3.2 Media and buffers	22
3.3 Methods	23
3.3.1 Mammalian cell culture	23
3.3.2 Basal culture conditions for <i>C. albicans</i>	23
3.3.3 Infection of HeLa cells with <i>C. albicans</i>	23
3.4 Phospholipase A <sub>2</sub> assay	23

3.5	iPLA <sub>2</sub> enzyme activity assay	24
3.6	Release of AA by <i>Candida albicans</i>	24
3.7	Determination of PGE <sub>2</sub>	24
3.8	Transient transfection of cell line	25
	3.8.1 Plasmids	25
3.9	Western blot analysis	26
	3.9.1 Preparation of total protein	26
	3.9.2 SDS-polyacrylamide gel electrophoresis and immunoblotting	26
	3.9.3 Nuclear extract preparation	27
3.10	Immunoprecipitation	27
3.11	Chromatin immunoprecipitation	28
3.12	RNA preparation	28
	3.12.1 Reverse transcription and polymerase chain reaction	28
	3.12.2 Real-time quantitative PCR	29
3.13	Reporter assay	30
	3.13.1 Luciferase assay	31
	3.13.2 $\beta$ -galactosidase assay	31
3.14	Assays for apoptosis	31
	3.14.1 Nuclear staining	31
	3.14.2 Cell death detection ELISA	31
	3.14.3 DNA ladder fragmentation assay	32
	3.14.4 Caspase-3 assay	32
3.15	Statistics	32
<b>4</b>	<b>RESULTS</b>	<b>33</b>
4.1	Activation of COX-2 gene	33
	4.1.1 <i>Candida</i> -induces transcriptional activation of COX-2 in HeLa cells	33
	4.1.2 Is COX-2 activation mediated by PGE <sub>2</sub> ?	34
	4.1.3 Activation of COX-2 is dependent from cAMP expression	35
4.2	NF- $\kappa$ B activity in HeLa cells infected by <i>C. albicans</i>	35
4.3	Suppression of HDACs upregulate the COX-2 and NF- $\kappa$ B expression in <i>Candida</i> -infected HeLa cells	36
	4.3.1 Specific role of HDAC in the activation by <i>C. albicans</i> of NF- $\kappa$ B	

	promoter is dependent on the upregulation of IKK activity	39
4.3.2	Gam-1 inhibits COX-2 and NF- $\kappa$ B activity by HDAC-1 in infected cells	39
4.3.3	Overexpression of HDAC-1 suppressed NF- $\kappa$ B mediated COX-2 activation	41
4.3.4	Inhibition of HDAC in HeLa cells infected with <i>C. albicans</i> cause increase of hyperacetylation of histone H3	42
4.3.5	Recruitment of p65 subunit of NF- $\kappa$ B by HDAC-1 in HeLa cells infected by <i>C. albicans</i>	43
4.3.6	Binding study of p65 subunit of NF- $\kappa$ B and HDAC-1 to COX-2 promoter in HeLa cells infected by <i>C. albicans</i>	44
4.4	Regulation of PLA <sub>2</sub> enzyme activity in HeLa cells by infection with <i>C. albicans</i>	45
4.4.1	Activation of COX-2 gene was depended candidial PLA <sub>2</sub> gene	45
4.5	Host cell PLA <sub>2</sub> activity during infection with <i>C. albicans</i>	46
4.5.1	PGE <sub>2</sub> production from host cells with <i>C. albicans</i> was dependent on iPLA <sub>2</sub> activity	47
4.5.2	Inhibition of iPLA <sub>2</sub> causes reduced activity of PKC $\alpha$	48
4.5.3	iPLA <sub>2</sub> is a key regulator of the cPLA <sub>2</sub> and COX-2 activity in HeLa cells challenged with <i>C. albicans</i>	49
4.5.4	Involvement of reactive oxygen species in the activation of iPLA <sub>2</sub>	50
4.5.5	In vitro binding of p65 subunit of NF- $\kappa$ B and iPLA <sub>2</sub> in HeLa cells infected with <i>C. albicans</i>	50
4.6	<i>Candida albicans</i> and host cell apoptosis	52
4.6.1	<i>Candida albicans</i> causes apoptosis in HeLa cell	52
4.6.2	A kinetic analysis of apoptosis induced by <i>C. albicans</i>	53
4.7	<i>C. albicans</i> induces caspase-3 activation	54
4.8	TLR2 in HeLa cells are activated by <i>C. albicans</i> infection	54
4.8.1.	<i>Candida</i> -induced TLR2 was not via COX-2 or PI-3 kinases	55
4.8.2.	TLR2 mRNA activation does not require <i>de novo</i> synthesis	56
4.8.3	Downstream signaling activation of TLR2 in <i>Candida</i> -infection	56
4.9	TLR2 mediates <i>C. albicans</i> -induced apoptosis	57
4.10	Overexpression of iPLA <sub>2</sub> inhibits apoptosis in <i>Candida</i> -infected HeLa cells	59
4.10.1	Inhibition of iPLA <sub>2</sub> but not PAP-1 induces apoptosis	

	in <i>Candida</i> -infected cells	62
4.11	Inhibition of iPLA <sub>2</sub> promotes TLR2-mediated apoptosis by <i>C. albicans</i>	64
<b>5</b>	<b>DISCUSSION</b>	<b>65</b>
<b>6</b>	<b>REFERENCES</b>	<b>73</b>
<b>7</b>	<b>CV</b>	<b>90</b>
<b>8</b>	<b>LIST OF PUBLICATIONS</b>	<b>91</b>



<b>LIST OF FIGURES AND SCHEMES</b>	<b>Page</b>
Fig. 1: Relative level of COX-2 mRNA expression induced by <i>C. albicans</i>	33
Fig. 2: The expression of COX-2 was not influenced by PGE <sub>2</sub> and EGF	34
Fig. 3: The COX-2 activation is dependent on the activation of cAMP	35
Fig. 4: Time course analysis of NF-κB	36
Fig. 5: Involvement of HAT on COX-2 promoter activity	37
Fig. 6: Inhibition of HDAC activity causes an increase of COX-2 and NF-κB activity	38
Fig. 7: Inhibition of IKK activity causes a decrease of NF-κB activity	39
Fig. 8: Inhibition of HDAC-1 activity causes an increase of COX-2 and NF-κB activity	40
Fig. 9: Overexpression of HDAC-1 promoter inhibits <i>C. albicans</i> induced COX-2 activation	41
Fig. 10: Treatment by TSA caused a dramatic increase in histone H3 acetylation	42
Fig. 11: Interaction of HDAC-1 and NF-κB p65 upon infection with <i>C. albicans</i>	43
Fig. 12: Time course analyse of <i>C. albicans</i> mediated binding of p65 subunit of NF-κB and HDAC-1 to COX-2 promoter	44
Fig. 13: Involvement of candidial PLA <sub>2</sub> gene in the induction of COX-2 gene expression	45
Fig. 14: A. The expression of cPLA <sub>2</sub> enzyme mRNA was decreased by <i>C. albicans</i> infection in HeLa cells	46
B. The expression iPLA <sub>2</sub> enzyme mRNA was decreased by <i>Candida</i> -infected cells	46
C. The iPLA <sub>2</sub> mRNA expression was decreased by <i>C. albicans</i> infection	47
Fig. 15: Inhibition of PLA <sub>2</sub> blocked the PGE <sub>2</sub> production in <i>Candida</i> -infected cells	48
Fig. 16: iPLA <sub>2</sub> inhibition caused decrease of PKC activity in HeLa cells by <i>C. albicans</i>	49
Fig. 17: BEL treatment inhibits the expression and activation of cPLA <sub>2</sub> and COX-2	49
Fig. 18: Depletion of ROS and inhibition of oxidative stress suppresses iPLA <sub>2</sub>	50
Fig. 19: A. Association of iPLA <sub>2</sub> with p65 subunit of NF-κB	51
B. Association of iPLA <sub>2</sub> with IκBα	51
Fig. 20: <i>C. albicans</i> causes nuclear shrinkage in HeLa cells	52
Fig. 21: <i>C. albicans</i> induces apoptosis in HeLa cells	53
Fig. 22: <i>C. albicans</i> induces apoptosis via activation of caspase-3	54

Fig. 23: <i>C.albicans</i> -induced TLR-2 activation is not mediated via COX-2, p38 <sup>MAPK</sup> or PI-3 kinases	55
Fig. 24: <i>De novo</i> protein synthesis is not required for induction of TLR2 mRNA	56
Fig. 25: <i>Candidal</i> -infection activates adapter protein MyD88	56
Fig. 26: A. <i>C. albicans</i> induces apoptosis in HeLa cells	57
B. TLR2 mediated <i>C. albicans</i> induces apoptosis in HeLa cells	58
C. Involvement of FADD in <i>Candida</i> -induced host cells apoptosis	59
Fig. 27: Time-course analysis of iPLA <sub>2</sub> protein by western blotting	60
Fig. 28: Time-course of overexpressed iPLA <sub>2</sub> protein in <i>Candida</i> -infected cells	60
Fig. 29: iPLA <sub>2</sub> enzymatic activity	61
Fig. 30: Overexpression of iPLA <sub>2</sub> inhibits <i>C. albicans</i> -induced apoptosis in HeLa cells	61
Fig. 31: Inhibition of iPLA <sub>2</sub> by BEL and MAFP but not by AACOCF3 of cPLA <sub>2</sub> triggers the early onset of <i>C. albicans</i> -induced apoptosis in HeLa cells	62
Fig. 32: DAPI staining of the <i>Candida</i> -infected cells pretreated with BEL	63
Fig. 33: PAP-1 treatment did not affect the onset of apoptosis induced by <i>C. albicans</i>	63
Fig. 34: The inhibition of iPLA <sub>2</sub> promotes TLR2-mediated apoptosis	64
Scheme 1: Classic AA cascade	4
Scheme 2: Toll-like receptor signaling pathway	6
Scheme 3: Regulatory elements in the human COX-1 and COX-2 promoters	11
Scheme 4: Signaling mechanism by <i>C. albicans</i> and 3-HETE in HeLa cells	16
Scheme 5: Overview of apoptotic signaling pathways	17

## ABBREVIATIONS

AA	Arachidonic acid (5Z,8Z,11Z,14Z eicosatetraenoic acid)
Acetyl-CoA	Acetyl coenzyme A
AIF	Apoptosis inducing Factor
ATP	Adenosin 5` triphosphate
APS	Ammonium persulphate
BEL	Bromo-enol lactone
BSA	Bovine serum albumin
cAMP	Cyclic adenosine 3`,5` phosphate
Caspase	Cysteine aspartyl-specific protease
COX-1	Cyclooxygenase-1
COX-2	Cyclooxygenase-2
CHX	cycloheximide
3,18-DiHETE	3,18-dihydroxy-5Z,8Z,11Z,14Z eicosatetraenoic acid
DAPI	4'-6-Diamidino-2-phenylindole
DAXX	Death domain-associated protein 6
DMEM	Dulbecco's modified eagles medium
Diablo	IAP-binding protein with low pI
DTT	Dithiothreitol
EET	Epoxy-eicosatetraenoic acid
EGF	Epidermal growth factor
EGTA	Ethylenglicol-tetraacetic acid
ELISA	Enzyme linked immuno-sorbent assay
ER	Endoplasmic reticulum
FBS	Fetal bovine serum
FADD	Fas-associating protein with death domain
IL	Interleukin
IRAK	IR-1R associated protein kinase
3-HETE	3-Hydroxy- 5Z,8Z,11Z,14Z eicosatetraenoic acid
HAT	Histone acetyltransferase
HDAC	Histone deacetylase
HPLC	High performance liquid chromatography
LB	Luria-Bertani medium

LRRs	Extracellular leucine-rich repeats
MAPKs	Mitogen-activated protein kinases
MAFP	Methyl arachidonylfluorophosphate
MOI	Multiplicity of Infection
NP-40	Nonidet P-40
ONPG	ortho-nitrophenyl-para-D-galactopyranoside
PAMPs	Pathogen-associated molecular patterns
PAP-1	Phosphatidate phosphohydrolase-1
PGE <sub>2</sub>	Prostaglandin E <sub>2</sub>
PGH <sub>2</sub>	Prostaglandin H <sub>2</sub>
PLA <sub>2</sub>	Phospholipase A <sub>2</sub>
PRR	Pattern recognition receptors
PAPC	1-palmitoyl-2-arachidonoyl phosphatidylcholine
PBS	Phosphate buffered saline (Phosphate Buffer)
RLU	Relative light units
RHD	Rel-homology domain
RIP	Receptor interacting protein
ROS	Reactive oxygen species
SDS	Sodium dodecyl sulphate
SMAC	Second mitochondrial-derived activator of caspase
SIMPs	Soluble intermembrane proteins
TNFR	Tumor necrosis factor receptor
TRADD	TNFR-associated death domain
TRAF6	Tumor necrosis factor receptor-activation factor 6
TLC	Thin layer chromatography
TIR	Toll-interleukin-1 receptor
Tris	Tris(hydroxymethyl)aminomethane
YNB	Yeast nitrogen base
YPD	Yeast-Peptone-Dextrone rich medium
VVC	Vulvovaginal candidiasis

## 1. INTRODUCTION

### 1.1 *CANDIDA ALBICANS* AND ITS PATHOGENESIS

Fungi are eukaryotic organisms with approximately 300 000 different species. Of these, about 200 are potential parasites, with only a few of these affecting humans [1]. Fungal diseases of mammals, mycoses, range from the common mild cutaneous or subcutaneous skin infections, such as athlete's foot, to the potentially lethal acute or chronic infection of deep tissues that are typically caused by *Candida* species. Of the *Candida* species afflicting humans, *Candida albicans* is by far the most common. *Candida albicans* belongs to the class Ascomycetes and the family, Saccharomycetaceae. This yeast can live as harmless commensal in many different body locations, and is carried in almost half of the population. However, in response to a change in the host environment, *C. albicans* can convert from a benign commensal into a disease-causing pathogen, causing infections in the oral, gastrointestinal and genital tracts [2]. The infection caused by *C. albicans* can be defined in two broad categories, superficial mucocutaneous [3] and systematic invasive, which involves the spread of *C. albicans* to the blood stream (candidemia) and to the major organs [4]. Systemic candidemia is often fatal. Superficial infections affect the various mucous membrane surfaces of the body such as in oral and vaginal thrush. The incidence of vulvovaginal candidiasis (thrush) has increased approximately 2 fold in the last decade. Approximately 75 % of all women experience a clinically significant episode of vulvovaginal candidiasis (VVC) at least once during the reproductive period [5]. VVC is a relatively benign condition that responds well to anti-fungal treatment. It is proposed that the infection is due to minor changes in epithelial conditions, such as pH, altered glucose/glycogen concentration or changes in epithelial integrity. During pregnancy the risk of vaginal thrush increases, possibly due to changes in hormone production, leading to increased glycogen content in the vagina [5, 6]. The pathogenesis of recurrent vaginal thrush involves a defect in the local immunity to candidiasis, possibly through inappropriate prostaglandin E<sub>2</sub> (PGE<sub>2</sub>) production [7]. The role of prostaglandins during the infection is not very clear, however it has been demonstrated that mononuclear cells from the patients suffering from recurrent vaginal candidiasis produce higher levels of PGE<sub>2</sub> as compared with cells from control women, indicating the important role of PGE<sub>2</sub> during infection. Recurrent vaginal candidiasis is also common in female patients with acquired immune deficiency syndrome (AIDS), suggesting a role for depressed cell-mediated immunity in candidiasis [8, 9]. Factors responsible for recurrent vaginal candidiasis may

originate from both the microorganism and the host cells, tissues and organs [10]. Therefore, the severity of *Candida* infection often depends upon the status of the host's immune system. However, there are differences in the pathogenicity of *C. albicans* strains which suggests that strain related virulence factors may play a role in disease severity. Numerous virulence factors have been attributed to the pathogenicity of *C. albicans* [11, 12]. These include dimorphism, phenotypic switching and immune interference.

**Dimorphism and phenotypic switching:** *Candida albicans* is a diploid asexual and dimorphic fungus and depending upon environmental conditions, can exist as unicellular yeast (blastospores and chlamydospores) as well as in different filamentous forms (hypha, pseudo-hyphae). Several studies suggest that the ability of *C. albicans* to switch between the yeast and mycelial forms is an important virulence factor [13, 14]. Increased adherence to oropharyngeal surfaces has been observed for the mycelial form. Decreased adherence has been demonstrated by a non-germ tube producing variant in experimental vaginitis [14]. Moreover, *C. albicans* can not only change its cellular morphology in response to growth conditions, but can also irreversibly switch its cellular phenotype both *in vitro* and *in vivo* [15]. This switching is most easily observed in the morphology of colonies [16]. These phenotypic differences are a product of differences in surface protein expression [17]. The different surface protein expression results in differential adherence characteristics for the switch variants and differential sensitivities to neutrophil and phagocytic leukocyte killing [18]. These data suggest that differences in the phenotype may allow for increased resistance to immune attack or increased invasiveness. The process of morphogenesis and phenotype switching is found to be dependent upon the lipid composition of *C. albicans* [19-21]. Lipids constitute about 3.8-4.3 % of the dry weight of the fungal cell and are important structural and functional molecules in *C. albicans*. Goyal and Khuller [22] showed variations in the lipid composition of yeast and mycelia forms in *C. albicans*. They found that total lipid, phospholipid and sterol contents of log phase mycelial cells were significantly higher than in yeast cells.


### **1.1.2 Lipid and fatty acid metabolism in *Candida albicans***

*Candida albicans* is able to utilise various monosaccharides, such as glucose and maltose but also other carbon sources like ethanol, saturated and lower unsaturated fatty acids [19, 23]. Fatty acid degradation in *C. albicans* is different from that of other eukaryotic organisms. Generally, *C. albicans* degrades fatty acids by peroxisomal beta-oxidation system, via a series of reactions

catalyzed by a multienzyme complex, MFE-2. The gene encoding the multifunctional protein of peroxisomal beta-oxidation was first discovered in *Saccharomyces cerevisiae* [24-26]. Fatty acid degradation occurs via different mechanisms, such as, alpha oxidation leading to formation of CO<sub>2</sub>, beta-oxidation in mitochondria and peroxisomes and omega-oxidation carried out by cytochrome P450. The last two mechanisms lead to the formation of hydroxylated fatty acids [27]. Beta-oxidation is a cyclic oxidation system of fatty acids in beta position and requires four different enzymes, which are: acyl-CoA dehydrogenase, enoyl-CoA hydratase,  $\beta$ -hydroxyacyl-CoA dehydrogenase and acyl-CoA acetyltransferase (thiolase). In general, fatty acyl-CoA thioester undergo enzymatic dehydrogenation by acyl-CoA dehydrogenase to form trans-enoyl CoA. The double bond of trans-enoyl CoA is hydrated to form 3-hydroxyacyl-CoA by the enzyme enoyl-CoA hydratase and is further dehydrogenated to form 3-ketoacyl-CoA. 3-ketoacyl-CoA further undergoes cleavage by thiolase by interaction with a molecule of free acetyl-CoA resulting in a fatty acid shorter by two carbon atoms [28]. Earlier, Dr. Nigam's laboratory reported that fungi in general do not contain higher fatty acids, such as arachidonic acid (AA), eicosapentaenoic acid, docosahexaenoic acid etc., but *C. albicans* was shown to grow on AA as a sole carbon source for energy supply. In addition, they reported for the first time that AA is transformed via glyoxalate shunt to carbohydrates by *C. albicans* [29]. This incomplete beta-oxidation takes place in mitochondria, causing 3R-hydroxylation of AA, and leading to formation of 3-HETE, which is the oxygenated and hydroxy derivative of this long-chain fatty acid [30]. Further, 3-HETE acts as a growth factor for the fungus and is involved in different biological activities in host cells and so a vicious cycle is turned on. This implies that the infection process can be assumed to be a host-pathogen interaction, in which host cell release AA, which is converted to 3-HETE by the pathogen [29]. 3-HETE is finally converted by eicosanoid-converting enzymes to novel bioactive 3-hydroxyeicosanoids [31]. These data accentuate a prominent role of host cell-derived arachidonic acid in the inflammatory events induced by *C. albicans* infections.

**The arachidonic acid cascade** AA is a 20 carbon atom containing unsaturated fatty acid distributed throughout the lipid bilayer of all mammalian cells. It is derived directly from the diet or via modification of linoleic acid, and normally resides in cell membranes esterified to phospholipids. Phospholipids are major components of biological membranes and membrane-bound vesicles, and contribute to their structure and function. Among the natural phospholipids

phosphatidylcholine (PC, lecithin) is most common and a suitable substrate for phospholipase A<sub>2</sub>. Other phospholipids are phosphatidylinositol (PI), phosphatidylserine (PS) and phosphatidylethanolamine (PE). In membrane glycerophospholipids, PC is enriched with long chain fatty acid including AA in the sn-2 position. Once liberated, free AA can be metabolised by one of three major enzymatic pathways: cyclooxygenase, lipoxygenase, or the cytochrome P450 (Scheme 1).



**Scheme 1.** Classic arachidonic acid cascade

## 1.2 HOST CELL RESPONSE TO FUNGAL INFECTION

Fungi have developed many mechanisms to colonize human hosts. The ability to grow at 37 °C is one of the most important. Production of keratinase allows dermatophytes to digest keratin in skin, hair and nails. Dimorphism allows many fungi that exist in nature in yeast form to change to a mycelial form in the host and thus become pathogenic. Thus, antiphagocytic properties of the *Cryptococcus neoformans* capsule and the adherence abilities of *C. albicans* allow pathogenic potential for these fungi. Fungi may spread locally such as dermatophytes on the skin or eumycotic mycetomas in subcutaneous tissue. *Sporothrix schenckii*, another subcutaneous pathogen, spreads via local lymphatics. Most common opportunistic mycoses include invasive aspergillosis, cryptococcal meningitis, mucormycosis and candidiasis. The fungi producing

systemic mycoses may initially cause pulmonary infection. The fungi are phagocytosed by alveolar macrophages but are not destroyed. Instead, the fungi are spread hematogenously to distant sites in the body. An exception is *Cryptococcus neoformans* which disseminates without being phagocytosed. The pathogenesis of some fungi may be at least partly due to the host reaction, such as allergic reactions elicited by some fungi.

### **1.2.1 Adherence as an initial step of host-pathogen interaction**


Adhesion of *Candida albicans* to host tissue is considered as an important virulence factor in the development of diseases. Poorly adherent strains of *C. albicans* are less virulent in animal models [32]. Invasive strains of *C. albicans* recovered from patients show greater adherence than strains recovered from asymptomatic carriers [33]. Attachment is believed to be due to a specific interaction of *C. albicans* cell wall components with cell surfaces. Infection of host cells by a pathogenic fungus is mediated through surface receptor [35, 36]. The nature of the components which mediate adhesion is controversial, but some findings indicate that mannan, mannanproteins or polysaccharides are responsible for the adhesion [34]. Factors that enhance adherence include fungal cell surface hydrophobicity, the phenotype of *C. albicans*, pH, temperature, pregnancy, diabetes and oral contraceptive usage [32, 33].

The ability of pathogenic fungus to establish a persistent infection is critically dependent on cellular signals that regulate release of factors from target cells responsible for host cell replication and establishment of the pathogen. Therefore, cell signaling is designed to serve the purpose of cell survival for both host and pathogen.

### **1.2.2 Toll-like receptors and cell signaling**

TLRs have been identified in humans as important components of innate immunity against microbial pathogens. Spaetzle/Toll and other similar proteins were first discovered in *Drosophila melanogaster* and their interactions were shown to induce antifungal defence by the production of drosomycin, an antifungal compound [37]. Recognition of invading fungi by the innate immune system is the very first step to activate a rapid response and to ensure survival after infection. The targets of innate immune recognition are conserved molecular patterns, so called pathogen-associated molecular patterns (PAMPs) [38]. Accordingly, the receptors of the innate immune system that recognise PAMPs are called pattern recognition receptors (PRR). It is important to note that PAMPs are not unique to pathogens and are produced by both pathogenic and

non-pathogenic microorganism [39]. Toll-like receptors (TLRs) are essential PRRs and constitute a novel protein family of cellular receptors that mediates recognition of microbial challenges and the subsequent inflammatory response in vertebrates. TLRs, homologues of *Drosophila* Toll, are type 1 transmembrane proteins belonging to a protein family characterized by extracellular leucine-rich repeats (LRRs) and intracellular Toll-interleukin-1 receptor (TIR) domain [39, 40]. The LRR motifs are sequentially arranged in the ectodomain of the receptors. In mammalian species there are at least ten TLRs, and each seems to have a distinct function in innate immune recognition. In the past few years, dozens of TLR ligands have been identified. Ligands for TLR-1, 2, 3 and TLR- 4, 5, 6, - 9 have been identified, but the ligands recognized by the other TLRs are unknown [40, 41]. During ligand-binding the TLR recruits the adapter protein myeloid differentiation marker-88 (MyD88) to the receptor (Scheme 2). Thus, in several myeloid cell systems MyD88 links the IL-1 receptor to IR-1R associated protein kinase (IRAK), a serine-threonine kinase that is related to the Pelle kinase of *Drosophila*. Upon binding of ligand to IL-1R, IRAK is phosphorylated, subsequently dissociated from the receptor complex and associated with tumour necrosis factor receptor-activation factor 6 (TRAF6) (Scheme 2).



**Scheme 2.** Toll-like receptor signaling pathway

Activation of TRAF6 results in the activation of two different pathways involving the c-Jun NH2-terminal kinase (JNK) and p38 mitogen activated protein kinase (p38<sup>MAPK</sup>) family and Rel family transcription factor NF- $\kappa$ B. Moreover, an additional adapter molecule called TRIP that has homology with MyD88 is required for MyD88-dependent signaling through TLR2 and TLR4 but not by the IL-1R or other TLR such as TLR-3, 5, 7 and 9 [40, 42]. In addition to their common activation of MyD88-IRAK-TRAF pathway, individual TLRs may activate different, alternative, signaling pathways. Characterization of the TLR signaling pathways should reveal the molecular mechanism that link the initial recognition of pathogens and elicitation of acquired immunity. A limited number of TLRs can respond to a broad spectrum of microbial products. The implication of TLR2 and TLR4 in the host defence to *C. albicans* was first described by Netea and co-workers [43]. Although growth of *C. albicans* was increased 10-fold in TLR4 mutant mice compared with wild type C3H/HeN mice, TLR4 did not affect the level of TNF- $\alpha$  and IL-1 $\beta$  production in mouse macrophages after stimulation with *C. albicans*. The data have implicated TLRs in the recognition of *C. albicans* cell wall PAMPs [39, 44]. The cell wall of *C. albicans* is mainly composed of chitin (a cellulose-like biopolymer consisting predominantly of N-acetyl-D-glucosamine), glucan (a  $\beta$ -linked branched chain polysaccharide of glucose), mannan (an  $\alpha$ -linked polymer of mannose), mannoproteins and glycolipids. Recognition of 1, 2, 3- $\beta$ -D-glucans by TLRs is dependent on MyD88 [44]. Furthermore, the discovery of Dectin-1 as a small type II transmembrane receptor for  $\beta$ -glucan containing particles, including *C. albicans* and zymosan, also emphasized the importance of other PRRs optionally interacting with TLRs [45]. Dectin-1 is involved in phagocytosis and is expressed on dendritic cells, monocytes and macrophages. It mediates immunological response, such as release of TNF- $\alpha$  and IL-12 in response to fungal derived  $\beta$ -glucans in cooperation with TLR2 [46, 47].

### 1.3 HOST CELL SURVIVAL

Earlier report from Castro *et al.* [48] showed that the stimulation by *C. albicans* of both rabbit alveolar macrophages and human monocytes caused a sizeable release of AA from pre-labelled cells, which was subsequently converted to cyclooxygenase and lipoxygenase-derived eicosanoids. It was also demonstrated that upon infection, *C. albicans* induced monocytes to

liberate proinflammatory cytokines like interleukin-6 (IL-6) and interleukin-8 (IL-8) [48, 49]. In human endothelial cells, the *in vitro* invasion of *C. albicans* has been reported to stimulate AA metabolism and the secretion of PGI<sub>2</sub> [50, 51].

### **1.3.1 Phospholipase A<sub>2</sub> (PLA<sub>2</sub>) enzymes**

The first step in the metabolism of AA is the cleavage of the *sn*-2 ester bond by the enzyme PLA<sub>2</sub> to release AA. A number of mammalian PLA<sub>2</sub> isotypes have been identified. These are divided into three major subfamilies: calcium dependent secretory PLA<sub>2</sub>s (sPLA<sub>2</sub>s), calcium dependent cytosolic PLA<sub>2</sub>s (cPLA<sub>2</sub>s), and Ca<sup>2+</sup>-independent PLA<sub>2</sub>s (iPLA<sub>2</sub>s) [52, 53]. sPLA<sub>2</sub>s are low molecular mass enzymes (14 kDa) that require millimolar concentration of Ca<sup>2+</sup> for activation. The cPLA<sub>2</sub> family consists of three isozymes cPLA<sub>2</sub>α, cPLA<sub>2</sub>β, and cPLA<sub>2</sub>γ, which are classified into groups IVA, ICB and IVC, respectively [54, 55]. cPLA<sub>2</sub> (85 kDa) enzyme activity is regulated by submicromolar levels of Ca<sup>2+</sup>. The activity of iPLA<sub>2</sub> is Ca<sup>2+</sup>-independent. It is mainly considered to be a remodeling enzyme that maintains the composition of membrane phospholipids. Generally, iPLA<sub>2</sub>s are 80-85 kDa proteins, which are not selective for AA containing phospholipids [52]. In the last decade at least two enzymatically active forms of the enzyme, termed iPLA<sub>2</sub> VIA-1 and iPLA<sub>2</sub> VIA-2, have been identified [56]. Structurally they contain eight ankyrin repeats at the N-terminus. cPLA<sub>2</sub> and iPLA<sub>2</sub> are intracellular enzymes, but cPLA<sub>2</sub>s are located in the cytosol and translocated into membrane, while iPLA<sub>2</sub>s are located both in the cytosol and in membrane fraction [57].

#### **1.3.1.1 Function of PLA<sub>2</sub>s in AA release and phospholipid remodeling.**

One of the key roles of any cell is the regulation of PLA<sub>2</sub> activity for AA release. A myriad of agents that exert effects on cells via receptor-dependent or independent pathways elicit a series of signals that ultimately lead to increased PLA<sub>2</sub> activity. Most cell types contain several PLA<sub>2</sub> forms, and all of them may eventually participate in the signaling process.

##### **1.3.1.1.1 Regulation of sPLA<sub>2</sub> activation**

Generally, sPLA<sub>2</sub>s (Groups I, II, III, V, IX, X, XI, XII), require millimolar levels of Ca<sup>2+</sup> for activity, have low molecular masses, and lack specificity for arachidonate-containing phospholipids. sPLA<sub>2</sub>s were initially found in reptile (group IA) and bee venoms (group III) and in mammalian pancreatic fluid (group IB). It was shown later that a variety of sPLA<sub>2</sub>s can be

expressed and released in human tissue [58]. Depending on the stimulation conditions, the cPLA<sub>2</sub> modulation of sPLA<sub>2</sub> cellular activity may occur at a gene regulatory level (delayed responses) [59] or at the level of regulation of enzyme activity itself (immediate responses) [60]. In the latter case, a variety of cellular mechanisms may account for this activation, such as cPLA<sub>2</sub>-induced rearrangement of membrane phospholipids that enables further sPLA<sub>2</sub> attack to more sophisticated mechanisms such as inactivation of endogenous sPLA<sub>2</sub> inhibitors or Ca<sup>2+</sup> fluxes. Therefore, cPLA<sub>2</sub> appears to initiate the AA release process and plays primarily a regulatory role, whereas the sPLA<sub>2</sub> acts in a second wave to amplify the response by providing the bulk of the AA liberation [62]. Increased levels of extracellular sPLA<sub>2</sub>s have been detected in the plasma of patients affected by systemic inflammatory diseases such as acute pancreatitis [62], septic shock [63], extensive burns [64], and autoimmune diseases [65].

#### **1.3.1.1.2 Regulation of cPLA<sub>2</sub> activation**

cPLA<sub>2</sub> has been reported to play a role in cellular proliferation, transformation and oncogenesis in certain cell types [66]. cPLA<sub>2</sub>, especially cPLA<sub>2</sub>α shows a remarkable selectivity towards phospholipids bearing AA at the *sn*-2 position. Thus, it was found that the Ca<sup>2+</sup>-dependent translocation of cPLA<sub>2</sub> from cytosol to the perinuclear membranes (Golgi, endoplasmic reticulum (ER), and nuclear envelope) is an essential step for the initiation of stimulus-coupled AA release [67, 68]. Duration of Ca<sup>2+</sup> increase stabilizes the association of cPLA<sub>2</sub> with the perinuclear membrane. This temporal perinuclear localization permits efficient functional coupling between cPLA<sub>2</sub> and downstream eicosanoid-biosynthetic enzymes, COXs and LOXs [69, 70]. Moreover, cPLA<sub>2</sub> mutants exhibit poor PGE<sub>2</sub> biosynthetic ability, indicating that the perinuclear translocation of cPLA<sub>2</sub> is important, if not obligatory, for its functional coupling with COX enzymes [71]. The maximum activation of cPLA<sub>2</sub> requires sustained dual phosphorylation of Ser<sup>505</sup> and Ser<sup>727</sup> sites of the enzyme by mitogen-activated protein kinases (MAPKs) and by MAPK-activated protein kinases, respectively [72]. As PLA<sub>2</sub> is an active component of many venoms and toxins, the secretion of cPLA<sub>2</sub> by *C. albicans* could play a part in the invasion of host cell tissues in candidiasis lesions. Thus, cPLA<sub>2</sub> found at the site of bud formation suggested a role for this enzyme in cell growth and possibly germ tube formation by hydrolysing phospholipids of cell and intracellular membranes [73]. The *C. albicans* isolates, which adhered most strongly to buccal epithelial cells and were most virulent in mice, exhibited the highest PLA<sub>2</sub> activity [74].


Isolates, which did not adhere and did not kill mice showed lower PLA<sub>2</sub> activity. Therefore, phospholipase activity of *C. albicans* is one of the most important pathogenenic factors.

#### **1.3.1.1.3 Regulation of iPLA<sub>2</sub> activation**

iPLA<sub>2</sub> has been proposed to participate in fatty acid release associated with phospholipid remodeling and to play a major role in signal transduction [75]. Beyond the housekeeping role of iPLA<sub>2</sub>-VIA in maintaining phospholipid homeostasis, several studies suggest that this enzyme is also involved in stimulus-coupled AA release [76, 77, 78]. For instance, agonist-induced PGE<sub>2</sub> production is attenuated by an antisense oligonucleotide for iPLA<sub>2</sub> [77], and the overexpression of iPLA<sub>2</sub> led to increased AA release in response to A23187 [76, 78]. Reactive oxygen species (ROS) have been reported as factors which potentiate the iPLA<sub>2</sub> activity. Birbes *et al.* [79] reported that in uterine stromal cells, H<sub>2</sub>O<sub>2</sub> caused a significant release of AA and an increase in iPLA<sub>2</sub> activity, which is independent of intracellular Ca<sup>2+</sup> concentration. These activations are almost completely inhibited by bromoenol lactone (BEL), a specific inhibitor of iPLA<sub>2</sub>. Furthermore, it was demonstrated that PKC $\alpha$  is also involved in the iPLA<sub>2</sub>-mediated AA release in response to zymosan [80]. In another study, the thrombin stimulation of vascular smooth muscle cells was found to increase the iPLA<sub>2</sub> activity, AA release, and DNA synthesis, which was, however, suppressed by BEL [81]. Moreover, the inhibitor of p38<sup>MAPK</sup> attenuated the thrombin responses in the cells, suggesting the implication of p38<sup>MAPK</sup> in thrombin-induced iPLA<sub>2</sub> activation [83]. Involvement of iPLA<sub>2</sub> has also been implicated in triggering apoptosis in various cell types [84, 85]. So, for instance, apoptosis of U937 cells by anti-Fas antibody is coupled with release of AA from membrane phospholipids which is independent of group IV and group II PLA<sub>2</sub>s, but can be inhibited by BEL [84]. Furthermore, caspase-3-catalyzed cleavage of iPLA<sub>2</sub> has been reported during apoptosis of U937 cells [85]. The resulting 62 kDa immunoreactive product was found to be more active than the full-length iPLA<sub>2</sub> [84]. Interestingly, several reports presented also contradicting results. Thus, even though the iPLA<sub>2</sub> inhibitor, BEL, was found to suppress the binding of IgM and Annexin V to the cell surface membrane of peripheral blood mononuclear (PBMT) cells, it failed to inhibit the cleavage of caspase-3 substrates, Phi-phi Lux or PARP or to attenuate nuclear condensation [86].

### 1.3.2 Cyclooxygenases and its transcriptional regulation

Host cells provide one source of prostaglandins during fungal infection, however, another potential source of prostaglandins is the fungal pathogen itself [87]. Since AA is a major precursor of mammalian eicosanoids, a role for eicosanoids in the host-pathogen interaction seems to be crucial. Thus, PGE<sub>2</sub> has been shown to stimulate germ tube formation in *C. albicans* [88]. Upon stimulation by the invading hyphae of *C. albicans*, cells of the vaginal tract release significant amounts of PGE<sub>2</sub> [89]. The free AA released through the infection acts as a substrate for the cyclooxygenases (COXs) and is converted to unstable PGG<sub>2</sub>, which is further converted to PGH<sub>2</sub> by the peroxidase activity of COXs. PGH<sub>2</sub> is the common intermediate for all prostaglandins and thromboxanes, which are formed by the action of the respective enzymes i.e. prostacyclin synthase, thromboxane synthase, PGE<sub>2</sub> synthase, and AA other isomerases [90]. COXs are rate-limiting enzymes in the synthesis of prostaglandins [91]. Two isomers of COX have been primarily identified. In general, cyclooxygenase-1 (COX-1) is constitutively expressed in many tissues and plays a major role in the cell and tissue homeostasis. Cyclooxygenase-2 (COX-2) is a primary response gene, not constitutively expressed in appreciable amounts by normal tissues, but, it is rapidly induced by proinflammatory cytokines, tumour promoters, oncogenes, and growth factors [92, 93]. The gene for COX-2 is approximately 8.3 kb long with 10 exons, and it is transcribed as 4.6, 4.0, and 2.8 kb mRNA variants [94]. The sequence analysis of the 5'-flanking region has shown several potential transcription regulatory elements, including a TATA box, NF-IL-6 motif, two AP-2 sites, three Sp1 sites, two NF-κB sites, a CRE motif and an E-box (Scheme 3) [95].



**Scheme 3.** Regulatory elements in the human COX-1 and COX-2 promoters.

Although, COX-2 was initially demonstrated in fibroblast cells [90, 92], the expression of the COX-2 gene is associated with several diseases. Overexpression of the COX-2 protein plays an important role in many pathophysiologic states, including inflammation, cancer, angiogenesis, and several forms of arthritis. The elevated COX-2 expression was associated with locally increased PGE<sub>2</sub> production, suggesting that COX-2 is responsible for the overproduction of PGE<sub>2</sub> [96]. The signaling pathways that mediate COX-2 expression are tissue-specific and depend on the stimulus. Therefore, the regulation of COX-2 gene expression can share other signaling pathways involving the NF-κB site, NF-IL6 motif, CRE and E box in the COX-2 promoter [97]. Previously, it has been demonstrated that hypoxia causes increased binding of NF-κB p65 to one out of the two NF-κB consensus elements in the COX-2 promoter, which is closest to the transcription start site of the COX-2 gene [98]. Thus, the intracellular signaling mechanism that leads to induction of COX-2 by hypoxia was found to include binding of p65 to the relatively 3' NF-κB consensus element in the COX-2 upstream promoter region in human vascular endothelial cells [98]. Recently, it was found that the high glucose treatment of human THP-1 monocyte cells increased the recruitment of NF-κB p65, CPB and p/CAF by the COX-2 promoter [99]. These authors showed that diabetic conditions can increase *in vivo* recruitment of NF-κB and HAT, as well as histone acetylation at the promoters of COX-2 gene.

### **1.3.3 Nuclear factor-κB and its activation**

In order to survive, all organisms are able to respond rapidly and efficiently to changes in their environment. To accommodate to the changing micro environment, cells adjust the pattern of gene expression. This regulation occurs primarily at the level of transcription and is controlled by the transcriptional factors, which are translocated from the cytoplasm into the nucleus, and bind to their cognate site to activate or repress transcription. One of these transcription factors is nuclear factor-κB (NF-κB). This transcription factor was first described as a nuclear factor that binds to a specific decameric DNA sequence, GGG ACT TTC C, within the intronic enhancer of the immunoglobulin kappa light chain in mature B-and plasma cells but not in pre B-cells. [100]. For a long time the transcription factor NF-κB has attracted attention because of its unique activation pathway and its physiological importance as a key regulatory molecule of the immune response, cell proliferation and apoptosis. Endogenous activation of NF-κB is a cellular defence mechanism that protects cells by inducing survival genes, such as  $\chi$ IAP and BCL<sub>X<sub>L</sub></sub> [101, 102].

There is also ample evidence for the independent upregulation of NF- $\kappa$ B to cause apoptosis [103, 104]. NF- $\kappa$ B is dimeric protein composed of various combinations of the five different DNA-binding subunits: NF- $\kappa$ B1 (p50 and its precursor p105), NF- $\kappa$ B2 (p52 and its precursor p100), cRel, RelB and p65 (RelA), although the most frequently observed form of NF- $\kappa$ B is a p50-p65 heterodimer. All NF- $\kappa$ B family members have a conserved N-terminal Rel-homology domain (RHD), which is responsible for dimerization, DNA binding and interaction with I $\kappa$ Bs (inhibitors of NF- $\kappa$ B) [105]. The precursor proteins, p105 and p100 can be processed by the proteasome to generate p50 and p52, respectively. Recently the three-dimensional structures of NF- $\kappa$ B I $\kappa$ B ternary complexes (composed of the RHDs of p50 and p65 and the ankyrin repeat core of I $\kappa$ B $\alpha$ ) were solved [106]. It was found that p50 can be produced by an alternative pathway, which involves the cotranslational dimerization of the RHD of p50 with p105. In unstimulated cells, NF- $\kappa$ B is maintained in an inactive form in the cytoplasm by association with I $\kappa$ Bs. Physical and chemical stresses, viruses, bacteria and pro-inflammatory cytokines like interleukins (IL) and tumour necrosis factor (TNF) activate NF- $\kappa$ B by inducing the rapid phosphorylation of I $\kappa$ B $\alpha$  at positions Ser32 and Ser36. Phosphorylated I $\kappa$ B $\alpha$  is then ubiquitinated on Lys21 and Lys22 to trigger the rapid degradation of the protein by the 26S proteasome [107]. Released p65 subunit of NF- $\kappa$ B then translocates to the nucleus, binds to its cognate DNA element and activates transcription of numerous target genes. The inducible phosphorylation of I $\kappa$ B is mediated by recently identified I $\kappa$ B kinases (IKK $\alpha$ ,  $\beta$ , and  $\epsilon$ ) [108]. The catalytic subunits, IKK $\alpha$  and IKK $\beta$  and the regulatory IKK $\gamma$ /NEMO (NF- $\kappa$ B essential modulator) subunit, form the prototypic core IB kinase complex (IKC) [109]. Importantly, this complex serves as an intracellular point of convergence for distinct signals that ultimately activate NF- $\kappa$ B. Therefore, activated NF- $\kappa$ B induces the expression of specific genes that encode negative regulators of NF- $\kappa$ B [110, 111]. One of these negative regulators induced by NF- $\kappa$ B is I $\kappa$ B $\alpha$  [112, 113]. Newly synthesized I $\kappa$ B $\alpha$  proteins can shuttle in and out of the nucleus and can physically remove NF- $\kappa$ B from DNA. Subsequent nuclear export of I $\kappa$ B $\alpha$  promotes the return of the new inactive NF- $\kappa$ B- I $\kappa$ B $\alpha$  complex to the cytoplasm and serves to terminate the NF- $\kappa$ B transcriptional response [114, 115].

### **1.3.4 Chromatin modification**

Chromatin modification is an important event for any gene activation. In eukaryotes, DNA is packaged into chromatin that interferes with DNA metabolic processes such as transcription, replication and DNA repair. Two known mechanisms that regulate chromatin structure are ATP-dependent chromatin remodeling, and histone replacement [116]. Whereas DNA is modified by cytosine methylation, histones are targets for acetylation (lysine), phosphorylation (serine and threonine), and methylation (lysine and arginine) [117, 118]. More than three decades ago, Allfrey and colleagues [119] found a correlation between increased histone acetylation and increased transcription. Since then, using both genetic and biochemical approaches, several mechanisms by which histone acetylation and deacetylation regulated the gene activity have been elucidated. Histone acetylation is catalysed by histone acetyl transferases (HATs), whereas the reverse reaction is performed by histone deacetylases (HDACs) [120, 121]. There are two main mechanisms that regulate the chromatin modification: a. post-translational modification, which is the chemical modification of a protein after its translation, b. protein-protein interaction [122].

#### **1.3.4.1 Post-translational modification**

Compared with methylation and phosphorylation, the acetylation of core histones is probably the best understood type of modification. Histone acetylation occurs at the  $\epsilon$  amino groups of evolutionarily conserved lysine residues located at the N-termini. All core histones are acetylated *in vivo*. Modification of histone H3 and H4 are, however, much more extensively characterized than those of H2A and H2B [123, 124]. Important positions for acetylation are Lys<sup>9</sup> and Lys<sup>14</sup> on histone H3, and Lys<sup>5</sup>, Lys<sup>8</sup>, Lys<sup>12</sup>, and Lys<sup>16</sup> on histone H4 [125]. In general, increased levels of histone acetylation (hyperacetylation) are associated with increased transcriptional activity, whereas decreased levels of acetylation (hypoacetylation) are associated with repression of gene expression [124, 126]. Therefore, acetylation is a key component in the regulation of gene expression. On the other hand, histone deacetylases act as transcriptional repressors or silencers of genes, which can catalyse the removal of acetyl groups on amino-terminal lysine residues [123, 124].

#### **1.3.4.2 Protein-protein interactions**


Both HATs and HDACs are usually part of large multimolecular complexes, which contain other components that are required for the enzyme activity. For instance, the activity of CBP (CREB-

binding protein) or the closely related p300 HAT has been shown to be stimulated in cells by a variety of sequence-specific transcription factors such as Sp1, NF-E2 and C/EBP [127]. Through this stimulation, these sequence-specific transcription factors are thought to increase the acetylation of histones or other transcription factors at their target promoters. Thus, binding of transcription factor to HAT can effect gene expression through other transcription factors. The activity of acetylation controlling enzymes can also be modulated through the recruitment to the complex of an enzyme that catalyzes the reverse reaction. Indeed, some complexes containing both HAT and HDAC activities have been characterized [128]. For example, p300 can interact with HDAC-6, and this interaction brings about transcriptional repression [128]. Therefore, it may be proposed that the HDAC enzyme seldom operates alone. Many proteins, transcription factors, with various functions such as recruitment, corepression or chromatin remodeling, are involved in forming a complex that results in the repressor complex.

#### **1.4 Earlier studies regarding host factors, that affect the pathogenicity of *C. albicans***

During infection by *C. albicans*, AA derived from the host cells, can be converted by the fungus to a novel growth factor, 3-hydroxy eicosotetraenoic acid (3-HETE) [31]. This compound was first detected by its immunoreactivity towards an antibody specific to the 3-OH group. This implies that an infection process can be assumed as host-pathogen interaction, in which the host cells release AA, and the pathogen converts it to 3-HETE. This 3-HETE acts as a growth factor for the fungus, and is involved in different biological activities in host cells and so a vicious cycle is turned on. The possible biological role of the oxylipins produced by *Candida* species is unknown. The ability to morphologically switch from yeast cells (blastospores) to filamentous forms (hyphae) is an important virulence factor which contributes to the dissemination of *Candida* in host tissues and which promotes infection and invasion. The filamentous forms of the fungus appear to be more infectious than the yeast forms, however, both morphogenetic forms are apparently necessary for colonisation and invasion by the pathogen under different environmental conditions within the host organism. Approaching both hyphal and yeast forms for the treatment could be the ideal treatment since different forms are involved in spread and progress of infection. Thus, it was found that aspirin, which inhibited formation of 3-hydroxyoxylipins, also inhibited formation of filamentous forms as well as yeast cell growth. Thus, pharmacological intervention by aspirin in the fatty acid metabolism along with classical therapy would be a good approach for the treatment of infection. The exact mechanism of


inhibition of 3-hydroxy oxylipins by aspirin is not yet known. It has been suggested that aspirin may inhibit beta-oxidation [29]. During the study of the infection process by *C. albicans* in Dr. Nigam's group Deva *et al.* [96] observed the ability of *C. albicans* to selectively upregulate the COX-2 gene in HeLa cells as well as the production of PGE<sub>2</sub> (Scheme 4). Deva *et al.* also found that the p38 MAP kinase activation by *C. albicans* was inhibited by the PKC inhibitor GF203190X, suggesting that the phosphorylation of p38<sup>MAPK</sup> is a downstream signal of PKC [96]. However, PD98059, ERK1/2 kinase inhibitor failed to modulate the phosphorylation state of p38<sup>MAPK</sup> suggesting that these are not involved in this pathway. These results suggest key roles for PKC as well as for p38MAP kinase cascades in the biosynthesis of PGE<sub>2</sub> by upregulating the induction of COX-2 in *C. albicans* infected HeLa cells. Moreover, they also investigated NF-κB activation. Remarkably, high levels of NF-κB binding activity were detected after *C. albicans* infection. The activation of COX-2 and NF-κB were inhibited by SB202190 and GF203190X [96]. This inhibitory effect was, however, significantly lower as compared to inhibitor-mediated repression of COX-2. This discrepancy suggested that PGE<sub>2</sub> production by *C. albicans* is not only dependent on the upregulation of COX-2, but may also involve COX-1 in the cell signaling.



**Scheme 4.** Signaling mechanism by *C. albicans* and 3-HETE in HeLa cells.

## 1.5 HOST CELL APOPTOSIS

Apoptosis, or programmed cell death, is considered as a normal physiological process and a major form of cell death that is used to remove damaged or infected cells throughout the life [129]. Apoptosis is also a mechanism by which the organism deals with stress, injury and factors threatening its integrity such as infection. Apoptosis is therefore important in normal cell development, occurring during embryogenesis as well as in the maintenance of tissue homeostasis [129].



**Scheme 5.** Overview of apoptotic signaling pathways (designed by Digizyme, Cell signaling technology, Beverly, MA 01915, USA).

### 1.4.1 General mechanisms of apoptosis

Apoptosis is a regulated physiological process characterized by cell shrinkage, membrane blebbing and DNA fragmentation [130]. Caspases, a family of cysteine proteases, are central elements of apoptosis. Initiator caspases (including 8, 9, 10 and 12) are closely coupled to pro-apoptotic signals. Once activated, these caspases cleave and activate downstream effector caspases (including 3, 6, and 7), which in turn cleave cytoskeletal and nuclear proteins and induce apoptosis [131]. Two pathways initiate the signaling cascade that results in apoptosis as shown in scheme 5:

**a. *Receptor-mediated apoptosis:*** One major pathway for the induction of apoptosis is the receptor-mediated or extrinsic pathway. External signals such as FasL (produced by cytotoxic T cells on their surface) and TNF $\alpha$  can activate pathway specific receptors of the TNF-R family known as death receptors (TNF-R1, Fas or CD95, TRAIL R1 and R2) which contain a cytosolic death domain (DD) [132, 133]. The receptor oligomerization results in the recruitment of specific adapter proteins such as FADD, TRADD, RIP and DAXX via their DDs [134, 135]. FADD in addition contains a death effector domain (DED), to which the DED of pro-caspase-8 can bind. This complex is designated as DISC (death- inducing signaling complex). The formation of DISC leads to the recruitment and cleavage of pro-caspase-8 and 10 to their active forms. Caspase-8 and 10 function as initiator caspases leading to the activation of effector caspases.

**b. *Intrinsic pathways:*** This pathway is triggered in response to DNA damage, oxidative stress, chemotherapeutic agents and other types of stress [136]. It involves the Bcl-2 family of proteins which consists of pro- and anti-apoptotic members [137]. The anti-apoptotic members such as Bcl-2 and Bcl-X<sub>L</sub> exist in the mitochondria [138, 139]. Upon receiving the stress signal, the proapoptotic members (bax, bid, bak, PUMA) translocate to the mitochondria and neutralize the anti-apoptotic members by oligomerisation [140]. This results in the permeabilisation of the membrane, resulting in the release of apoptogenic factors such as SMAC/Diablo, cytochrome c, SIMPs and AIF. Cytochrome c binds to Apaf-1 to form the apoptosome resulting in the cleavage of caspase-9 and progression of the cascade *via* the effector caspases [141, 142].

## 2. AIMS AND OBJECTIVES

*C. albicans* is an important pathogen for those afflicted with AIDS and is also of great concern for those undergoing immunosuppressive therapy for cancer or organ transplants. The ability of *C. albicans* to establish a persistent infection is critically dependent on cellular signals that regulate the release of factors from target cells responsible for replication of pathogen. The inflamed host tissue in vulvovaginal candidiasis has been shown to release huge amount of AA, which can be taken up by *C. albicans* and transformed to 3-OH oxylipins. These compounds can have effects on one side related to morphogenesis of the attaching pathogen and on the other side to immunomodulatory activation in host muscle cells. During host cell signaling, significant release of PGE<sub>2</sub> was observed. Because COX-2 is an inducible enzyme, it was highly activated by *C. albicans* infection. Although it was known that COX-2 activation was mediated via NF-κB dependent mechanism, the exact nature of the influence these factors in the pathogenesis of inflammatory fungal diseases are not clear. HeLa cells were chosen because in a previous study we found enhancement of PGE<sub>2</sub> synthesis in HeLa cells upon infection with *C. albicans*. In addition, this model HeLa cell/*C. albicans* closely represents the VVC. Therefore, this study was performed to clarify the host cells signaling by fungal infection at the cellular and molecular level.

Aims and objectives of this study are as follows:

- I.** To define the regulatory network for COX-2 gene expression by *C. albicans* infection in the cervical carcinoma cell line, HeLa. Experiments were aimed at elucidating the signal transduction pathways involved. We focussed on understanding the changes occurring in the chromatin structure, especially histone modifications and the interaction between the various transcription factors and co-activators required for the induction of COX-2 mRNA synthesis.
- II.** To determine the role of PLA<sub>2</sub> enzymes in the host-pathogen-interaction process. We investigated whether the host cell infection requires *Candidal* PLA<sub>2</sub> or host cell PLA<sub>2</sub> or both. We aimed to show the activity and ability of candidial PLB gene (PLA<sub>2</sub> gene analogue in mammalian cells) in the host cells.
- III.** To investigate the nature of the host-pathogen-interaction process with respect to host cell apoptosis during fungal infection. The critical role of iPLA<sub>2</sub> and TLR2 were examined during the host cells apoptosis.

### 3. MATERIALS AND METHODS

#### 3.1 MATERIALS

##### Culture reagents

Fetal bovine serum (FBS), Dulbecco's modified eagles medium (DMEM), Trypsin/EDTA, Streptomycin/penicillin – Seromed (Germany); Yeast nitrogen base, Yeast extract, Tryptone, Peptone, Agar– DIFCO Co (USA).

##### Separation media

Agarose, Silica gel-60, Rotiphorese acrylamide Gel 30 - ROTH (Germany); TLC plates - Merck (Germany).

##### Kits

RNeasy mini kit and QIAshredder - Qiagen (Germany); Protein BCA kit – PIERCE (USA); Chemiluminiscent system - Santa Cruz (Germany); Luciferase reporter assay – Promega (Germany); Polyfect transfection kit- Qiagen (Germany); Cell death detection ELISA – Roche (Germany); PGE<sub>2</sub> ELISA kit - Cayman (USA) Chromatin immunoprecipitation assay kit - Upstate (USA).

##### Inhibitors

Forskolin, Trichostatin A and Pyrrolidine Dithiocarbamate (PDTC) – Sigma (Germany); BEL, MAFP and AACOOFCF3 - Cayman (USA); H89 and SB203580 - Calbiochem (Germany); NS398 – Cayman (USA); Wortmannin - Biomol (Germany); Propranololhydrochlorid (PAP-1) - AstraZeneca GmbH (Germany).

##### Antibodies

Actin – Sigma (Germany); histone H3 and H4 and acetyl histone H3 or H4 – Upstate (Germany); TLR2 - eBioscience (UK); HDAC-1, MyD88, COX-2, p65, cRel, iPLA<sub>2</sub> (T-14), cPLA<sub>2</sub>, Protein A agarose, anti-mouse, anti-rabbit, and anti-goat secondary antibodies

conjugated with horse radish peroxidase – Santa Cruz (Germany); iPLA<sub>2</sub> antisera- Cyaman (USA); PKC $\alpha$ -Transduction Laboratories, Inc (USA).

### **RT-PCR reagents**

Expand reverse transcriptase – Roche Biochemicals (Germany); Taq DNA polymerase - Invitrogen (Germany); Pfu turbo polymerase – Stratagene (USA); Platinum Taq polymerase – Invitrogen (Germany); TaqMan assays - Applied Biosystems (Germany).

### **Caspase substrate and inhibitor**

Caspase-3 substrate Ac-DEVD-pNA and inhibitor Z-VAD-FMK – Calbiochem (Germany).

### **Enzymes**

Proteinase K- Roche Biochemicals (Germany); RNase A was from Fermentas (USA).

### **Radiochemicals**

<sup>14</sup>C-Arachidonic acid (55 mCi/mmol); 1-palmitoyl-2-[1-<sup>14</sup>C]-palmitoyl-*sn*-glycero-3-phosphorylcholine) and  $\alpha^{32}$  P- dCTP was from NEN (Germany).

### **Primers**

All primers were purchased from TIB Biomol (Germany).

### 3.2 MEDIA AND BUFFERS

#### **LB medium**

10 g/L Tryptone

5 g/L Yeast extract

5 g/L NaCl

The pH was adjusted to 7.2 and autoclaved.

#### **Universal medium for yeast: (dl)**

Yeast extract            0.3

Malt extract            0.3

Peptone                 0.5

Glucose                 1.0

Agar                     1.5

pH 5.6

#### **YPD medium: (dl)**

Peptone                 2.0

Yeast extract           1.0

Glucose                 4.0

pH 7.4

### 3.3 METHODS

#### 3.3.1 Mammalian cell culture

HeLa (DSMZ, Braunschweig, Germany) were cultured in Dulbecco's modified eagle's medium (DMEM) supplemented with 10 % fetal bovine serum, 50 U/ml penicillin, and 50 µg/ml streptomycin and incubated at 37 °C with 5 % CO<sub>2</sub>. Before starting experimental procedure cells were incubated in DMEM medium containing maximum 1 % FBS for over night. For microscopic examination the cells were grown on cover slips to 60-70 % confluence.

#### 3.3.2 Basal culture conditions for *C. albicans*

*C. albicans* was suspended in YPD containing 2 % peptone and grown in a rotary shaker at 150 rpm for 12 h at 37 °C. The cells were separated from the medium by centrifugation at 3000 × g for 5 min, washed three times with phosphate-buffered saline (PBS) and finally resuspended in 1 ml fresh medium of proper composition for the respective experiments.

#### 3.3.3 Infection of HeLa cells with *C. albicans*

*C. albicans* 1386 was grown at 37 °C for 12 h. Cells were centrifuged at 3000 x g and washed three times with PBS and suspended in DMEM containing 1 % FBS. HeLa cells (2 x 10<sup>6</sup>) were taken as a monolayer in 25 mm<sup>2</sup> in DMEM medium containing 1 % FBS and infected by above prepared *Candida* cells. For the inhibitor studies, a stock solution was diluted in the culture medium and preincubated with HeLa cells for one hour with each inhibitor at appropriate concentrations.

### 3.4 Phospholipase A<sub>2</sub> assay

Pure substrates, 1-Palmitoyl-2-arachidonoyl phosphatidyl choline (PAPC) and PAPC-OH were prepared as described previously by Chaitidis *et al.* (1998). Each substrate at a concentration of 25 µM, was dissolved in the assay buffer containing 10 mM Tris-HCl, pH 8, 180 mM NaCl, and 5 mM CaCl<sub>2</sub> by sonication for five minute. *C. albicans* cells were broken down mechanically using protein lysis buffer containing aluminium or glass beads with sonication on ice, and centrifuged at 5000 x g for 10 min. to remove the cell debris. 50 µg protein of *Candida albicans* lysate was added to the assay buffer and was incubated for one hour, the pH was adjusted to 3.5

and extracted using ethyl acetate. Products were analysed by reverse-phase HPLC using solvent system, methanol: acetonitrile: water 90:6:4 with 20 mM choline chloride. The column used was a Nucleosil 1005 C8 column (250 x 4.6 mm, Macherey and Nagel, Germany). The detection was performed with a diode array detector SPD-M10A (Shimadzu, Japan) at wavelengths 210 and 235 nm.

### **3.5 iPLA<sub>2</sub> enzyme activity assay**

iPLA<sub>2</sub> activity was assayed using established methods [143]. Briefly, cell homogenates were prepared in 10 mM HEPES (pH 7.4), 0.34 M sucrose, 1 mM EDTA, 1 mM DTT, 10 µg/ml leupeptin, 10 µg/ml aprotinin, 1 mM phenylmethylsulfonyl fluoride (assay homogenization buffer) by sonication on ice. Each assay contained 400 µM Triton X-100, 100 µM dipalmitoylphosphatidylcholine (DPPC) (containing 400,000 cpm 1-palmitoyl-2-[1-<sup>14</sup>C] palmitoyl-*sn*-glycero-3- phosphorylcholine), 100 mM Hepes, pH 7.5, 5 mM EDTA, and 0.1 mM ATP in a final volume of 500 µl. Assays were started by adding cell homogenates (250 µg) and incubating at 40 °C for 45 min with agitation. The released [<sup>14</sup>C] fatty acid was extracted according to the method of Dole [144] and quantified by reading radioactivity on a scintillation counter. Control reactions lacking enzyme were routinely carried out and subtracted from the reported activities.

### **3.6 Release of Arachidonic acid by *Candida albicans***

HeLa cells were grown in 75 cm<sup>2</sup> flask and were labelled with 1 µCi [1-<sup>14</sup>C] AA for 18 h. Cells were washed three times with PBS, and lysed with RIPA buffer on ice for 30 min as whole cell lysate. *C. albicans* cells were washed with PBS and lysed using a lysis buffer containing 1.2 M sorbitol, 10 mg/ml lyticase and aluminium. To the HeLa cell lysate, 0.04 mg of *C. albicans* protein was added and incubated for 1 h. After incubation Bligh and Dyer extraction of lipids was performed. The Lipids were separated by TLC using the solvent diethyl ether: n-hexane: acetic acid 50:50:1 and analysed by radio TLC (automatic TLC linear analyser, Berthold, Berlin, Germany) for the liberated labeled arachidonic acid.

### **3.7 Determination of PGE<sub>2</sub>**

HeLa cells were grown as a confluent monolayer in 6-well plate and pretreated with inhibitors. Infection by *C.albicans* was performed as described above. The reaction was stopped by keeping

the culture on ice. The plate was centrifuged at 2000 x g for 10 min and the supernatant was stored at -80 °C until analysis for PGE<sub>2</sub> by ELISA (Cayman, Ann Arbor, MI). ELISA analysis was performed in triplicate.

### **3.8 Transient transfection of cell lines**

Transient transfection of DNA plasmids and their mutants were performed using polyfect reagent as described earlier [96]. 5 x 10<sup>5</sup> cells were seeded into 6-well plates. The experiment was performed after at least 24 hours of culture. 1.5 µg of plasmid DNA was mixed with 12 µl of polyfect reagent in 100 µl antibiotic and serum free medium and DNA-liposome complexes were allowed to form at room temperature for 15 minutes. The complexes were gently seeded onto the cells and incubated at normal conditions for 24 h. The cells were used for further experiments at the end of this period. For the cotransfection study the ratio of DNA was 9:1. The cells were cotransfected with 0.1 µg of control plasmid pRSVLACZ to normalise for transfection efficiency. Transfection efficiency was determined by performing β-galactosidase assay.

#### **3.8.1 Plasmids**

Plasmids for FADD-DN vector was a kind gift from Dr. Schmitz, M.L (Cancer Research Center, Heidelberg, Germany). IKK-DN plasmid was kindly provided by Dr. Ghosh, S (Yale University, New Haven, USA). TLR2 - DN was kindly provided by Dr. Kirschning, C.J (Immunologie und Hygiene Technical University of Munich, München, Germany) and iPLA<sub>2</sub>β was kindly provided by Dr. Ma, A.Z (Mount Sinai School of Medicine, New York, USA). *C. albicans* wild type and mutants were kind gift from Dr. Agabian, N (University of California, S. Francisco, USA), COX-2 plasmid and promoter constructs were kindly provided by Dr. Prescott, S (University of Utah, Salt Lake city, USA), E1A and mutant oncoprotein were provided by Dr. Hecht, A (University of Freiburg, Germany), Expression vectors for HDAC-1 and Gam-1 and their mutants were generously provided by Dr. Seiser, C (University Institutes at the Vienna Biocenter, Vienna, Austria) and Dr. Chiocca, S (European Institute of Oncology, Milan, Italy), respectively. Other plasmids were constructed in our laboratory by cloning required fragments. All the fragments and the cloning procedure were confirmed by DNA sequencing (SeqLab, Germany).

### **3.9 Western blotting**

#### **3.9.1 Preparation of total protein from cells**

Cells were washed 3 times with ice cold PBS and lysed directly on the plates or flasks after addition of RIPA protein lysis buffer [50 mM TRIS-HCl pH 7.4, 150 mM NaCl, 1 % nonidet P-40 (NP- 40), 0.5 % sodium deoxycholate, 0.1 % SDS, 1 mM EDTA, 1 mM PMSF, 10  $\mu$ M sodium orthovanadate 10 mM, 20  $\mu$ g/ml, leupeptin, 10  $\mu$ g/ml pepstatin A, 20  $\mu$ g/ml of aprotinin]. The cells were scraped and lysed by sonication for 20 seconds on ice using UW70 type dounce homogenizer and kept on ice for 20 min and centrifuged at 10.000 x g for 12 min. The protein concentration was determined using BCA protein assay kit (PIERCE).

#### **3.9.2 SDS-Polyacrylamide gel electrophoresis and immunoblotting**

10-12 % SDS Polyacrylamide gel was prepared according to the following recipe: for separating gel of 10 ml volume: 4 - 3.3 ml of distilled water, 2.5 ml of 1.5 M Tris-HCl (pH 8.8), 3.3 – 4.0 ml of 30 % Polyacrylamide mix (37.5 : 1 ratio of mono and bis acrylamide), 100  $\mu$ l of 10 % SDS, 100  $\mu$ l 10 % ammonium persulphate (APS) and 4  $\mu$ l N, N, N', N' tetramethylethylenediamine (TEMED). For 5 ml of stacking gel: 3.4 ml of distilled water, 630  $\mu$ l of 1 M Tris-HCl (pH 6.8), 830  $\mu$ l 30 % polyacrylamide mix, 50  $\mu$ l 10% SDS, 50  $\mu$ l 10 % APS and 5  $\mu$ l TEMED. The gel was cast in MiniProtean III apparatus (BioRad, Germany). The protein samples were mixed with SDS sample solution (Rotiload, Roth, Germany) and boiled for 5 minutes for complete denaturation. This mixture was loaded onto the gel and electrophoresed. Immunoblotting was performed utilising the semi-dry transfer method. Nitrocellulose membrane (Schleich and Schuell, Germany) and 6 layers of Whatman 3 paper were cut exactly to the size of the gel and soaked in transfer buffer along with the gel. A stack was made with 3 sheets on the top and bottom of the gel and membrane and placed in between the graphite plates of the transfer apparatus (Biometra, Germany). Transfer was performed at 0.8 mA/cm<sup>2</sup> current for 1 hour. The efficiency of the transfer was confirmed by staining the membrane with a 0.1 % solution (containing 1 % acetic acid) of Ponceau S (Sigma, Germany). The excess stain was removed with water. After visualisation of the protein, the blot was completely washed off the stain with water and put into blocking solution (5 % nonfat milk powder in PBS containing 0.05 % tween 20) for 1 h at room temperature or over night at 4 °C. The blots were then incubated in the blocking solution containing 1: 500 –1:1000 dilution of the primary antibody for 1 h at RT. After washing

with wash buffer (PBS containing 0.05 % tween 20) for 10 minutes, the blot was incubated with the secondary antibody (against the species of the primary antibody and linked to horse radish peroxidase) (1:2000 dilution) for 1 h at RT. After 3 washes of 5 minutes each with wash buffer, the specific bands were developed using Chemiluminiscent system (Santa Cruz, Germany). Equal volumes of solution A and B were mixed and the blot was incubated in this solution for 1 minute. The blot was immediately exposed to an X-Ray film in dark for varying periods of time ranging from 5 sec to 2 min and developed automatically. The specific bands were scanned and quantified densitometrically using TINA version 2.09 g. All immunoblots were sequentially incubated with anti- $\beta$ -actin as control, and specific signals adjusted in relation to the expression of this house-keeping gene.

### **3.9.3 Nuclear extract preparation**

Cells were washed with ice cold PBS, scraped and pelleted at 10.000 x g, 4 °C. The pellet was resuspended in 400  $\mu$ l of hypotonic buffer (10 mM HEPES, pH 7.9, 1.5 mM MgCl<sub>2</sub>, 10 mM KCl, 0,5 mM DTT, 1 mM PMSF) and incubated on ice for 15 minutes. Simultaneously, cells were lysed by addition of 100  $\mu$ l of 2.5 % NP40. Nuclei were pelleted for 1 minute at 2000 x g at 4 °C. The nuclear pellet was resuspended in 50  $\mu$ l extraction buffer (20 mM HEPES, pH 7.9, 0.48 M NaCl, 1.5 mM MgCl<sub>2</sub>, 0.2 mM EDTA, 25 % glycerol) and incubated for 30 minutes on ice. Nuclei were pelleted by centrifugation for 10 min at 12000 x g. For long term storage, the supernatant was mixed with 50  $\mu$ l of freeze buffer (20 mM HEPES, pH 7.9, 0.1 mM KCl, 0.2 mM EDTA, 20 % glycerol) and stored at -70 °C

### **3.10 Immunoprecipitation**

Immunoprecipitations were performed by incubating the protein extracts (500  $\mu$ g ) or 500-1000  $\mu$ l whole cell lysate [which should be precleared with protein A/G agarose (in 1 ml cell lysate + 100  $\mu$ l A/G agarose slurry 50 % beads ) for 30 min at 4 °C], with 2 – 4  $\mu$ g of the primary antibody for 2 hours or overnight at 4 °C. The immune complexes were captured with protein-A agarose (Santa Cruz, Germany) for 1-2 hours at 4 °C. The beads were spun down (2500 x g, 2 min, 4 °C), washed 3 times with RIPA buffer (1 % NP-40, 0.5 % deoxycholate, and 0.1 % SDS in PBS) and the immune complex released by boiling in SDS sample solution. The complex was then electrophoresed. The proteins were eluted from the beads with 2 x SDS sample buffer and western blot analysis was performed.

### **3.11 Chromatin immunoprecipitation**

Formaldehyde was added to the cells at a final concentration of 1 % and incubated for 30 minutes at 37 °C. The reaction was stopped by the addition of glycine to a final concentration of 0.125 M. The cells were washed with cold PBS containing protease inhibitors and harvested. The nuclear extract was prepared according to Dignam *et al.* [145] and sonicated on ice at maximal power for 30 seconds twice to shear the genomic DNA. Immunoprecipitations were performed with various antibodies. Crosslinking was reversed in the immunoprecipitated complexes by the addition of NaCl to a final concentration of 200 mM and incubation at 65 °C for 6 hours. The DNA was purified by proteinase K treatment (150 µg/ml) for 1 h followed by phenol/chloroform extraction chloroform washing and precipitation by ethanol. The presence of specific promoters was detected by PCR with specific primers. The extract aliquoted prior to the immunoprecipitations was used to prepare control input genomic DNA, which was also used for PCR analysis.

### **3.12 RNA preparation**

Total RNA was prepared using RNAsy kit, from Qiagen, Germany. Cells were washed 3 times with PBS and lysed in 350 µl RNA lysis buffer and sonicated at maximum wattage for 30 seconds. The lysate was mixed with equal volumes of 70 % ethanol and loaded onto the column. The column was spun at maximum speed for 15 seconds at RT. The column was then washed with RW1 and RPE buffer and RNA was eluted in 30-50 µl RNase free water by centrifugation and stored at -80 °C.

#### **3.12.1 Reverse transcription and polymerase chain reaction (RT-PCR)**

Reverse transcription was performed using 2-4 µg of RNA, which was denatured at 65 °C for 10 minutes. 50 pmoles of random hexamer primer and 1 µl of AMV reverse transcriptase (Roche, Germany) was added to reaction buffer (1.5 mM MgCl<sub>2</sub>, 1.0 mM dNTPs, 10 mM DTT). The reaction was performed at 42 °C for 1 h. 1/20th of the resultant cDNA was used in the subsequent PCR reaction. PCR was performed with 5 pmoles of forward and reverse primer, 200 µM of each dNTP and 1 U of Taq polymerase. GAPDH primers were used to perform control reactions to quantitate the product formed. Negative and positive controls were used with each set of PCR reaction. The primers and reaction conditions are listed below:

Homo sapiens phospholipase A<sub>2</sub>, group VI (cytosolic, calcium-independent) gene:

5' AATACCTTCAGTGGCGTCAC 3'

5' CTGATGATACGGCTGTGATG 3'

94 °C 3 min; 94 °C 1 min, 54 °C 1 min, 72 °C 1 min for 30 cycles; 72 °C for 7 min; 4 °C.

Human phospholipase A<sub>2</sub>, group IVA (cytosolic, calcium-dependent) gene:

5' CCAAAGTGACAAAGGGGGCC3'

5' GCTACCACAGGCACATCACG3'

94 °C 3 min; 94 °C 1 min, 59 °C 1 min, 72 °C 1 min for 25 cycles; 72 °C for 7 min; 4 °C.

Human cyclooxygenase-2 gene:

5' GTCACAAGATGGCAAATGCTG3'

5' TAAGATAACACTGCAGTGGCTC3'

94 °C 3 min; 94 °C 1 min, 52 °C 1 min, 72 °C 1 min for 30 cycles; 72 °C for 7 min; 4 °C.

Human cyclooxygenase-2 promoter:

5' CAAGGCGATCAGTCCAGAAC3'

5' GGTAGGCTTTGCTGTCTGAG3'

94 °C 3 min; 94 °C 1 min, 55 °C 1 min, 72 °C 1 min for 35 cycles; 72 °C for 10 min; 4 °C.

Human Toll-Like receptor-2 gene:

5' GCCAAAGTCTTGATTGATTGG3'

5' TTGAAGTTCTCCAGCTCCTG3'

94 °C 2 min; 95 °C 40 s, 54 °C 40 s, 72 °C 1 min for 24 cycles; 72 °C for 7 min; 4 °C.

Human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene:

5' TCCATGACAACCTTTGGTATCGTGG3'

5' GACGCCTGCTTCACCACCTTCT3'

95 °C 2 min; 94 °C 30 s, 62 °C 30s, 72 °C 30 s for 40 cycles; 72 °C for 10 min; 4 °C.

The PCR mixture was mixed with DNA loading buffer and electrophoresed in 2 % agarose gel in 1 x TBE at 7 volts/cm of gel. DNA was visualised under UV after staining the gel with 0.5 µg/ml ethidium bromide.

### 3.12.2 Real-time quantitative PCR

Relative levels of mRNA were quantified with real-time, quantitative RT-PCR using fluorescent TaqMan technology. The TaqMan assay ID for iPLA<sub>2</sub> (Hs 00185926), for COX-2 (Hs 00153133) or for TLR2 (Hs 00152932 ) from Applied Biosystems were used . Equal amounts of total RNA

were reverse transcribed with the TaqMan Reverse Transcription Reagents (Applied Biosystems, Weiterstadt, Germany) according to the manufacturer's instructions using random hexamers. All samples that were compared were reverse transcribed from the same reverse transcription master mix in order to minimize differences in reverse transcription efficiency. Negative control reactions omitting the reverse transcriptase were also performed. The fluorogenic hybridization probes (i.e., TaqMan probes) were labelled with the quencher dye TAMRA attached to the 3' end and the reporter dye FAM (6-carboxyfluorescein) covalently linked to the 5' end of the oligonucleotide (Applied Biosystems). 18s RNA was used as an endogenous control to normalize the amount of sample RNA (TaqMan Ribosomal RNA Control Reagents, Applied Biosystems). The PCR was performed in the GeneAmp 5700 sequence detection system (Applied Biosystems) using the TaqMan Universal PCR Master Mix (Applied Biosystems) according to the manufacturer's protocol. Each reaction (total volume 25  $\mu$ l) for the quantification of iPLA<sub>2</sub> contained 50 ng RNA equivalents as well as 400 nM forward primer, 400 nM reverse primer and 200 nM TaqMan probe. For the quantification of 18S RNA, 25 ng RNA equivalents, 100 nM forward primer, 100 nM reverse primer, and 50 nM TaqMan probe were used. The reactions were performed in MicroAmp 96-well plates capped with MicroAmp optical caps (Applied Biosystems). The reactions were incubated at 50 °C for 2 min, at 95 °C for 10 min followed by 45 cycles of 15 s at 95 °C and 1 min at 62 °C. Each sample was measured in triplicate. The comparative Ct method was used for relative quantification. The amount of target, normalized to 18S RNA and relative to a calibrator, is given by  $2^{-\Delta\Delta Ct}$ , where Ct is the cycle number at which the fluorescence signal of the product crosses an arbitrary threshold set within the exponential phase of the PCR, and  $\Delta\Delta Ct = (Ct_{\text{target (unknown sample)}} - Ct_{18S \text{ (unknown sample)}}) - (Ct_{\text{target (calibrator sample)}} - Ct_{18S \text{ (calibrator sample)}})$  the  $\Delta\Delta Ct$  calculation for the relative quantification could be used without running standard curves [146].

### **3.13 Reporter assay**

The cells were washed twice with ice-cold PBS and lysed with 200  $\mu$ l luciferase lysis buffer (Promega, Germany). The lysis was completed by freezing and thawing. After centrifugation at 12000 x g for 2 min at 4 °C the supernatant was assayed for luciferase and  $\beta$ -galactosidase activity according to manufactures instruction.

### **3.13.1 Luciferase assay**

The luciferase assay was performed by vortexing 5  $\mu$ l of the extract with 50  $\mu$ l of luciferase assay solution (Promega, Germany). The bioluminescence was measured by scintillation counting.

### **3.13.2 $\beta$ -galactosidase assay**

For quantification of  $\beta$ -galactosidase activity, 50  $\mu$ l of the above prepared extract was incubated at 37 °C for 10 min, then 100  $\mu$ l of pre-warmed 4 mg/ml o-nitrophenyl para-D-galactopyranoside (ONPG) in 0.1 M sodium phosphate buffer (pH 7.5) was added. After a suitable (2-3 h) reaction time, 300  $\mu$ l of 1 M Na<sub>2</sub>CO<sub>3</sub> was added, and the absorbance of the solution was measured at 420 nm with a spectrophotometer. The  $\beta$ -galactosidase activity was expressed as ONPG unit (1 unit: the activity producing 1 mmol o-nitrophenol per minute normalised against the inoculated cell number). The  $\beta$ -galactosidase activity was determined as the average value from triplicate dishes under the same transfection conditions.

## **3.14 ASSAYS FOR APOPTOSIS**

### **3.14.1 Nuclear staining**

HeLa cells were grown on coverslips and infected with *C. albicans* as described before. After washing by PBS, the cells were fixed by 4 % paraformaldehyde for 15 min at room temperature and washed again with PBS. The solution containing DAPI (1:1000 dilution in PBS ) was added and incubated for 2 min at RT. After washing the cells with PBS and water, the nuclei were observed under fluorescence microscope at 350 nm.

### **3.14.2 Cell Death Detection ELISA**

The Cell Death Detection ELISA kit (Roche Biochemicals, Germany) was used to quantify the apoptosis in cells. 4 x 10<sup>5</sup> cells were plated on 6-well plates in DMEM medium. The plates were first centrifuged for 10 min at 2000 x g and after removing supernatant the cells were lysed for 30 min by a hypotonic solution added directly onto the 6-well plate. The cytoplasmic extract was incubated with anti-histone and anti-DNA antibodies. The complexes bound to the ELISA plate were quantified using horse radish peroxidase enzyme and DTNB reagent. Effectors or inhibitors

of apoptosis were added, and apoptotic cell death was determined after incubation for various time periods.

### **3.14.3 DNA ladder fragmentation assay**

HeLa cells ( $1.5 \times 10^7$ ) in 10 ml medium were incubated with *C. albicans* at a MOI of 5. After incubation the cells were lysed by addition of 500  $\mu$ l hypotonic lysis buffer containing 10 mM Tris, 1mM EDTA, 0.25 % NP-40 (pH 7.4) for 20 min on ice. The cell debris was removed by centrifugation at 12.000 x g for 15 min. The supernatant was treated with RNAse (100  $\mu$ g/ml) at 50 °C for 1 h, followed by the treatment with proteinase K (100  $\mu$ g/ml) at 37 °C for 1 h. DNA was extracted using phenol-chloroform-isoamyl alcohol (50:49:1) three times followed by a chloroform wash. DNA was precipitated with 100 % ethanol containing 1/10 % 3 M sodium acetate and separated by electrophoresis in 2 % agarose gel. In a parallel experiment 1  $\mu$ M staurosporin was added to HeLa cells for 12 h as a reference positive control.

### **3.14.4 Caspase-3 assay**

The Caspase-3 assay was performed using Ac-DEVD-pNA as substrate. Cells were lysed with lysis buffer (50 mM HEPES, pH7.4, 100 mM NaCl, 0.1 % CHAPS, 1 mM DTT, 100  $\mu$ M EDTA, 1 mM PMSF, 20  $\mu$ g/ml leupeptin, 20  $\mu$ g/ml aprotinin) and centrifuged at 10.000 x g for 10 min. 100  $\mu$ g of protein were incubated with 200  $\mu$ M solution of Ac-DEVD-pNA (Calbiochem, Germany) in a reaction buffer (lysis buffer with 10 mM DTT and 10 % glycerol) at 37 °C. The development of yellow colour at 405 nm indicated caspase-3 activity. The reaction was monitored periodically for 1-3 hours. The rate of reaction was calculated as the difference in the absorbance at 405 nm per unit time. The results were represented as fold increase in caspase-3 activity over the control reactions. Z-VAD-FMK (Calbiochem, Germany) was used as inhibitor of caspase-3 at the concentrations of 100  $\mu$ M an hour prior to standard treatment.

### **3.16 Statistics**


All experiments were repeated at least three times and only the representative pictures are shown. The data are presented as mean  $\pm$  SD of after three separate experiments. Statistical comparisons between groups were made using Student's test for paired observations. Significance was achieved at  $p < 0.05$  level. All calculations were performed using [www.graphpad.com](http://www.graphpad.com).

## 4. RESULTS

### 4.1 Activation of COX-2 gene

#### 4.1.1 *C. albicans* induces transcriptional activation of COX-2 in HeLa cells.

In a recent report from Dr. Nigam's laboratory Deva *et al.* [96] showed that *C. albicans* can selectively inducing COX-2 mRNA and protein expression. However, they did not find any change in the COX-1 expression. Interestingly, these authors reported enhancement of mRNA expression upto 24 hours, whereas the protein levels reached maximum at 6 hours. This discrepancy between COX-2 protein and COX-2 mRNA expressions was attributed to posttranscriptional regulation of the COX-2 gene, in which RNA-binding proteins were presumably bound to the 3'-untranslated region of the COX-2 mRNA to abrogate its translation. Since it is known that semiquantitative RT-PCR in certain cases may not reflect the true mRNA expression, we verified the observation of Deva *et al.* [96] with quantitative real-time PCR. Upon infection of HeLa cells with *C. albicans* at MOI 5 for various periods of time, we found a gradual time dependent decrease in COX-2 mRNA expression (Fig. 1), which is consistent with several reports cited in the literature.




**Figure 1. Relative level of COX-2 mRNA expression induced by *C. albicans*.** HeLa cells were infected with *C. albicans* for different time periods and total RNA was extracted. 2  $\mu$ g of RNA was reverse transcribed and quantified using real-time PCR the fluorescent TaqMan technology. 18S RNA was used as an endogenous control to normalize the amount of RNA. For further experimental details, see materials and methods. Values represent the mean  $\pm$  SEM of 3 separate experiments.

Following infection the COX-2 mRNA reached maximum at 6 hours, which was almost 32 fold of the basal level. As can be seen in Figure 1 the COX-2 mRNA declined in dependence of time reaching a steady level at 24 hours (2.5 fold) of the control. This clarifies the divergence between PCR -based reports on COX-2 mRNA and protein expression by Deva *et al.* [96].

#### 4.1.2 Is COX-2 activation mediated by PGE<sub>2</sub>?

Deva *et al.* [96] reported earlier that initially synthesized PGE<sub>2</sub> by *Candida*-infected HeLa cells may exert an autocrine affect and function as trigger for further induction of COX-2. To investigate this we pre-and cocubated HeLa cells with 100 nM PGE<sub>2</sub> prior to infection with *C. albicans*. No additional upregulation of the COX-2 gene was observed by PCR (Fig. 2). To investigate if PGE<sub>2</sub> receptors on activation by PGE<sub>2</sub> participate in transactivation of EGF receptors, we also cocubated HeLa cells with 100 ng/ml of EGF and measured the upregulation of COX-2 by PCR.




**Figure 2. The expression of COX-2 was not influenced by PGE<sub>2</sub> and EGF.** Cell were exposed to PGE<sub>2</sub> (100 nM) or EGF (100 ng/ml) along with infection by *C. albicans* for 6 hours. Total RNA was extracted and 2 µg RNA was assayed by RT-PCR for COX-2 mRNA detection.

In our hands, we were unable to detect any additional induction of COX-2 gene by cross talk between PGE<sub>2</sub> and EGF receptors.

#### 4.1.3 Activation of COX-2 is dependent from cAMP expression.

COX-2 gene promoter is known to contain cAMP responsive elements, NF- $\kappa$ B and NF-IL-6 [95, 97]. Therefore, we investigated whether increasing cAMP levels would enhance the COX-2 expression. HeLa cells were preincubated with forskolin, a direct activator of adenylyl cyclase, before challenging with *C. albicans*. Cells were harvested after 6 hours, and total proteins were extracted and immunoblotting was performed. As Figure 3 shows, forskolin has slightly increased COX-2 expression when compared with unstimulated cells. When cells were pretreated with PKA inhibitor H89 (10  $\mu$ M) and forskolin, *C. albicans* did not increase the COX-2 expression, which is indicative of important role of cAMP-mediated activation of COX-2 gene.




**Figure 3. The COX-2 activation is dependent on the activation of cAMP.** Cells were exposed to forskolin (20  $\mu$ M) alone or together with H89 (10  $\mu$ M) along with infection *C. albicans* for 6 hours. COX-2 expression was assayed by western analysis as described in material and methods.

#### 4.2 NF- $\kappa$ B activity in HeLa cells infected by *C. albicans*.

Inasmuch as PDTC, a free radical scavenger, has been shown to suppress the activation of COX-2 gene, it was implicated that NF- $\kappa$ B is involved in the upregulation of COX-2 gene [96]. This role of NF- $\kappa$ B in the activation of COX-2 gene was confirmed by transfection of pNF- $\kappa$ B Luc plasmid and mutants of IKK and I $\kappa$ B $\alpha$  [96]. After challenging transfected cells with *C. albicans* for 6 hours significant inhibition of NF- $\kappa$ B and COX-2 promoter activities were observed. To dissect and verify these data we performed western analysis specifically of the p65 subunit of NF- $\kappa$ B and cRel. After stimulation with *C. albicans*, I $\kappa$ B $\alpha$  is cleaved and phosphorylated by IKK complex and then degraded by the 26S proteasome [106, 107]. The p65 subunit of NF- $\kappa$ B translocates to the nucleus, where it docks to DNA binding sites within the

promoter region of the target genes. Upon infection of HeLa cells by *C. albicans* (MOI 5) p65 NF- $\kappa$ B rapidly increased in about 3 hours and its level was almost maintained till 12 hours, then markedly decreased to below the basal level at 18 hours. Moreover, the cRel subunit of NF- $\kappa$ B, which is responsible for the growth of the cell and whose deficiency in various cell types may lead to apoptosis [103, 104], increased significantly after 3 hours and remained stable till 18 hours. These data suggest the stimulatory role of NF- $\kappa$ B in the activation of COX-2 gene. Since cRel has been shown to be stimulated by catalytic subunit of PKA (PKA-C $\beta$ ), possibly through the interaction with p300/CBP, we can assume a vital role of cRel in cell proliferation and COX-2 activation in *Candida*-infected cells.




**Figure 4. Time course analyse of NF- $\kappa$ B.** HeLa cells were infected with *C. albicans* for indicated periods of time. Whole cell lysate was prepared and 50  $\mu$ g proteins were used for western blotting. Immunoblotting was performed as described in materials and methods.

#### **4.3 Suppression of HDACs upregulate the COX-2 and NF- $\kappa$ B expression in *Candida*-infected HeLa cells.**


Regulation of nuclear histone acetylation is emerging as a crucial mechanism for controlling gene expression. However, the degree of histone acetylation depends on the activity of histone deacetylases. That means, acetylation of histones is controlled by HAT and HDAC activity. In stimulated cells thus exists an equilibrium state of acetylation and deacetylation processes. Any disturbance by inhibitor or coactivator of either process may shift the equilibrium in either direction. To investigate if histone acetylation induced by coactivator p300/CBP, which displays

strong HAT activity, is important for *C. albicans* induced COX-2 expression, we performed experiment with viral oncoprotein E1A, which has been identified as an endogenous inhibitor of p300/CBP, and its mutant E1AmCBP. Figure 5 shows that acetylation of histone by p300/CBP was completely inhibited by the E1A. However, cells transfected with E1AmCBP did not restore completely the COX-2 promoter activity.



**Figure 5. Involvement of HAT on COX-2 promoter activity.** HeLa cells were transfected with E1A and COX-2 or CBPmE1A and COX-2 promoters as described before. After 24 hours of transfection cells were infection by *C. albicans* for 6 hours. Cell lysate were analysed for luciferase activity of COX-2 promoter, and values reported as mean RLU  $\pm$  SD (n=3)

But, suppressors of HDAC activity showed likewise that they act synergistically with *C. albicans* or may even induce COX-2 expression without fungal infection. To verify this, HeLa cells were transfected with COX-2 promoter or NF- $\kappa$ B Luc plasmid ligated to luciferase vector, and treated with HDAC inhibitor trichostatin A (TSA), a specific inhibitor of multiple HDACs, and luciferase activity for both NF- $\kappa$ B and COX-2 promoters was measured after infection with *C. albicans*.




**Figure 6. Inhibition of HDAC activity caused an increase of COX-2 and NF-κB promoter activity.** HeLa cells were transfected with COX-2 and NF-κB promoters as described before. After 24 hours of transfection cells were treated with TSA (200 nM) for 18 hours before infection by *C. albicans* for 6 hours. Cell lysate were analysed for luciferase activity of COX-2 and NF-κB promoters, and values reported as mean RLU  $\pm$  SD (n=3)

Figure 6 shows that TSA alone induced both promoter activities, almost 10-fold for COX-2 and 20-fold for NF-κB over the basal value. The stimulation of promoter activities in *Candida*-infected cells was found to be almost 2.5 fold for COX-2 and about 4-fold for NF-κB. Moreover, inhibition of HDAC by TSA in *Candida*-infected cells increased COX-2 5.5-fold and NF-κB more than 10-fold. These findings suggest that repression of the inducible enzyme COX-2 in unstimulated cells maybe due to the dominance of deacetylation process over the acetylation process.

#### 4.3.1 Specific role of HDAC in the activation of NF- $\kappa$ B promoter by *C. albicans* is dependent on the upregulation of IKK activity.

In Figure 6 we showed that TSA stimulated COX-2 activity in infected cells was increased by 5.5- fold but NF- $\kappa$ B activity was increased by 10-fold. This discrepancy led us to investigate if IKK activation in unstimulated and stimulated cells is caused by TSA. Therefore, we cotransfected HeLa cells with NF- $\kappa$ B and IKK dominant negative plasmid and measured NF- $\kappa$ B promoter activity in cells preincubated with TSA before challenging with *C. albicans*. Indeed, *Candida*-stimulated NF- $\kappa$ B expression was completely abolished in IKK-DN-transfected cells (Fig. 7). Moreover, TSA treatment did not cause the gene upregulation in these cells. This finding clearly pinpoints the specific role of IKK in relation to HDAC.




**Figure 7. Inhibition of IKK activity causes a decrease of NF- $\kappa$ B activity.** HeLa cells were cotransfected with IKK-DN and NF- $\kappa$ B promoters as described before. After 24 hours of transfection cells were treated with TSA (200 nM) for 18 hours before infection by *C. albicans* for 6 hours. Cell lysate were analysed for luciferase activity of NF- $\kappa$ B promoter, and values reported as mean RLU  $\pm$  SD (n=3)

#### 4.3.2 Gam-1 inhibits COX-2 and NF- $\kappa$ B activity by HDAC-1 in infected cells.

Gam-1 is an avian CELO adenovirus early gene product, which does not show any homology to known proteins, and has been reported to be an important inhibitor of HDAC [147]. Gam-1 has been shown to stimulate several target genes by inactivating HDAC-1 [147]. To assess Gam-1

mediated transcriptional upregulation of COX-2 and NF- $\kappa$ B genes, we transfected HeLa cells with Gam-1 or Gam-1 mutant plasmids and challenged with *C. albicans*.




**Figure 8. Inhibition of HDAC-1 activity causes an increase of COX-2 and NF- $\kappa$ B activity.** HeLa cells were cotransfected with COX-2 and Gam-1 or NF- $\kappa$ B and Gam-1 and after 24 hours of transfection cells were infected by *C. albicans* for 6 hours at MOI 5. Cell lysate were analysed for luciferase activity of COX-2 and NF- $\kappa$ B promoters, and values reported as mean RLU  $\pm$  SD (n=3)

Figure 8 shows a significant elevation of Gam-1-mediated expression of COX-2 and NF- $\kappa$ B. COX-2 promoter activity was increased by 2-fold over the infected cells, whereas NF- $\kappa$ B promoter activity was augmented 4-fold (Fig. 8). Although both HDAC inhibitors, TSA and Gam-1, enhanced HAT-mediated COX-2 and NF- $\kappa$ B promoter activities, TSA was found to be more potent transcriptional activator than Gam-1. When both inhibitors Gam-1 and TSA were incubated together, we did not observe any additional transcription by Gam-1, which suggests an identical mechanism of action for Gam-1. Furthermore, to check whether Gam-1 directly interacts with HDAC-1, we transfected Gam-1 mutant protein, which has been reported to express reduced binding to HDAC-1, into HeLa cells before infection with *C. albicans*. Whereas wild type Gam-1 strongly stimulated COX-2 and NF- $\kappa$ B promoter activities Gam-1 mutant

protein was almost ineffective. These data are consistent with previous report of Chiocca *et al.* [147] and suggested that Gam-1 directly binds to HDAC-1.

### 4.3.3 Overexpression of HDAC-1 suppressed NF- $\kappa$ B mediated COX-2 activation.

As discussed in 4.3.1- 4.3.3 we can predict regulatory role of HDAC-1 inhibition in the *C. albicans*-mediated transcriptional activation of NF- $\kappa$ B and COX-2. Thus, overexpression of HDAC-1 in cells should suppress the NF- $\kappa$ B and COX-2 expression. To verify this, we transiently transfected HDAC-1 plasmid as well as COX-2 promoter into HeLa cells before challenging with *C. albicans*. Empty vectors for HDAC-1 and COX-2 were transfected into cells to give the controls. This treatment of cells yielded a 4.5-fold induction of the COX-2 promoter activity in the cells transfected with only COX-2 promoter alone. However, the cells overexpressing HDAC-1 reduced the *C. albicans*-mediated induction of the COX-2 gene by more than 60 %. Strikingly, the COX-2 promoter activity in HDAC-1 overexpressed cells was still two-fold over the basal level. This implicates that the regulation of the COX-2 is supported by factors other than HDAC-1.




**Figure 9. Overexpression of HDAC-1 inhibits *C. albicans* induced COX-2 activation.** HeLa cells were transiently corransfected the HDAC-1 reporter gene and COX-2 promoter. After 24 hours of transfection HeLa cells were challenged with *C. albicans* for 6 hours. Cell lysate were analysed for luciferase activity of COX-2 promoter. Values represent the mean  $\pm$  SEM of 3 separate experiments.

#### 4.3.4 Inhibition of HDAC in HeLa cells infected with *C. albicans* caused increase of hyperacetylation of histone H3.

Intracellular balancing of histone acetylation and deacetylation during gene expression and cellular differentiation is crucial event for histone modification [148]. Our previous results showed that inhibition of HDACs caused stimulation of NF- $\kappa$ B-mediated COX-2 expression. It is known that increased histone acetylation increased the transcription of genes.

Therefore, we focussed to identify histone modification, such as acetylation in our system. HeLa cells were treated with TSA (200 nM) for 18 hours and followed by infection with *C. albicans* for 6 hours. Nuclear proteins were extracted as described in materials and methods and were examined by western blot analysis using specific antibodies against acetyl-H3 and acetyl-H4.


As expected, we found that *C. albicans*-infection enhanced the histone H3 acetylation in HeLa cells. Moreover, TSA treatment also resulted a dramatic increase of acetylation of histone H3 as compared with untreated cells. When we checked for acetyl-H4 protein, we did not find any expression of this protein, indicating that no acetylation of histone H4 protein occurred in HeLa cells upon infection with *C. albicans*.



**Figure 10. Treatment by TSA caused a dramatic increase in histone H3 acetylation.** HeLa cells were infected by *C. albicans* with or without preincubation with TSA. Acetyl-H3 was detected by western blotting in nuclear extracts (see materials and methods).

#### 4.3.5 Recruitment of p65 subunit of NF- $\kappa$ B by HDAC-1 in HeLa cells infected by *C. albicans*.


In order to determine if NF- $\kappa$ B p65 and HDAC-1 undergo physical binding in *Candida*-infected HeLa cells we transfected expression plasmids for NF- $\kappa$ B p65 and HDAC-1 into HeLa cells upon infection by *C. albicans* at MOI 5, and coimmunoprecipitations were performed. As shown in Figure 11A, NF- $\kappa$ B p65 was immunoprecipitated with HDAC-1 in cells cotransfected with HDAC-1 and NF- $\kappa$ B p65. From the results, we observed that the p65 subunit of NF- $\kappa$ B was recruited by HDAC-1 upon infection by *C. albicans*. This interaction was dependent if both NF- $\kappa$ B p65 and HDAC-1 were present, because HDAC-1 was not immunoprecipitated with p65 in control cells or in cells transfected with NF- $\kappa$ B p65 or HDAC-1 alone. As a control, an immunoprecipitation and western blotting for HDAC-1 (Fig. 11A, right panel) or NF- $\kappa$ B p65 (Fig. 11B, right panel) from cells transfected with HDAC-1 or NF- $\kappa$ B p65 were performed. Figure 11B shows that HDAC-1 was coimmunoprecipitated with NF- $\kappa$ B p65 in cells transfected with p65 subunit of NF- $\kappa$ B and HDAC-1. The previous observation from the result A was confirmed by this coimmunoprecipitation experiment. Thus, HDAC-1 and NF- $\kappa$ B p65 can interact mutually with each other upon infection for 6 hours by *C. albicans* in HeLa cells.



**Figure 11. Mutual interaction of HDAC-1 and NF- $\kappa$ B p65 upon infection by *C. albicans*.** Initial steps for coimmunoprecipitation experiment with HeLa cells were transfection of NF- $\kappa$ B p65 and HDAC-1 plasmids into cells after 48 hours of transfection, cells were infected with *C. albicans* for 6 hours. Cells were lysed and protein concentration was determined. Total 300  $\mu$ g proteins were used for immunoprecipitation as described in materials and methods.

#### 4.3.6 Binding study of p65 subunit of NF- $\kappa$ B and HDAC-1 to COX-2 promoter in HeLa cells infected by *C. albicans*.

From Figure 11, it was concluded that HDAC-1 and NF- $\kappa$ B p65 can interact with each other in *Candida*-infected cells. It was reported already that COX-2 activation is mediated by NF- $\kappa$ B upregulation. Therefore, the next experiments were aimed at addressing the question of whether or not of these factors can bind to COX-2 promoter *in vivo*. For this purpose we used chromatin immunoprecipitation (ChIP) assay, a powerful technique to determine true *in vivo* finding of transcription factors and other nucleosomal proteins to chromatin in response to an agonist [149, 150]. After the ChIP protocol, gene for COX-2 promoter region was amplified by semiquantitative PCR using specific primers. Figure 12 showed the time-course of *C. albicans* infection effect and it indicates that p65 subunit of NF- $\kappa$ B is recruited to the COX-2 promoter upon 6 hours of infection by *C. albicans*. One interesting result observed is that transcriptional repressor protein HDAC-1 is associated with the COX-2 promoter, and this association was higher in infected cells than in non-infected cells.




**Figure 12. Time course analyse of *C. albicans* mediated binding of p65 NF- $\kappa$ B and HDAC-1 to COX-2 promoter.** HeLa cells were cultured with or without infection *C. albicans* for various time periods. The protein-nucleic acid complexes were immunoprecipitated with anti-p65, or anti-HDAC-1 antibodies. The cross-linked DNA was purified and analysed by PCR for the presence of COX-2 promoter DNA. An aliquot of the complexes was removed before the immunoprecipitations and was similarly processed and used as a control for the PCR reaction. This DNA was referred to as input chromatin.




#### 4.5 Host cell PLA<sub>2</sub> activity during infection by *C. albicans*

It is known, that the first event in the production of prostaglandins is the release of arachidonic acid from membrane phospholipids by PLA<sub>2</sub> [50, 51]. Therefore, it was important to study PLA<sub>2</sub> expression in host cells. cPLA<sub>2</sub> and iPLA<sub>2</sub> were studied by determination of mRNA levels in HeLa cells infected by *C. albicans* for various time periods (Figs. 14A and B). Total RNA was extracted from HeLa cells and mRNA was analysed by semiquantitative and real time RT-PCR.



**Figure 14A and B.** The expression of cPLA<sub>2</sub> and iPLA<sub>2</sub> mRNA were decreased by *C. albicans* infection. HeLa cells were infected with *C. albicans* for indicated periods, cells were harvested and total RNA was extracted. Semi quantitative RT-PCR was performed to detect the A. cPLA<sub>2</sub> and B. iPLA<sub>2</sub>. GAPDH RT-PCR was used to normalize cPLA<sub>2</sub> expression.


Strikingly, as shown in Figure 14B iPLA<sub>2</sub> mRNA level increased after 6 hours of infection by *C. albicans*, while the cPLA<sub>2</sub> expression remained constant. However, cPLA<sub>2</sub> and iPLA<sub>2</sub> expression in HeLa cells decreased markedly after 18 hours of infection by *C. albicans* and disappeared after 24 hours. This iPLA<sub>2</sub> mRNA decrease could be verified by real-time quantitative PCR as shown in Figure 14C.



**Figure 14C. The expression of iPLA<sub>2</sub> mRNA was decreased by *C. albicans* infection.** HeLa cells were infected with *C. albicans* for indicated periods, cells were harvested and total RNA was extracted. Real-time RT-PCR was performed to detect the iPLA<sub>2</sub> as described in materials and methods. 18S RT-PCR was used to normalize iPLA<sub>2</sub> expression. Values represent the mean of 2 separate experiments.

#### 4.5.1 PGE<sub>2</sub> production from host cells infected by *C. albicans* was dependent on iPLA<sub>2</sub> activity.


Earlier reports from Dr. Nigam's group demonstrated that the enhancement of COX-2 protein synthesis coincided with increased PGE<sub>2</sub> formation [96]. Therefore, the very first question to be answered was to find the relation of PLA<sub>2</sub> on PGE<sub>2</sub> production. PGE<sub>2</sub> production was measured in supernatants of HeLa cells-*C. albicans* incubation mixture in the presence or absence of MAFP (inhibitor of both cPLA<sub>2</sub> and iPLA<sub>2</sub>) and BEL, a widely used selective inhibitor of iPLA<sub>2</sub>. The PGE<sub>2</sub> production was completely inhibited by treatment with BEL and MAFP, exhibiting the important role of the PLA<sub>2</sub>, especially iPLA<sub>2</sub>, in the signaling of PGE<sub>2</sub> production (Fig. 15).



**Figure 15. Inhibition of PLA<sub>2</sub> blocked the PGE<sub>2</sub> production in HeLa cells infected by *C. albicans*.** HeLa cells were treated with selective iPLA<sub>2</sub> inhibitor BEL (20 μM) or cPLA<sub>2</sub> and iPLA<sub>2</sub> inhibitor MAFP (25 μM) for 1 hour before challenging with *C. albicans* for 6 hours at MOI 5. The supernatant was collected, and the PGE<sub>2</sub> production was determined by ELISA as described in material and methods. Values represent the mean ± SEM of 3 separate experiments.

#### 4.5.2 Inhibition of iPLA<sub>2</sub> causes reduced activity of PKCα.

Protein kinase C (PKC) is an enzyme which transduces the cellular signals that promote lipid hydrolysis. The key role of PKC as well as p38<sup>MAPK</sup>, which are upstream signals for COX-2 activation and biosynthesis of PGE<sub>2</sub>, is to rapidly phosphorylate several proteins, such as iPLA<sub>2</sub> and cPLA<sub>2</sub>. This is in line with a previous report in which it was demonstrated that iPLA<sub>2</sub>-mediated AA liberation could be downstream of PKC activation in P388D1 cells [77]. Therefore, we examined the effect of BEL, a relatively selective inhibitor of iPLA<sub>2</sub>, on PKCα expression. From the results, we observed that infection by *C. albicans* resulted in a continuous decline of PKCα protein level (Fig. 16). Moreover, the BEL treatment inhibited significantly expression of PKCα even in the control cells and *C. albicans* infection caused a marked decline in infected cells as compared with non-infected cells. This suggests that iPLA<sub>2</sub> activation is mediating PKCα activation and subsequently activation of cPLA<sub>2</sub> and COX-2.




**Figure 16. iPLA<sub>2</sub> inhibition caused decrease in the PKC activity in HeLa cells infected with *C. albicans*.** HeLa cells were pretreated with BEL (20 μM) for 1 hour before infection by *C. albicans* for 12 hours. In addition, untreated cells were challenged directly with *C. albicans* for 6 and 12 hours. The cell lysates were then analyzed for PKCα protein expression using a specific antibody. The amount of protein was normalized by western blotting with β-actin antibody.

#### 4.5.3 iPLA<sub>2</sub> is a key regulator of cPLA<sub>2</sub> and COX-2 activity in HeLa cells challenged with *C. albicans*.

From previous results, it was concluded that the calcium-independent PLA<sub>2</sub> enzyme is an important regulatory element in host cell signaling induced by *C. albicans*. The inhibition of iPLA<sub>2</sub> blocked of PGE<sub>2</sub> production by host cells. Moreover, inhibition by BEL of iPLA<sub>2</sub> decreased the PKCα activity. Therefore, the next series of experiments were aimed at addressing the question of whether or not cPLA<sub>2</sub> and COX-2 expression are dependent on iPLA<sub>2</sub> expression. For this purpose, HeLa cells were cultured and were exposed to *C. albicans* for 6 hours in the presence of iPLA<sub>2</sub> inhibitor BEL (20 μM) for 1 hour. Levels of mRNA for cPLA<sub>2</sub> and COX-2 were analyzed by semiquantitative RT-PCR with specific primers.


Interestingly, COX-2 activation and cPLA<sub>2</sub> expression were completely blocked by the inhibition of iPLA<sub>2</sub> with the selective inhibitor BEL (Fig. 17).



**Figure 17. BEL treatment inhibits the activation of cPLA<sub>2</sub> and COX-2.** Cells were harvested and total RNA was extracted. Semi-quantitative RT-PCR was performed to detect cPLA<sub>2</sub> and COX-2. GAPDH was used to normalize cPLA<sub>2</sub> and COX-2 expression.

#### 4.5.4 Involvement of reactive oxygen species in the activation of iPLA<sub>2</sub>.

Reactive oxygen species (ROS) are also called "free radicals" and are extremely unstable. Radicals quickly react with other molecules or radicals to achieve the stable configuration of 4 pairs of electrons in their outermost shell. Increased ROS formation is the common consequence of many pathologies, including infection and inflammation, and provides a link between signaling pathways and transcriptional elements regulating a large number of genes [151]. The previous report from Dr Nigam's group regarding intracellular glutathione content in HeLa cells, revealed that *C. albicans* infection alone caused a drastic depletion of glutathione, thus enhancing the oxidative stress and consequently remarkably enhancing COX-2 promoter activity [96]. They showed that antioxidants NAC and PDTC strongly inhibited the COX-2 activity [96]. Moreover, we observed that iPLA<sub>2</sub> is an important regulator in host cells signaling with infected by *C. albicans*, it was important to investigate the involvement of ROS in the expression of iPLA<sub>2</sub>. iPLA<sub>2</sub> mRNA was determined by mRNA levels in cells pretreated with NAC (200 μM) or PDTC (25 μM) for 1 hour. These experiments indicated that PDTC and NAC treatment caused inhibition of iPLA<sub>2</sub> mRNA after 6 hours of infection by *C. albicans* (Fig. 18).




**Figure 18. The depletion of ROS and inhibition of oxidative stress suppressed the activation of iPLA<sub>2</sub>.** Cells were harvested and total RNA was extracted. Semi-quantitative RT-PCR was performed to detect the iPLA<sub>2</sub>. GAPDH was used to normalize iPLA<sub>2</sub> mRNA expression.

#### 4.5.5 In vitro binding of NF-κB p65 and iPLA<sub>2</sub> in *Candida*-infected cells.


From the findings so far we can conclude that the inhibition of iPLA<sub>2</sub> represses the expression of cPLA<sub>2</sub>, COX-2 and PKC and therefore, the production of PGE<sub>2</sub>. We have already demonstrated that COX-2 activity is mediated via NF-κB activation. Next, we asked whether iPLA<sub>2</sub> and NF-κB p65 not only functionally but also physically interact in HeLa cells. Therefore, we

investigated the association of iPLA<sub>2</sub> and NF-κB p65 in untreated and *Candida*-infected HeLa cells by immunoprecipitation experiments. iPLA<sub>2</sub> or NF-κB p65 subunit was precipitated from the lysate of cells with or without *Candida*-infection with specific monoclonal antibodies, and were analysed by immunoblotting for iPLA<sub>2</sub> and NF-κB p65. As can be seen in Figure 19A iPLA<sub>2</sub> was found in the precipitate obtained by NF-κB p65 antibody in *Candida*-infected cells (*left panel*). Such an association was absent in uninfected cells. Similarly, NF-κB p65 was detected in the immunoprecipitate obtained by iPLA<sub>2</sub> antibody in *Candida*-infected cells. However, uninfected cells also displayed the physical association of iPLA<sub>2</sub> with NF-κB p65 (*left panel*).



**Figure 19A. Association of iPLA<sub>2</sub> with p65 subunit of NF-κB.** HeLa cells were infected by *C. albicans* for 6 hours. Immunoprecipitation of iPLA<sub>2</sub> or p65 was carried out as described in materials and methods. Samples were subjected to immunoblot analysis with anti iPLA<sub>2</sub> or p65 antibodies.

From these results we assume that iPLA<sub>2</sub> protein may undergo binding with the whole IκBα/p65 complex. To verify this we coimmunoprecipitated IκBα and detected iPLA<sub>2</sub> and thus confirmed our conception (Fig. 19B).




**Figure 19B. Association of iPLA<sub>2</sub> with IκBα.** HeLa cells were infected by *C. albicans* for 6 hours. Immunoprecipitation of IκBα was carried out as described in materials and methods. Samples were subjected to immunoblot analysis with anti iPLA<sub>2</sub> antibody.

## 4.6 *Candida albicans* and host cell apoptosis

### 4.6.1 *Candida albicans* causes apoptosis in HeLa cells.

An earlier report from Ibata-Ombetta *et al.* [152] showed that *C. albicans* causes macrophage death by inducing changes specifically in the MEK-ERK signal transduction pathway. Moreover, it has been demonstrated that *C. albicans*, which was isolated from a HIV-infected individual, induced early apoptotic changes in macrophages that phagocytosed them *in vitro* [153]. In order to see if *C. albicans* can induce apoptosis in human epithelial cells, we infected HeLa cells with *C. albicans* at MOI 5 and cells were assessed for apoptosis by nuclear staining as described in materials and methods. The results showed that HeLa cells underwent significant morphological changes after 24 hours of infection by *C. albicans* (Fig. 20). This method was performed to discriminate between apoptosis and necrosis. Necrosis is a process considered as unprogrammed cell death caused by injury, infection, infarction or inflammation. The basal frequency of apoptosis in control cells was around 1 %, which increased to more than 50 % in *C. albicans*-infected cells.




**Figure 20.** *C. albicans* causes nuclear shrinkage in HeLa cells. Nuclear staining was performed with DAPI after 24 hours of infection by *C. albicans*. The *right panel* shows apoptotic nuclei of HeLa cells as compared with nuclei of uninfected cells (*left panel*).

#### 4.6.2 A kinetic analysis of apoptosis induced by *C. albicans*.

One of the hallmarks of apoptosis is the digestion of genomic DNA by an endonuclease, generating a ladder of small fragments of double-stranded DNA. Therefore, *C. albicans* induced apoptosis was confirmed by a kinetic analysis of genomic DNA ladder fragmentation.


For this HeLa cells were challenged with *C. albicans* for 12 hours, 18 hours, 24 hours and 30 hours periods of time. Although after 12 hours of infection with *C. albicans*, an apoptotic change was observed (Fig. 26A), at this time period no DNA ladder fragmentation was detected (Fig. 21). Apoptosis continued to increase through 30 hours, and DNA fragmentation was detected after 18 hours of infection by *C. albicans* (Fig. 21).



**Figure 21. *C. albicans* induces apoptosis in HeLa cells.** HeLa cells ( $10^7$ ) were treated with *C. albicans* at MOI 5 for 12, 18, 24 and 30 hours. DNA was extracted and electrophoresed on 2 % agarose gel. Bands displayed after infection for 18 hours (lane 3) and longer (lanes 3-5) are indicative of apoptosis, whereas DNA from uninfected and 12 hours infected cells (lanes 1 and 2) remained intact. Staurosporine ( $1 \mu\text{M}$ ) was used as a positive control for 12 hours treatment (lane 6).

#### 4.7 *C. albicans*-induces caspase-3 activation.

Caspase-3 activation, which is fundamental to the execution of apoptosis, was investigated. Caspase-3 mediates the cleavage of multiple substrates to cause the characteristic changes that occur in apoptotic cells. Upon incubation with peptide DEVD-pNA as substrate, increased activity of caspase-3 was found in *Candida*-infected HeLa cells (Fig. 22). This effect was, however, abrogated when cells were preincubated with 100  $\mu$ M Z-VAD-FMK, a specific peptide inhibitor of caspase-3 (Fig. 26C).




**Figure 22. *C. albicans*-induced apoptosis via activation of caspase-3.** The caspase-3 activity of cells was measured using Ac-DEVD-pNA as substrate. Cell lysate (100  $\mu$ g protein) was incubated with 200  $\mu$ M Ac-DEVD-pNA and the reaction was monitored for 1-3 hours at 405 nm. Values represent the mean  $\pm$  SEM of 3 separate experiments.

#### 4.8 TLR2 in HeLa cells are activated by *C. albicans* infection.

##### 4.8.1 *C. albicans*-induced TLR2 activation was not mediated via COX-2, p38 or PI-3 kinases.

Earlier, it was shown that toll-like receptors are involved in the antifungal defence mechanism in *Drosophila* as well as in antibacterial defence in humans [154, 155]. In a previous report from


Dr. Nigam's group, the crucial role of TLR2 in mediating COX-2 gene activation by *C. albicans* was described. Neutralization of TLR2 by mAb specific for human TLR2 completely abolished the COX-2 activation [96]. Therefore, we studied the activation of TLR2 by *Candida* infection in HeLa cells. An increased TLR2 mRNA expression was observed in HeLa cells after 6 hours of infection by *C. albicans*. In order to determine whether this TLR2 activation could be involved in the *Candida*-triggered signaling cascades such as PI-3 and p38<sup>MAPK</sup>, cells were pretreated with inhibitors of PI-3-kinase, p38<sup>MAPK</sup> and COX-1/2, namely wortmannin, SB203190, NS398 and aspirin, respectively, before challenging with *C. albicans*. We found that TLR2 mRNA expression was not affected (Fig. 23).



**Figure 23. *C. albicans* induced TLR2 activation was not mediated via COX-2, p38 or PI-3 kinases.** Cells were pretreated with 10  $\mu$ M wortmannin, 20  $\mu$ M SB203, 10  $\mu$ M NS398 or 1 mM aspirin for 1 hour before challenging with *C. albicans* at MOI 5 for 6 hours. Total RNA (2  $\mu$ g) was extracted, and RT-PCR analysis was performed. PCR was done for TLR2, as well as for GAPDH as a control to ensure that RNA amounts were equal.

#### 4.8.2 TLR2 mRNA activation does not require *de novo* protein synthesis


Since we found TLR2 activation by *C. albicans* infection, it was probable that *de novo* synthesis of additional regulatory factors was required. To test this hypothesis, HeLa cells were challenged with *C. albicans* in presence of cycloheximide (0.07 mM), a protein synthesis inhibitor. Activation of TLR2 mRNA was measured by PCR. As shown in Figure 24 cycloheximide did not affect the activation of TLR2 gene.



**Figure 24. *De novo* protein synthesis was not required for the induction of TLR2 mRNA.** Cells were exposed to cycloheximide (0.07 mM) along with *C. albicans* for 6 hours. TLR2 expression was assayed by RT-PCR.

#### 4.8.3 Downstream signaling activation of TLR2 in HeLa cells infected by *C. albicans*.

The MyD88 adapter protein links members of the TLRs and IL-1R superfamily to the downstream activation of NF- $\kappa$ B and MAPKs. Although originally identified as a myeloid-differentiation marker, MyD88 is now known to play an essential role in the innate immune response of insects and mammals [40, 42]. Therefore, in our study we aimed to determine downstream signaling of TLR2 activation. We performed immunoblotting with specific antibody for activation of MyD88 expression by HeLa cells infected by *C. albicans*. MyD88 activation was detected after 3 hours of infection and was expressed continuously over the period studied (Fig. 25).




**Figure 25. *Candida* infection caused activation of adapter protein MyD88.** HeLa cells were infected with *C. albicans* for various periods. The 50  $\mu$ g cell lysates were analysed by western blotting for the MyD88 and  $\beta$ -actin.

#### 4.9 TLR2 mediates *C. albicans*-induced apoptosis

*Candida*-induced apoptosis in HeLa cells was also measured using cell death detection ELISA. This method assays the presence of DNA-histone nucleosomal complex, which is an indicator of apoptosis, in the cytoplasm. HeLa cells were infected by *C. albicans* at MOI 5 for various times and DNA-histone complexes were detected as early as 12 hours after exposure to *C. albicans* and continued to increase through 24 h and finally declined to basal levels at 48 hours (Fig. 26A). This decrease in apoptosis may result from the recovery of a subpopulation of HeLa cells insensitive to *C. albicans* after 48 hours.


A.



**Figure 26A. *C. albicans* induces apoptosis in HeLa cells.** *C. albicans* was added at MOI 5:1 for various time periods. Cell death detection ELISA experiments were performed with the cell lysates. Significant apoptosis was detected as early as 12 hours and continued to increase until 24 hours. Values represent the mean  $\pm$  SEM of 3 separate experiments.

Furthermore, we examined the specific role of TLR2 in apoptosis. Surface TLR2 were blocked by neutralizing with a monoclonal Ab before infection of cells by *C. albicans* at MOI 5. As shown in Figure 26B, when compared with untreated controls, *C. albicans*-induced apoptosis was significantly inhibited within 24 hours as measured by cell death detection ELISA. The abrogation of apoptosis was also observed when HeLa cells were transiently transfected with TLR2-DN plasmid prior to infection by *C. albicans* (Fig. 26B).


**B.**



**Figure 26B. TLR2 mediated *C. albicans* induces apoptosis in HeLa cells.** HeLa cells were transfected with TLR2-DN or were preincubated for 1 hour with 20  $\mu\text{g/ml}$  monoclonal antibody against TLR2. *C. albicans* was then added at MOI 5:1 for 24 hours. Cell death detection ELISA experiments were performed with the cell lysates.

Moreover, activation of Caspase-3 in *Candida*-infected HeLa cells (Fig. 22) was, however, abrogated when cells were treated with 100  $\mu\text{M}$  of a specific peptide inhibitor of caspase-3 Z-VAD-FMK for 1 hour (Fig. 26C). The activation of caspase-3 requires the recruitment of Fas-associating death domain (FADD) containing protein and Apaf-1 [156]. FADD in turn recruits caspase-8 and -9 to activate downstream effector caspase-3, -6 and -7. To check if FADD is involved in *C. albicans*-mediated apoptosis of HeLa cells, apoptosis was studied in cells transfected with FADD-DN plasmid. The results (Fig. 26C) showed complete inhibition of *C. albicans*-induced apoptosis in FADD-DN transfected cells.


C.



**Figure 26C. Involvement of FADD in *Candida*-induced host cells apoptosis.** HeLa cells were transiently transfected with FADD-DN plasmid or were preincubated for 1 hour with 100  $\mu$ M Z-VAD-FMK, a caspase-3 inhibitor. *C. albicans* was then added at MOI 5:1 for 24 hours. Cell death detection ELISA experiments were performed with the cell lysates.


#### 4.10 Overexpression of iPLA<sub>2</sub> inhibits apoptosis in *Candida*-infected HeLa cells.

Previous observations of iPLA<sub>2</sub> mRNA in HeLa cells over various periods showed an initial increase with a maximum at 6 hours after infection by *C. albicans*, which then subsequently declined in a time-dependent manner and disappeared after 24 hours (Fig. 14B and C). We determined the iPLA<sub>2</sub> protein expression for the same periods and observed that protein expression followed the same pattern as mRNA levels, i.e. an initial increase followed by a subsequent decline and disappearance after 24 hours of infection by *C. albicans* (Fig. 27).




**Figure 27. Time-course analysis of iPLA<sub>2</sub> protein expression in HeLa cells infected with *C. albicans*.** Equal amount of HeLa cell lysates were analysed by western blotting with specific antibody against iPLA<sub>2</sub>. Anti-actin antibody was used as a control to ensure that equal amounts of proteins were loaded.

Since iPLA<sub>2</sub> expression declined after infection, we overexpressed iPLA<sub>2</sub> in HeLa cells by transfection with iPLA<sub>2</sub> plasmid. iPLA<sub>2</sub> protein expression was then determined in overexpressed cells after infection with *C. albicans* at various time points. Transfection with the iPLA<sub>2</sub> plasmid prevented decline and disappearance of iPLA<sub>2</sub> expression till 24 hours of infection (Fig. 28).




**Figure 28. Time-course analysis of overexpressed iPLA<sub>2</sub> protein expression in HeLa cells infected with *C. albicans*.** Equal amount of lysate of HeLa cell, transfected with and without iPLA<sub>2</sub> plasmid and were analysed for western blotting with specific antibody against iPLA<sub>2</sub>.

Next, we investigated the iPLA<sub>2</sub> enzymatic activity in iPLA<sub>2</sub>- transfected and non- transfected cells challenged with *C. albicans* at various time points. Activity assay as shown in Figure 29 indicated that the overexpression of iPLA<sub>2</sub> activity was increased at 6 hours of infection. The activity then remained constant till 24 hours. However, the iPLA<sub>2</sub> activity in non-transfected cells showed a similar initial increase at 6 hours, which however decreased to basal level over the time period studied (Fig. 29).



**Figure 29. iPLA<sub>2</sub> enzymatic activity.** Transfected or non-transfected HeLa cells were infected with *C. albicans* for indicated periods and homogenizates were assayed for iPLA<sub>2</sub> activity as described in materials and methods. The enzyme activity is plotted as percentage of the control non infected cells.


Assuming that the activation of iPLA<sub>2</sub> protects *Candida*-induced apoptosis, cells overexpressing iPLA<sub>2</sub> were studied for *Candida*-induced apoptosis by DNA ladder fragmentation assay. Strikingly, no apoptosis of HeLa cells was observed up to 24 hours after infection with *C. albicans*. These results pinpoint clearly the regulatory role of iPLA<sub>2</sub> in the execution of apoptosis (Fig. 30).



**Figure 30. Overexpression of iPLA<sub>2</sub> inhibits *C. albicans*-induced apoptosis in HeLa cells.** HeLa cells were transfected with iPLA<sub>2</sub> plasmid. After 24 hours cells were challenged with *C. albicans* for 24 hours and total DNA was electrophoresed for DNA ladder fragmentation.


#### 4.10.1 Inhibition of iPLA<sub>2</sub> and not PAP-1 induces apoptosis in *C. albicans*-infected cells

From the above study we presumed that this dynamic expression of iPLA<sub>2</sub> activity is related to the progression of cellular apoptosis and if so, BEL should shorten the time for induction of apoptosis. To confirm this, cells were pretreated with BEL, MAFP or AACOCF3 before challenging with *C. albicans* for 8 hours. DNA was extracted and separated by agarose gel electrophoresis. Indeed, measurement of apoptosis in the absence and presence of the inhibitors BEL and MAFP (lane 6 and 7) revealed that inhibition of iPLA<sub>2</sub> accelerates the onset of apoptosis to less than 8 hours (Fig. 31). But AACOCF3, the inhibitor of cPLA<sub>2</sub>, did not accelerate the onset of *C. albicans* induced apoptosis (lane 8). These results clearly indicate that iPLA<sub>2</sub> alone is playing a key role in host cells programmed death.




**Figure 31. Inhibition of PLA<sub>2</sub> by BEL and MAFP but not by AACOCF3 triggers *C. albicans*-induced apoptosis in HeLa cells.** DNA ladder fragmentation assay was performed after 8 hours of infection with *C. albicans* in HeLa cells pretreated with 20  $\mu$ M of BEL, MAFP and AACOCF3 for 1 hour. DNA was extracted and electrophoresed on 2 % agarose gel. Apoptosis can be seen in cells pretreated with BEL or MAFP and *C. albicans* infected cells (lane 6 and 7), whereas DNA from uninfected cells or from cells only infected with *C. albicans* for 8 hours or treated with inhibitors alone remained intact.

In addition, the apoptosis was confirmed by nuclear staining with DAPI. For this cells were pretreated with BEL before challenging with *C. albicans* for 8 hours. The results showed clear changes in the nucleus of the BEL treated cells (Fig. 32).



**Figure 32. Nuclear staining of cells pretreated with BEL before infection with *C. albicans*.** Cells were pretreated by BEL at 20  $\mu$ M for 1 h and infected by *C. albicans* as mentioned above and nuclear staining performed with DAPI.

To determine if this apoptosis is caused by the inhibition of phosphatidate phosphohydrolase-1 (PAP-1) as reported by Fuentes *et al.* [157], we pretreated one set of cells with propranolol, an inhibitor of PAP-1. Apoptosis was assayed after 8 hours by DNA ladder fragmentation. No proapoptotic effect of propranolol was observed, and the time point for the onset of apoptosis remained unaltered (Fig. 33). We can therefore rule out the possible involvement of PAP-1 in apoptosis.




**Figure 33. PAP-1 treatment did not affect the onset of apoptosis induced by *C. albicans*.** DNA ladder fragmentation assay was performed on HeLa cells which were pretreated with 50-150  $\mu$ M propranolol (PAP-1 inhibitor) before infection with *C. albicans* for 8 hours.


#### 4.11 Inhibition of iPLA<sub>2</sub> promotes TLR2-mediated apoptosis by *C. albicans*

Concluding from the above study that the inhibition of iPLA<sub>2</sub> accelerated the onset of apoptosis, we expected that the inhibition of iPLA<sub>2</sub> by BEL should also upregulate the TLR2 mRNA expression to promote apoptosis. As shown in Figure 34A, treatment of cells with BEL upregulated the TLR2-mRNA expression significantly. Moreover, the overexpression of iPLA<sub>2</sub> completely inhibited the activation of TLR2 (Fig. 34B). This effect on TLR2 on the cell membrane is clearly attributed to attenuation of iPLA<sub>2</sub>. In conclusion, these results strongly suggest that endogenous iPLA<sub>2</sub> is involved in the upregulation of TLR2.

A.



B.



**Figure 34. The inhibition of iPLA<sub>2</sub> promotes TLR2 mediated apoptosis.**

Cells were pretreated with 20  $\mu$ M BEL for 1 hour (A) or transfected with iPLA<sub>2</sub> plasmid for 24 hours (B) before infection with *C. albicans*. Total RNA was extracted, and RT-PCR analysis was performed. GAPDH was used as a control to ensure that RNA amounts were equal.

## 5. DISCUSSION

### 5.1 *C. albicans* infection mediated host cell signaling.

COX-2 enzyme expression is elevated in numerous reproductive tract carcinomas, including cervical carcinoma, endometrial adenocarcinoma and ovarian adenocarcinoma [96, 159, 160]. In cervical and endometrial carcinomas, enhanced expression of COX-2 enzyme is associated with elevated synthesis of eicosanoids in neoplastic epithelial and endothelial cells [161], suggesting that COX enzyme products such as PGE<sub>2</sub> may be involved in neoplastic cell transformation and reproductive tract tumourgenesis. Moreover, host cells are a source of eicosanoids during fungal infection. As a pathogenic yeast, *C. albicans* is able to release arachidonic acid from HeLa cells and subsequently convert it into eicosanoids [29], such as PGE<sub>2</sub>, which plays a major role in morphogenesis of *C. albicans* [88], and candidiasis [162]. The primary observation from our data is that *Candida albicans* able to upregulate the activation of COX-2 enzyme in HeLa cells and the production of PGE<sub>2</sub>. COX enzymes convert AA to PGG<sub>2</sub>, which is further converted to PGH<sub>2</sub> by the peroxidase activity of prostaglandin H synthase. The significant upregulation of COX-2 was clearly evident within 6 hours of infection with *C. albicans* (Fig. 1). The *C. albicans*-induced upregulation of COX-2 is related to a drastic increase of activation of NF-κB and MAPKs. P38<sup>MAPK</sup> cascade is also critical to the magnitude and duration of COX-2 expression. It is known that p38<sup>MAPK</sup> and cAMP/PKA pathway interact to transactivate the COX-2 promoter in response to IL-1β in human synoviocytes [97]. The data presented in this study confirmed that *C. albicans* induced COX-2 activation was through the cAMP/PKA activation (Fig. 3).

As a signaling event it plays a pivotal role in cytokine, LPS, or stress induced gene expression [96, 163]. In addition, to regulate cellular responses to cytokines, oxidative stress and pathogens, NF-κB play also an important role in inflammation [110] and tumour proliferation. Several members of the Rel/NF-κB family have been implicated in the control of cell proliferation and differentiation [110, 111]. Therefore, markedly high levels of NF-κB promoter activity as well as activation of cRel and Rel A subunit of NF-κB are detected in HeLa cells following infection with *C. albicans* (Fig. 4 and 7). This activity was abolished by sodium salicylate, an inhibitor of COX-2 [96]. The NF-κB promoter construct and dominant negative plasmid of IKK kinase showed that COX-2 activation is mediated through p38<sup>MAPK</sup> and NF-κB pathways, whereas NF-κB upregulates the phosphorylation of p38 protein [96]. Several consensus sequences for NF-κB binding sites of the COX-2 gene have been reported as regulatory sequences in COX-2

induction by various agonists in different cell types [164]. Activation of transcription by NF- $\kappa$ B has been shown to require a number of different coactivator proteins including CBP/p300, p/CAF, and SRC-1 [165]. These activator proteins possess histone acetyltransferase activity and are capable of acetylating the histone proteins. Acetylation of proteins is a common principle to modify their biological activity. It impacts protein chemical properties and, thus may alter protein-protein interaction, DNA recognition and protein stability. Histones were the first proteins that have been identified as targets for protein acetylation. Although there are several lines of experimental evidence suggesting the importance of histone acetylation in the transcription of a variety of genes, its precise role in nucleosome remodeling is still elusive. The data presented in this study clearly indicate that *C. albicans* induced transcription of the COX-2 gene requires upregulation of histone H3 acetylation (Fig. 10), which is mainly due to activation of the acetyltransferase activity of CBP/p300. This conclusion may be drawn from the following experimental data that the viral oncoprotein wtE1A, an inhibitor of acetyltransferase activity of CBP/p300, prevented histone H3 acetylation, and expression of the functional enzyme (Fig. 5). In contrast, its non-inhibitory mutant E1AmCBP was unable to do so (Fig. 5). It should, however, be stressed that the acetylation degree of cellular proteins is a resultant of acetylating and deacetylating processes. Thus, an increase in the acetylation degree of histone H3 can either be achieved by activation of acetyltransferases (CBP/p300) or by inhibition of deacetylases [122-125]. Deacetylases have been shown to occur in the nucleus and appear to play an important role in transcriptional repression [123]. Whether they are recruited by nuclear hormone receptors bound to certain nuclear corepressors, is not clear. Recently, the data demonstrated that treatment the cells with TSA caused an increase in TNF-induced expression of NF- $\kappa$ B regulated IL-8 gene [166]. In addition, TSA treatment resulted in hyperacetylation of the IL-8 promoter. Moreover, increased PGE<sub>2</sub> production can stimulate the activation of IL-8 gene in human colonic epithelial cells [167]. In agreement with these data, we observed a drastic increase of COX-2 and IL-8 production in HeLa cells under the fungal infection. TSA treatment showed drastic increase of IL-8, as well as NF- $\kappa$ B and COX-2 production (Fig. 6) suggested an important role of HDAC complex in *C. albicans*-induced signaling cascade. This activation by HDACs inhibitors occurred in a relatively straightforward manner: the inhibition of HDACs led to histone hyperacetylation and the opening of the promoter region for basal transcription machinery. Recent results from gene microarray data showed that HDAC inhibition does not trigger global gene activation [168]. In fact, most genes remain unaffected by HDAC inhibitors. Our results showed that treatment of

cells with HDACs inhibitors TSA or Gam-1 before challenging with *C. albicans*, led to increase in both basal and *C. albicans* induced activation of COX-2 and NF- $\kappa$ B genes (Fig. 6 and 8). Gam-1 expression increased the level of transcription of COX-2 in a similar way as potent HDAC inhibitor, TSA. Therefore, Gam-1 can binds to HDAC-1 both in vitro and in vivo and effectively inhibit histone deacetylation by HDAC-1. The effect of Gam-1 having the specific function of binding and inactivating HDAC-1 suggests that deacetylase complexes play an important role in limiting early gene expression by invading microorganisms. In support of this, we showed that transient transfection of HDAC-1 is able to repress *C. albicans* induced NF- $\kappa$ B mediated COX-2 gene activation (Fig. 9).

Acetylation may induce conformational changes of the histone octamer, which then may provide access to transcription factors for binding to the promoter of relevant genes. In addition, we showed that, *C. albicans* infection specifically leads not only to an increase in histone H3 acetylation, but is also associated with the activation of specific HDACs. Therefore, TSA and Gam-1 alone is capable of inducing COX-2 and NF- $\kappa$ B expression in HeLa cells suggest that transcriptional repression of the COX-2 and NF- $\kappa$ B gene in resting cells may be due to a preponderance of deacetylating processes over acetyltransferases. Using both in co-immunoprecipitation and western blot analysis, we showed that HDAC-1 interacts directly with the p65 subunit of NF- $\kappa$ B and likely exerts its corepressor function (Fig. 11). The increased basal expression of the COX-2 gene as well as NF- $\kappa$ B, in presence of HDAC-1 inhibitor, shows that HDAC-1 protein represses COX-2 expression through the direct interaction with NF- $\kappa$ B. These factors enable to increase recruitment of p65 and HDAC-1 to the promoter of key *C. albicans* induced NF- $\kappa$ B dependent gene, COX-2. We used ChIP assays (Fig. 12) effectively to study these changes in the nuclear transcription. Thereby, we conclude that fungal infection can induce *in vivo* chromatin remodeling events to induce inflammatory genes.

## 5.2 Host cell PLA<sub>2</sub> enzyme and its role in the activation of COX-2 gene.

In the classification based upon the Ca<sup>2+</sup> requirement for their activities, PLA<sub>2</sub>s can be divided into three categories: sPLA<sub>2</sub> that require millimolar concentration of Ca<sup>2+</sup>; cPLA<sub>2</sub> that require micromolar concentration of Ca<sup>2+</sup>; and iPLA<sub>2</sub>, which do not require Ca<sup>2+</sup> for the activity. In many cases, several of these enzymes are present in the same cell. For example, Group II, IV, and Ca<sup>2+</sup>

independent enzymes are present in P388D1 macrophage-like cells [143], Group II, Group IV, and a phosphatidylserine-specific,  $\text{Ca}^{2+}$ -dependent  $\text{PLA}_2$  are all present in rat mast cells.

AA, the precursor of eicosanoids, that are the mediators of inflammation, is released from membrane phospholipids by the catalytic action of  $\text{PLA}_2$  in cells exposed to stimuli. Cellular expression of specific  $\text{PLA}_2$  enzymes is dependent on cell type and state of differentiation. For instance, specific expression of c $\text{PLA}_2$  (group IV) enzymes include: human primary monocytes [169], U937 [170], and THP-1 cells [171], while group VI i $\text{PLA}_2$  is reported in murine P388D macrophages [143]. Both c $\text{PLA}_2$  and i $\text{PLA}_2$  enzymes are expressed in HeLa cells. Infection of HeLa cells with *C. albicans* induces activation of a defense mechanism, in which the host cells produce AA by the activation of  $\text{PLA}_2$  enzymes, which is converted into eicosanoids that mediate inflammation. Previous studies from Dr. Nigam's group showed that AA released from host cells, can be converted by *C. albicans* to 3-HETE (a growth factor), although these fungi do not contain AA. This implies that an infection process can be assumed as host-pathogen interaction. Thus, AA is an appropriate substrate for the human fungal pathogen *Candida albicans* [29], and that *C. albicans* at MOI as low as 5 can selectively upregulate the COX-2 gene in HeLa cells and produce  $\text{PGE}_2$ .  $\text{PGE}_2$  has been shown earlier to trigger morphogenetic changes in *C. albicans* [88]. Since inflamed and infected tissues release large amount of prostanoids including  $\text{PGE}_2$ , the above process plays an important role in vulvovaginal candidiasis. Although  $\text{PLA}_2$  enzymes are important catalysts of the AA release process, it is unclear whether *Candida* or host cell  $\text{PLA}_2$  is the effector for AA release. Dr. Nigam's laboratory has investigated the role of the candidial  $\text{PLA}_2$  gene, PLB3, in *C. albicans* strain 44808 and its PLB3 knockout (KO) mutants in cleavage of AA from synthetic substrates 1-palmitoyl-*sn*-2-arachidonoyl phosphatidylcholine (PAPC) and 1-palmitoyl-*sn*-2 (15-OH)-arachidonoyl phosphatidylcholine (PAPC-OH). The heterozygous mutant maintained half of the  $\text{PLA}_2$  activity as compared with the wild type *C. albicans* cells (manuscript in preparation). Moreover, they found that the AA release process from host cells was totally  $\text{Ca}^{2+}$  independent (unpublished observations). In this study we found that PLB gene mutated *C. albicans* could not induce the COX-2 activity from host cells (Fig. 13). Therefore, *C. albicans* seems to possess a potent active calcium-independent PLB enzyme capable of releasing the AA from membrane phospholipids of the host cell. This suggests that the PLB activity of *C. albicans* and not host cell  $\text{PLA}_2$  causes the cleavage of AA from membrane phospholipids of host cell (unpublished observations). This process then leads to activation of host cell  $\text{PLA}_2$ . A previous study from Dr. Nigam's group demonstrated that *C. albicans* isolated

from the vaginal tract of a patient with VVC when cocultured with HeLa cells caused significant release of PGE<sub>2</sub> [29]. In addition, they also observed significant activation of COX-2. P38<sup>MAPKs</sup> are member of the MAPK superfamily and can be activated in response to cellular stress [172], endotoxins and inflammatory cytokines [173]. Thus, *C. albicans*-induced activation of COX-2 was found to be mediated by p38<sup>MAPK</sup> pathway. The p38<sup>MAPK</sup> pathway was not only suppressed by p38<sup>MAPK</sup> inhibitor SB202190, but also by GF203190X, a PKC inhibitor, which suggested that the PKC activation occurs upstream of p38<sup>MAPK</sup> and is an obligatory event in *C. albicans*-mediated COX-2 induction in HeLa cells [96]. Strikingly, our data in this study demonstrated that inhibition of iPLA<sub>2</sub> enzymes by BEL or MAFP resulted in complete inhibition of *C. albicans*-induced COX-2 activation and PGE<sub>2</sub> production in HeLa cells (Fig. 17 and 15). Moreover, the inhibition of iPLA<sub>2</sub> also resulted in the marked decline of PKC $\alpha$  in HeLa cells challenged with *C. albicans* (Fig. 16). These results are in agreement with a recent report regarding the involvement of PKC $\alpha$  as a regulatory factor in the iPLA<sub>2</sub>-mediated AA release in response to zymosan [77]. Contrastingly, the PGE<sub>2</sub> production in human embryonic kidney cell was found to be dependent on cPLA<sub>2</sub> and sPLA<sub>2</sub> enzyme activities, iPLA<sub>2</sub>, however, failed to activate COX-2 [174]. To sum up, we can conclude that iPLA<sub>2</sub> not only plays a crucial role in phospholipid remodeling, but also a key role in the signaling of AA release and PGE<sub>2</sub> production in HeLa cells infected by *C. albicans*.

ROS, including superoxide anion, hydroxyl radical, and hydrogen peroxide, have been known to trigger a variety of biological responses within cells exposed to stimuli. Cleavage of I $\kappa$ B requires an oxidizing milieu and appears to be one of the mechanisms by which ROS activate NF- $\kappa$ B [175]. Recent findings have suggested that ROS potentate iPLA<sub>2</sub> activity. So, it was demonstrated in uterine stromal cells, that H<sub>2</sub>O<sub>2</sub> caused a significant release of AA, which is independent of intracellular Ca<sup>2+</sup> concentration. Both AA release and iPLA<sub>2</sub> activity could be inhibited almost completely by BEL [79]. We also found similar results with the free radical scavenger, PDTC and NAC (Fig. 18). This is in line with the report of Xu *et al.* [176], who have shown the involvement of the both iPLA<sub>2</sub> and cPLA<sub>2</sub> in H<sub>2</sub>O<sub>2</sub>-induced AA release in murine astrocytes. In order to gain support for our observation regarding ROS-iPLA<sub>2</sub>-NF- $\kappa$ B regulation, we asked whether iPLA<sub>2</sub> and NF- $\kappa$ B p65 subunit not only functionally but also physically interact in HeLa cells. Therefore, we investigated the *in vivo* association of iPLA<sub>2</sub> and NF- $\kappa$ B p65 subunit in untreated and *Candida*-infected HeLa cells by immunoprecipitation experiments. As can be seen in Figure 19A, iPLA<sub>2</sub> was found in the immunoprecipitate obtained by NF- $\kappa$ B p65 antibody in

*Candida*-infected cells (*left panel*). Such an association was absent in uninfected cells. Similarly, NF- $\kappa$ B p65 was detected in the immunoprecipitate obtained by iPLA<sub>2</sub> antibody in *Candida*-infected cells. However, uninfected cells also displayed the physical association of iPLA<sub>2</sub> with NF- $\kappa$ B p65. The latter observation (Fig. 19B) pinpoints that iPLA<sub>2</sub> may undergo physical binding with the whole I $\kappa$ B $\alpha$ -p50/c-Rel-p65 complex.

### 5.3 *Candida albicans* induced host apoptosis

Various pathogens have been shown to control host cell apoptosis in order to promote their own survival [177, 178]. Although the exact mechanism for apoptosis is far from clear, COX-2-mediated upregulation of mcl-1, a Bcl-2 family member, has been defined as a dominant antiapoptotic factor for following reasons: **(a)** it inhibits apoptosis induced by c-Myc overexpression [179], **(b)** it interacts directly with proapoptotic factor Bak inhibiting its capability to induce apoptosis [180], and **(c)** its upregulation is promoted by the COX-2-mediated activation of phosphatidylinositol-3-kinase (PI3K)/Akt pathway [181]. In the present study, however, we show that *C. albicans* induces apoptosis in HeLa cells after 12 hours infection. In contrast to a few previous studies in which apoptosis of host cells by *C. albicans* has been primarily attributed to the cell wall component phospholipomannan [156], we describe here a mechanism, which pinpoints the regulatory role of iPLA<sub>2</sub> in the TLR2-mediated programmed death of *Candida*-infected HeLa cells. Upon infection of HeLa cells with *C. albicans* our data demonstrate a time-dependent apoptosis of cells as determined by DNA ladder fragmentation, DAPI-nuclear staining and cell death detection ELISA (Figs. 20, 21 and 22). Apoptosis was evident after 12 hours of infection and continued to increase through 30 hours. Caspase-3 activation, which mediates the cleavage of multiple substrates to cause characteristic alteration that occur during apoptosis, was maximally elevated almost 6 hours, which means 6 hours before the onset of apoptosis (Fig. 22). Moreover, caspase-3-mediated apoptosis of HeLa cells followed the extrinsic pathway in which TLR2 triggers the signaling by recruitment of FADD containing protein (Fig. 26) and caspase-8.

The central observation in the host-pathogen interaction was initiated from host cell survival by inducing the inflammatory genes such as COX-2 [96] to host cell apoptosis. The time-course for COX-2 stimulation and apoptosis in HeLa cells were surprising. This led us to investigate various factors such as PLA<sub>2</sub>s and TLR2, which also played a pivotal role in the COX-2 activation. During the investigation of caspase-dependent apoptosis, the most striking observation was the

time point for the onset of *Candida*-mediated apoptosis of host cells and the concomitant alterations in the expression of iPLA<sub>2</sub>. Several lines of evidence suggested the involvement of iPLA<sub>2</sub> in triggering apoptosis. Thus, induction of apoptosis of U937 cells by anti-Fas antibody or by IL-1 $\beta$  through the activation of inducible nitric oxide synthesis (iNOS) and 12-lipoxygenase (12-LOX) was suppressed by iPLA<sub>2</sub> inhibitor BEL [84, 182]. Moreover, iPLA<sub>2</sub> and cPLA<sub>2</sub> both have been shown to be activated and cleaved by caspase-3 during apoptosis [86]. Whereas the cleaved form of cPLA<sub>2</sub> was reported to act as dominant negative inhibitor of apoptosis, cleaved iPLA<sub>2</sub> activity was found to cause increased phospholipid turnover [85]. However, our data revealed primarily a time-dependent decrease in iPLA<sub>2</sub> expression (Fig. 14B and C and 27). Decrease of cPLA<sub>2</sub> expression was also observed in HeLa cells (Fig. 14A), which, however, did not affect the apoptotic process when inhibited by AACOCF3. In contrast, the inhibition of iPLA<sub>2</sub> by BEL abrogated the apoptosis (Fig. 31). The decline in apoptosis to basal level after 48 hours may be a result of the proliferation of a subpopulation of HeLa cells insensitive to *C. albicans*. Furthermore, gradual decline of iPLA<sub>2</sub> upto 18 hours was coupled with a concomitant increase in apoptosis for the same period. In order to verify if iPLA<sub>2</sub> is a genuine inhibitor of apoptosis, we preincubated cells with BEL, a specific inhibitor of iPLA<sub>2</sub>, and followed apoptosis (Fig. 31 and 32). Indeed, time for the onset of apoptosis was reduced by 4 hours. Conversely, HeLa cells overexpressing iPLA<sub>2</sub> failed completely to exhibit any apoptosis upto 24 hours (Fig. 30). These findings present a clear-cut evidence for the regulatory role of iPLA<sub>2</sub> in *Candida*-induced apoptosis in HeLa cells. Recently, it was claimed that BEL-induced apoptosis in various cell types is not due to inhibition of iPLA<sub>2</sub>, but due to inhibition of phosphatidic acid phosphohydrolase-1 (PAP-1) [157]. Our observations are in disagreement with this report, since BEL-induced apoptotic effect was not imitated by propranolol-treated cells, so that the involvement of PAP-1 as causative agent for apoptosis can be ruled out (Fig. 33).

The correlation between the diminution of iPLA<sub>2</sub> expression and increased caspase-3 like protease activity in apoptotic cells is intriguing. Recently, Ramanadham *et al.* [183] reported that the endoplasmic reticulum stress-induced apoptosis is associated with activation of iPLA<sub>2</sub> and caspase-3 activities, and that the latter protease cleaves iPLA<sub>2</sub> to a 62 kDa product that couples with nuclei. In this report the induction of apoptosis is attributed to activation of iPLA<sub>2</sub>. Interestingly, the data presented in our study showed clearly the down-regulation of iPLA<sub>2</sub> and not its activation during apoptosis. In order to determine if iPLA<sub>2</sub> protein is cleaved by caspase-3 like protease activity to a protein fragment with increasing catalytic activity, we determined the

time-course of iPLA<sub>2</sub> activity in normal HeLa cells as well as in cells overexpressing iPLA<sub>2</sub> before challenging with *C. albicans*. As shown by iPLA<sub>2</sub> activity assay and western analysis in Figures 27, 28, and 29 neither catalytic activity could be detected in degradation products nor was a truncated form of iPLA<sub>2</sub> protein visible with western blot analysis.

TLRs have been identified in humans as critical component of innate immunity against microbial agents. For macrophages, antimicrobial defences are primarily based on recognition of TLR2, TLR4 and TLR6, depending upon the ligand nature [184]. Whereas deletion of TLR4 and TLR6 genes have been shown to alter a limited response to *C. albicans* in induction of TNF $\alpha$  [185], deletion of the TLR2 gene or neutralization with TLR2 antibodies of TLR2 receptors completely abolished the cell response [96, 185]. Induction of the TLR2 gene by *C. albicans* in our experiments was relatively specific, because the use of inhibitors of downstream signaling cascade, such as PI-3-K, p38<sup>MAPK</sup> or COX-1/2 failed to abolish the expression of TLR2 (Fig. 23). Moreover, neutralization of TLR2 by monoclonal antibodies against TLR2 prior to infection significantly inhibited apoptosis. To determine whether TLR2 gene activation is affected by *Candida albicans* infection, we transfected cells with TLR2-DN plasmid before infection. A complete inhibition of apoptosis was observed (Fig. 26B).

Next, we investigated the relationship between iPLA<sub>2</sub> activity and TLR2 gene expression. The iPLA<sub>2</sub> inhibitor BEL has been shown to attenuate significantly cell surface membrane changes [86]. It inhibited the binding of both IgM and annexin V to the cell surface membrane. Because neither cleavage of caspase-3 substrates nor nuclear condensation was attenuated, a general inhibition of apoptosis by BEL as a cause can be excluded [86]. On contrary, inhibition of iPLA<sub>2</sub> by BEL should be capable of upregulating TLR2 gene expression and promote apoptosis in *C. albicans*-infected cells. Indeed, in our experimental set-up, BEL caused an early onset of apoptosis (Figs. 31 and 32) and a significant increase in TLR2 mRNA expression (Fig. 34A). Conversely, overexpression of iPLA<sub>2</sub> abrogated TLR2 gene expression (Fig. 34B). Taken together, our results indicate that the downregulation of iPLA<sub>2</sub> activity is inevitably required for the transcriptional activation of TLR2 expression following infection with *C. albicans*. It seems unlikely that iPLA<sub>2</sub> would directly interact with TLR2 in *C. albicans*-infected cells. However, if we look at the mycobacterial infection of macrophages, we find that the induction of TLR2 transcription requires not only NF- $\kappa$ B and Sp1 elements within the TLR2 promoter region, but also chromatin remodeling [186, 187].

## 6. REFERENCES

1. Richardson, M.D. 1991. Opportunistic and pathogenic fungi in developments in the management of fungal infection. *Supplement A. Antimicrobial Chemotherapy*. **28**: 1-11.
2. Müller, J. 1989. Pathogenesis of opportunistic fungal infections. In: International Congress and Symposium series 153. London, United Kingdom: *Royal Society of Medicine*. 25-28.
3. Ashman, R.B., and Papadimitriou, J.M. 1990. What's new in the mechanisms of host resistance to *Candida albicans* infection. *Pathol. Res. Prac.* **186**: 527-534.
4. Bodey, G.P., and Anaissie, E.J. 1989. Chronic systemic candidiasis. *Eur. J. Clin. Microbiol. Infect. Dis.* **8**: 855-857.
5. Odds, F.C. 1988. Genital Candidiasis. 2nd ed. *London: Bialliere Tindall*. 124-135.
6. Khardori, N. 1989. Host- Parasite interaction in fungal infection. *Eur. J. Microbiol. Infect. Dis.* **8**: 331-351.
7. Kalo, K.A., and Witkin, S.S. 1990. Prostagalandin E<sub>2</sub> enhances and gamma interferon inhibits germ tube formation in *Candida albicans*. *Infect. Immun.* **58**: 260-262.
8. Fidel, P.L. 2002. Immunity to Candida. *Oral Disl.* **8**: 69-75.
9. Bodey, G.P. 1993. Hematogenous and major organ candidiasis. *Candidiasis: Pathogenesis, diagnosis, and treatment*. 2nd ed. *Raven Press, New York*: 279-330.
10. Sobel, J.D., Muller, G., and Buckley, H.R. 1984. Critical role of germ tube formation in the pathogenesis of candidal vaginitis. *Infect. Immun.* **44**: 576-580.
11. McCourtie, J., and Douglas, L.J. 1984. Relationship between cell surface composition, adherence, and virulence of *Candida albicans*. *Infect. Immun.* **45**: 6-12.
12. Vartivarian, S., and Smith, C.B. 1993. Pathogenesis, host resistance, and predisposing factors. *Candidiasis: Pathogenesis, diagnosis, and treatment*. 2nd ed. *Raven Press, New York* : 59-84.
13. Kimura, L.H., and Pearsall, N.N. 1980. Relationship between germination of *Candida albicans* and increased adherence to human buccal epithelial cells. *Infect. Immun.* **28**: 464-468.
14. Sobel, J.D., Muller, G., and Buckley, H.R. 1984. Critical role of germ tube formation in the pathogenesis of candidal vaginitis. *Infect. Immun.* **44**: 576-580.

15. Slutsky, B., Staebell, M., Anderson, J., Risen, L., Pfaller, M., and Soll, D.R. 1987. "White –opaque transition " a second high-frequency switching system in *Candida albicans*. *J. Bacteriol.* **169**: 189-197.
16. Slutsky, B., Buffo, J., and Soll, D.R. 1985. High-frequency switching of colony morphology in *Candida albicans*. *Science.* **230**: 666- 669.
17. Anderson, J., Cundiff, L., Schnars, B., Gao, M.X., Mackenzie, I., and Soll, D.R. 1989. Hypha formation in the white-opaque transition of *Candida albicans*. *Infect. Immun.* **57**: 458-467.
18. Kolotila, M.P., and Diamond, R.D. 1990. Effects of neutrophils and in vitro oxidants on survival and phenotypic switching of *Candida albicans*. *Infect. Immun.* **58**: 1174-1179.
19. Mishra, P., Bolard, J., and Prasad, R. 1992. Emerging role of lipids of *Candida albicans*, a pathogenic dimorphic yeast. *Biochim. Biophys. Acta.* **1127**: 1-14.
20. Barrett-Bee, K.Y., Hayes, R., Wilson, G., and Ryley, J.F. 1985. A comparison of phospholipase activity, cellular adherence and pathogenicity of yeasts. *J. Gen. Microbiol* **131**: 1217-1221.
21. Calderone, R.A., Cihlar, R.L., Lee, D.D., Hoberg, K., and Scheld, W.M. 1985. Yeast adhesion in the pathogenesis of endocarditis due to *Candida albicans*: studies with adherence-negative mutants. *J. Infect. Dis.* **152**: 710-715.
22. Goyal, S., and Khuller, G.K. 1994. Structural and functional role of lipids in yeast and mycelial forms of *Candida albicans*. *Lipids.* **29**: 793-797
23. Lozinov, A.B., Glazunova, L.M., and Ermakova, I.T. 1976. The activity of citrate glyoxylate and pentosephosphate cycle enzymes during yeast growth on hexadecane and glucose. *Mikrobiologia.* **45**: 33-40.
24. Hiltunen, J.K., Wenzel, B., Beyer, A., Erdmann, R., Fossa, A., and Kunau, W.H. 1992. Peroxisomal multifunctional beta-oxidation protein of *saccharomyces cerevisiae*. Molecular analysis of the fox2 gene and gene product. *J. Biol. Chem.* **267**: 6646-6653.
25. Ueda, M., Yamanoi, K., Morikawa, T., Okada, H., and Tanaka, A. 1985. Peroxisomal localisation of enzymes related to fatty acid beta-oxidation in an n-alkane-grown yeast, *Candida tropicalis*. *Agric. Biol. Chem.* **49**: 1821-1828.
26. Tanaka, A., Osumi, M., and Fukui, S. 1982. Peroxisomes of alkane-grown yeasts: fundamental and practical aspects. *Ann. N. Y. Acad. Sci.* **386**: 183-199.

27. Meussdoerffer, F. 1988. Omega-hydroxytalions. In: Proceedings of the World Conference on Biotechnology for the Fats and Oils Industry. USA. 142–147.
28. Kunau, W.H., Kionka, C., Ledebur, A., Mateblowski, M., Moreno de la Garza, M., Schultz-Borchard, U., Thieringer, R., and Veenhuis, M. 1987. Beta-oxidation systems in eukaryotic microorganisms in Peroxisomes in biology and medicine. Fahimi, H. D. and Seis, H., Eds., Springer-Verlag, Berlin. 128-140.
29. Deva, R., Ciccoli, R., Schewe, T., Kock, J.L., and Nigam, S. 2000. Arachidonic acid stimulates cell growth and forms a novel oxygenated metabolite in *Candida albicans*. *Biochim. Biophys. Acta.* **1486**: 299-311.
30. Van Dyk, M.S., Kock, J.L., Coetzee, D.J., Augusttyn, O.P., and Nigam, S. 1991. Isolation of a novel arachidonic acid metabolite 3-hydroxy-5, 8, 11, 14-eicosatetraenoic acid (3-HETE) from the yeast *Dipodascopsis uninucleata* UOFs-Y128. *FEBS Lett.* **283**: 195-198. *ibid.* Venter, P., Kock, J.L., Kumar, G.S., Botha, A., Coetzee, D.J., Botes, P.J., Bhatt. R.K., Falck. J.R., Schewe, T., and Nigam, S. 1997. Production of 3R-hydroxy-polyenoic fatty acids by the yeast *Dipodascopsis uninucleata*. *Lipids.* **32**: 1277-1283.
31. Ciccoli, R., Sahi, S., Singh, S., Prakash, H., Zafiriou, M.P., Ishdorj, G., Kock, J.L., and Nigam, S. 2005. Oxygenation by cyclooxygenase-2 (COX-2) of 3-Hydroxyeicosatetraenoic acid (3-HETE), a fungal mimetic of arachidonic acid, produces a cascade of novel bioactive 3-hydroxy-eicosanoids. *Biochem. J.* **390**: 737-747.
32. Calderone, R.A., Cuhlar, R.L., Lee, D.D., Hoberg, K., and Scheld, W.M. 1985 Yeast adhesion in the pathogenesis of endocarditis due to *Candida albicans*: studies with adherence-negative mutants. *J. Infect. Dis.* **152**: 710-715.
33. Calderone, R.A., and Fonzi, W.A. 2001. Virulence factors of *Candida albicans*. *Trends Microbiol.* **9**: 327-335.
34. Calderone, R.A., and Braun, P.C. 1991. Adherence and receptor relationships of *Candida albicans*. *Microbiol. Rev.* **55**: 1-20.
35. Hazen, K.C. 1990. Cell surface hydrophobicity of medically important fungi, especially *Candida* species. *American Society for Microbiology*, Washington. DC. 249-295.
36. Kanbe, T.H., Jutila, M.A., and Cutler, J.E. 1993. Evidence that mannans from *Candida albicans* are responsible for the adherence of yeast forms to spleen and lymph nodes. *Infect. Immun.* **61**: 2578–2583.

37. Aliprantis, A.O., Yang, R.B., Mark, M.R., Suggett, S., Devaux, B., Radolf, J.D., Klimpel, G.R., Godowski, P., and Zychlinsky, A. 1999. Cell activation and apoptosis by bacterial lipoproteins through toll-like receptor-2. *Science*. **285**: 736-742.
38. Takeuchi, O., and Akira, S. 2001. Toll like receptors: their physiological role and signal transduction system. *Int. Immunopharmacol.* **1**: 625-631.
39. Roeder, A., Kirschning, C.J., Rupec, R.A., Schaller, M., and Korting, H.C. 2003. Toll-like receptors and innate antifungal responses. *Trends Microbiol.* **12**: 44-49.
40. Akira, S., Takeda, K., and Kaisho, T. 2001. Toll-like receptors: critical proteins linking innate and acquired immunity. *Nat. Immunol.* **2**: 675-80.
41. Beutler, B. 2004. Inferences, questions and possibilities in Toll-like receptor signaling. *Nature*. **430**: 257-263
42. Medzhitov, R. 2001. Toll-like receptors and innate immunity. *Nat. Rev. Immunol.* **1**: 135-145.
43. Netea, M.G., Van Der Graaf, C.A., Vonk, A.G., Verschueren, I., Van Der Meer, J.W., and Kullberg, B.J. 2002. The role of toll-like receptor (TLR)2 and TLR4 in the host defence against disseminated candidiasis. *J. Infect. Dis.* **185**: 1483-1489.
44. Keiko, K., Tatsushi, T., Soh, Y., and Koichiro, T. 2002. Activation of macrophages by linear (1→3)-beta-D-glucans. Implications for the recognition of fungi by innate immunity. *J. Biol. Chem.* **277**: 36825–36831.
45. Willment, J.A., Gordon, S., Brown, G.D. 2001. Characterization of the human beta-glucan receptor and its alternatively spliced isoforms. *J. Biol. Chem.* **276**: 43818–43823.
46. Gantner, B.N., Simmons, R.M., Canavera, S.J., Akira, S., Underhill, D.M. 2003. Collaborative induction of inflammatory responses by Dectin-1 and Toll-like receptor 2. *J. Exp. Med.* **197**: 1107–1117.
47. Brown, G.D., Herre, J., Williams, D.L., Willment, J.A., Marshall, A.S.J., and Gordon, S. 2003. Dectin-1 mediates the biological effects of  $\beta$ -Glucans. *J. Exp. Med.* **197**: 1119–1124.
48. Castro, M., Ralston, N.V.C., Timothy, I., Rohrbach, M.M.S., and Limper, A.H. 1994. *Candida albicans* stimulates arachidonic acid liberation from alveolar macrophages through  $\alpha$ -Mannan and  $\beta$ -Glucan cell wall components. *Infection and Immunity.* **62**: 3138-3145.

49. Castro, M., Bjoraker, J.A., Rohrbach, M.S., and Limper, A.H. 1996. *Candida albicans* induces the release of inflammatory mediators from human peripheral blood monocytes. *Inflammation*. **20**: 107–122.
50. Filler, S.G., Ibe, B.O., Luckett, P.M., Raj, J.U., and Edwards, J.E.Jr.. 1991 *Candida albicans* stimulates endothelial cell eicosanoid production. *J. Infect. Dis.* **164**: 928–935.
51. Filler, S.G., Ibe, B.O., Ibrahim, A.S., Ghannoum, M.A., Raj, J.U., and Edwards, J.E.Jr. 1994. Mechanisms by which *Candida albicans* induces endothelial cell prostaglandin synthesis. *Infection and Immunity*. **62**: 1064-1069.
52. Balsinde, J., and Dennis, E.A. 2003. Phospholipase A<sub>2</sub> signaling and arachidonic acid release. *Cell signaling*. **2**: 261-263.
53. Ghannoum, M.A. 1998. Extracellular phospholipases as universal virulence factor in pathogenic fungi. *Nippon Ishinkin Gakkai Zasshi*. **39**: 55-59.
54. Underwood, K.W., Song, C., Kriz, R.W., Chang, X.J., Knopf, J.L., and Lin, L.L. 1998. A novel calcium-independent phospholipase A<sub>2</sub>, cPLA<sub>2</sub>-gamma that is prenylated and contains homology to cPLA<sub>2</sub>. *J. Biol. Chem.* **273**: 21926-21932.
55. Clark, J.D., Lin, L.L., Kriz, R.W., Ramesha, C.S., Sultzman, L.A., Lin, A.Y., Milona, N., and Knopf, J.L. 1991. A novel arachidonic acid-selective cytosolic PLA<sub>2</sub> contains a Ca<sup>2+</sup>-dependent translocation domain with homology to PKC and GAP. *Cell*. **65**: 1043-1051.
56. Akiba, S., and Sato, T. 2004. Cellular function of calcium-independent phospholipase A<sub>2</sub>. *Biol. Pharm. Bull.* **27**: 1174-1178.
57. Evans, J.H., Spencer, D.M., Zweifach, A., Leslie, C.C. 2001. Intracellular calcium signals regulating cytosolic phospholipase A<sub>2</sub> translocation to internal membranes. *J. Biol. Chem.* **276**: 30150-30160.
58. Six, D.A., and Dennis, E.A. 2000. The expanding superfamily of phospholipase A<sub>2</sub> enzymes: classification and characterization. *Biochim. Biophys. Acta*. **1488**: 1-19.
59. Balsinde, J., Shinohara, H., Lefkowitz, L.J., Johnson, C.A., Balboa, M.A., Dennis, E.A. 1999. Group V phospholipase A<sub>2</sub>-dependent induction of cyclooxygenase-2 in macrophages. *J. Biol. Chem.* **274**: 25967-25970.
60. Balsinde, J., and Dennis, E.A. 1996. Distinct roles in signal transduction for each of the phospholipase A<sub>2</sub> enzymes present in P388D1 macrophages. *J. Biol. Chem.* **271**: 6758-6765.

61. Balsinde, J., and Dennis, A.E. 2003. Phospholipase A<sub>2</sub> signaling and arachidonic acid release. *Handbook of Cell Signaling*. **2**: 261-265.
62. Schroder, T., Kivilaakso, E., Kinnunen, P.K., and Lempinen, M. 1980. Serum phospholipase A<sub>2</sub> in human acute pancreatitis. *Scand. J. Gastroenterol.* **15**: 633-636.
63. Vadas, P. 1984. Elevated plasma phospholipase A<sub>2</sub> levels: correlation with the hemodynamic and pulmonary changes in gram-negative septic shock. *J. Lab. Clin. Med.* **104**: 873-881.
64. Nakae, H., Endo, S., Inada, K., Yamashita, H., Yamada, Y., Takakuwa, T., Kasai, T., Ogawa, M., and Uchida, K. 1995. Plasma concentrations of type II phospholipase A<sub>2</sub>, cytokines and eicosanoids in patients with burns. *Burns*. **21**: 422- 426.
65. Vadas, P., and Pruzanski, W. 1986. Role of secretory phospholipases A<sub>2</sub> in the pathobiology of disease. *Lab. Invest.* **55**: 391-404.
66. Leslie, C.C. 1997. Properties and regulation of cytosolic phospholipase A<sub>2</sub>. *J. Biol. Chem.* **272**: 16709-16712.
67. Hirabayashi, T., Kume, K., Hirose, K., Yokomizo, T., Iino, M., Itoh, H., and Shimizu, T. 1999. Critical duration of intracellular Ca<sup>2+</sup> response required for continuous translocation and activation of cytosolic phospholipase A<sub>2</sub>. *J. Biol. Chem.* **274**: 5163-5169.
68. Balsinde, J., Balboa, M.A., Li, W.H., Llopis, J., and Dennis, E.A. 2000. Cellular regulation of cytosolic group IV phospholipase A<sub>2</sub> by phosphatidylinositol bisphosphate levels. *J. Immunol.* **164**: 5398-5402.
69. Das, S., and Cho, W. 2002. Roles of catalytic domain residues in interfacial binding and activation of group IV cytosolic phospholipase A<sub>2</sub>. *J. Biol. Chem.* **277**: 23838–23846.
70. Niewerth, M., and Korting, H.C. 2001. Phospholipases of *Candida albicans*. *Mycoses*. **44**: 361-367.
71. Murakami, M., Das, S., Kim, Y.J., Cho, W., and Kudo, I. 2003. Perinuclear localization of cytosolic phospholipaseA<sub>2</sub> alpha is important but not obligatory for coupling with cyclooxygenases. *FEBS Lett.* **546**: 251- 256.
72. Lin, L.L., Wartmann, M., Lin, A.Y., Knopf, J.L., Seth, A., and Davis, R.J. 1993. cPLA<sub>2</sub> is phosphorylated and activated by MAP kinase. *Cell*. **72**: 269-278.
73. Hefner, Y., Borsch-Haubold, A.G., Murakami, M., Wilde, J.I., Pasquet, S., Schieltz, D., Ghomashchi, F., Yates, J.R., Armstrong, C.G., Paterson, A., Cohen, P., Fukunaga, R., Hunter, T., Kudo, I., Watson, S.P., and Gelb, M.H. 2000. Serine 727 phosphorylation and

- activation of cytosolic phospholipase A<sub>2</sub> by MNK1-related protein kinases. *J. Biol. Chem.* **275**: 37542-37551.
74. Barrett-Bee, K., Hayes, Y., Wilson, R.G., and Ryley, J.F. 1985. A comparison of phospholipase activity, cellular adherence and pathogenicity of yeasts. *J. Gen. Microbiol.* **131**: 1217-1221.
75. Balsinde, J., Bianco, I.D., Ackermann, E.J., Conde-Frieboes, K., and Dennis, E.A. 1995. Inhibition of calcium-independent phospholipase A<sub>2</sub> prevents arachidonic acid incorporation and phospholipid remodeling in P388D1 macrophages. *Proc. Natl. Acad. Sci USA.* **92**: 8527-8531.
76. Murakami, M., Shimbara, S., Kambe, T., Kuwata, H., Winstead, M.V., Tischfield, J.A., and Kudo, I. 1998. The functions of five distinct mammalian phospholipase A<sub>2</sub>s in regulating arachidonic acid release. Type II a and type V secretory phospholipase A<sub>2</sub>s are functionally redundant and act in concert with cytosolic phospholipase A<sub>2</sub>. *J. Biol. Chem.* **273**: 14411-14423.
77. Akiba, S., Mizunaga, S., Kume, K., Hayama, M., and Sato, T. 1999. Involvement of group VI Ca<sup>2+</sup>-independent phospholipase A<sub>2</sub> in protein kinase C-dependent arachidonic acid liberation in zymosan-stimulated macrophage-like P388D1 cells. *J. Biol. Chem.* **274**: 19906-19912.
78. Murakami, M., Kambe, T., Shimbara, S., and Kudo, I. 1999. Functional coupling between various phospholipase A<sub>2</sub>s and cyclooxygenases in immediate and delayed prostanoid biosynthetic pathways. *J. Biol. Chem.* **274**: 3103-3115.
79. Birbes, H., Gothie, E., Pageaux, J.F., Lagarde, M., and Laugier, C. 2000. Hydrogen peroxide activation of Ca<sup>2+</sup>-independent phospholipase A<sub>2</sub> in uterine stromal cells. *Biochem. Biophys. Res. Commun.* **276**: 613-618.
80. Akiba, S., Mizunaga, S., Kume, K., Hayama, M., and Sato, T. 1999. Involvement of group VI Ca<sup>2+</sup>-independent phospholipase A<sub>2</sub> in protein kinase C-dependent arachidonic acid liberation in zymosan-stimulated macrophage-like P388D1 cells. *J. Biol. Chem.* **274**: 19906-19912.
81. Wolf, M.J., Wang, J., Turk, J., and Gross, R.W. 1997. Depletion of intracellular calcium stores activates smooth muscle cell calcium-independent phospholipase A<sub>2</sub>. A novel mechanism underlying arachidonic acid mobilization. *J. Biol. Chem.* **272**: 1522-1526.

82. Steer, S.A., Wirsig, K.C., Creer, M.H., Ford, D.A., and McHowat, J. 2002. Regulation of membrane-associated iPLA<sub>2</sub> activity by a novel PKC isoform in ventricular myocytes. *Am. J. Physiol. Cell. Physiol.* **283**: C1621-1626.
83. Atsumi, G., Tajima, M., Hadano, A., Nakatani, Y., Murakami, M., and Kudo I. 1998. Fas-induced arachidonic acid release is mediated by Ca<sup>2+</sup>-independent phospholipase A<sub>2</sub> but not cytosolic phospholipase A<sub>2</sub>, which undergoes proteolytic inactivation. *J. Biol. Chem.* **273**:13870–13877.
84. Wissing, D., Mouritzen, H., Egeblad, M., Poirier, G.G., and Jaattela, M. 1997. Involvement of caspase-dependent activation of cytosolic phospholipase A<sub>2</sub> in tumour necrosis factor-induced apoptosis. *Proc. Natl. Acad. Sci. USA.* **94**: 5073–5077.
85. Atsumi, G., Murakami, M., Kojima, K., Hadano, A., Tajima, M., and Kudo, I. 2000. Distinct roles of two intracellular phospholipase A<sub>2</sub>s in fatty acid release in the cell death pathway: proteolytic fragment of type IVA cytosolic phospholipase A<sub>2</sub> alpha inhibits stimulus-induced arachidonate release, whereas that of type VI Ca<sup>2+</sup>-independent phospholipase A<sub>2</sub> augments spontaneous fatty acid release. *J. Biol.Chem.* **275**: 18248 –18258.
86. Kim, S.J., Gershov, D., Ma, X., Brot, N., and Elkon, K.B. 2002. iPLA<sub>2</sub> activation during apoptosis promotes the exposure of membrane lysophosphatidylcholine leading to binding by natural immunoglobulin M antibodies and complement activation. *J. Exp. Med.* **196**: 655-665.
87. Noverr, M.C., Phare, S.M., Toews, G.B., Coffey M.J., and Huffnagle, G.B. 2001. Pathogenic yeasts *Cryptococcus neoformans* and *Candida albicans* produce immunomodulatory prostaglandins. *Infect. Immun.* **69**: 2957-2963.
88. Kalo-Klein, A., and Witkin, S.S. 1990. Prostaglandin E<sub>2</sub> enhances and gamma interferon inhibits germ tube formation in *Candida albicans*. *Infect. Immun.* **58**: 260-262.
89. Deva, R., Ciccoli, R., Kock, L., and Nigam, S. 2001. Involvement of aspirin-sensitive oxylipins in vulvovaginal candidiasis. *FEMS. Microb. Lett.* **198**: 37-43.
90. DeWitt, D.L. 1991. Prostaglandin endoperoxide synthase: regulation of enzyme expression. *Biochim. Biophys. Acta.* **1083**: 121–134.
91. Ottem, E.N., Zuloaga, D.G., and Breedlove, S.M. 2004. Brain gender: prostaglandins have their say. *Nature Neuroscience.* **7**: 570 – 572.

92. Kujubu, D.A., Fletcher, B.S., Varnum, B.C., Lim, R.W., and Herschman, H.R. 1991. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. *J. Biol. Chem.* **266**: 12866-12872.
93. Xie, W.L., Chipman, J.G., Robertson, D.L., Erikson, R.L., and Simmons, D.L. 1991. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. *Proc. Natl. Acad. Sci. USA.* **88**: 2692-2696.
94. Hla, T., and Neilson, K. 1992. Human cyclooxygenase-2 cDNA. *Proc. Natl. Acad. Sci. USA.* **89**: 7384-7388.
95. Tanabe, T., and Tohnai, N. 2002. Cyclooxygenase isozymes and their gene structures and expression. *Prostaglandins Other Lipid Mediat.* **68**: 95-114.
96. Deva, R., Shankaranarayanan, P., Ciccoli, R., Nigam, S. 2003. *Candida albicans* induces selectively transcriptional activation of cyclooxygenase-2 in HeLa cells: pivotal roles of toll-like receptors, p38 mitogen-activated protein kinase, and NF- $\kappa$ B. *J. Immunol.* **171**: 3047-3055.
97. Faour, W.N., He, Q.W., de Ladurantaye, M., Quintero, M., and Mancini, A. 2001. ProstaglandinE<sub>2</sub> regulates the level and stability of COX-2 mRNA through activation of p38<sup>MAPK</sup> in interleukin-1 $\beta$ -treated human synovial fibroblasts. *J. Biol. Chem.* **276**: 31720-31731.
98. Schmedtje, J.F.Jr., Ji, Y.S., Liu, W.L., DuBois, R.N., and Runge, M.S. 1997. Hypoxia induces cyclooxygenase-2 via the NF- $\kappa$ B p65 transcription factor in human vascular endothelial cells. *J. Biol. Chem.* **272**: 601-608.
99. Miao, F., Gonzalo, I.G., Lanting, L., Natarajan, R. 2004. In vivo chromatin remodeling events leading to inflammatory gene transcription under diabetic conditions. *J. Biol. Chem.* **279**: 18091-18097.
100. Sen, R., and Baltimore, D. 1986. Multiple nuclear factors interact with the immunoglobulin enhancer sequence. *Cell.* **46**: 705-716.
101. Stehlik, C., de Martin, R., Kumabashiri, I., Schmid, J.A., Binder, B.R., and Lipp, J. 1998. Nuclear factor NF- $\kappa$ B-regulated X-chromosome-linked IAP gene expression protects endothelial cells from tumor necrosis factor-induced apoptosis. *J. Exp. Med.* **188**: 211-216.

102. Chen, C., Edelstein, L.C., and Gelinas, C. 2000. The Rel/NF- $\kappa$ B family directly activates expression of the apoptosis inhibitor Bcl-xl. *Mol. Cell. Biol.* **20**: 2687–2695.
103. Levkai, B., Scatena, M.C., Giachelli, M., Ross, R., Raines, E.W. 1999. Apoptosis overrides survival signals through a caspase-mediated dominant-negative NF- $\kappa$ B loop. *Nat. Cell. Biol.* **1**: 227–233.
104. Ravi, R., Bedi, G.C., Engstrom, L.W., Zeng, Q., Mookerjee, B., Gelinas, C., Fuchs, E.J., and Bedi, A. 2001. Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF- $\kappa$ B. *Nat. Cell. Biol.* **3**: 409–416.
105. Baeuerle, P., and Baltimore, D. 1988. A specific inhibitor of the NF- $\kappa$ B transcription factor. *Science*. **242**: 540–546.
106. Siebenlist, U., Franzoso, G., and Brown, K. 1994. Structure, regulation and function of NF- $\kappa$ B. *Annu. Rev. Cell. Biol.* **10**: 405–455.
107. May, M.J., and Ghosh, S. 1998. Signal transduction through NF- $\kappa$ B. *Immunol. Today*. **19**: 80–88.
108. Karin, M. 1999. How NF-kappaB is activated: The role of the IkappaB kinase (IKK) complex. *Oncogene*. **18**: 6867–6874.
109. Ghosh, S., and Karin, M. 2002. Missing pieces in the NF- $\kappa$ B puzzle. *Cell*. **109**: S81–S96.
110. Karin, M., Cao, Y., Greten, F.R., and Li, Z.W. 2002. NF- $\kappa$ B in cancer: from innocent bystander to major culprit. *Nat. Rev. Cancer*. **2**: 301–311.
111. Senftleben, U., and Karin, M. 2002. The IKK/NF- $\kappa$ B pathway. *Crit. Care. Med.* **30**: S18–S26.
112. Beg, A.A., Finco, T.S., Nantermet, P.V., and Baldwin, A.S.Jr. 1993. Tumour necrosis factor and interleukin-1 lead to phosphorylation and loss of I $\kappa$ B $\alpha$ : a mechanism for NF- $\kappa$ B activation. *Mol. Cell. Biol.* **13**: 3301–3310.
113. Sun, S.C., Ganchi, P.A., Ballard, D.W., and Greene, W.C. 1993. NF- $\kappa$ B controls expression of inhibitor I $\kappa$ B $\alpha$ : evidence for an inducible autoregulatory pathway. *Science*. **259**: 1912–1915.
114. Arenzana-Seisdedos, F., Thompson, J., Rodriguez, M.S., Bachelier, F., Thomas, D., and Hay, R.T. 1995. Inducible nuclear expression of newly synthesized I $\kappa$ B $\alpha$  negatively regulates DNA-binding and transcriptional activities of NF- $\kappa$ B. *Mol. Cell. Biol.* **15**: 2689–2696.

115. Arenzana-Seisdedos, F., Turpin, P., Rodriguez, M., Thomas, D., Hay, R.T., Virelizier, J.L., and Dargemont, C. 1997. Nuclear localization of I $\kappa$ B $\alpha$  promotes active transport of NF- $\kappa$ B from the nucleus to the cytoplasm. *J. Cell. Sci.* **110**: 369–378.
116. Polo, S.E., and Almouzni, G. 2004. Histone metabolic pathways and chromatin assembly factors as proliferation markers. *Cancer Letters.* **220**: 1- 9.
117. Fischle, W., Wang, Y., and Allis, C.D. 2003. Binary switches and modification cassettes in histone biology and beyond. *Nature.* **425**: 475-479.
118. Legube, G., and Trouche, D. 2003. Regulating histone acetyltransferases and deacetylases. *EMBO Rep.* **4**: 944-947.
119. Allfrey, V.G., Faulkner, R., and Mirsky, A.E. 1964. Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis. *Proc. Natl. Acad. Sci. U S A.* **51**: 786-794.
120. Roth, S.Y., Jenu, J.M., and Allis, C.D. 2001. Histone acetyltransferases. *Annu. Rev. Biochem.* **70**: 81-120.
121. De Ruijter, A.J., Van Gennip, A.H., Caron, H.N., Kemp, S., and van Kuilenburg, A.B. 2003. Histone deacetylases (HDACs): characterization of the classical HDAC family. *Biochem. J.* **370**: 737-749.
122. Strahl, B.D., and Allis, C.D. 2000. The language of covalent histone modifications. *Nature.* **403**: 41- 45.
123. Wade, P.A. 2001. Transcriptional control at regulatory checkpoints by histone deacetylases: molecular connections between cancer and chromatin. *Hum. Mol. Genet.* **10**: 693–698.
124. Bjerling, P., Silverstein, R.A., Thon, G., Caudy, A., Grewal, S., and Ekwall, K. 2002. Functional divergence between histone deacetylases in fission yeast by distinct cellular localization and in vivo specificity. *Mol. Cell. Biol.* **22**: 2170–2181.
125. Ito, K., Barnes, P.J., and Adcock, I.M. 2000. Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1 $\beta$ -induced histone H4 acetylation on lysines 8 and 12. *Mol. Cell. Biol.* **20**: 6891–6903.
126. Forsberg, E.C., and Bresnick, E.H. 2001. Histone acetylation beyond promoters: long-range acetylation patterns in the chromatin world. *Bioassays.* **23**: 820–830.

127. Chen, C.J., Deng, Z., Kim, A.Y., Blobel, G.A., and Lieberman, P.M. 2001. Stimulation of CREB binding protein nucleosomal histone acetyltransferase activity by a class of transcriptional activators. *Mol. Cell. Biol.* **21**: 476-487.
128. Girdwood, D., Bumpass, D., Vaughan, O.A., Thain, A., Anderson, L.A., Snowden, A.W., Garcia-Wilson, E., Perkins, N.D., and Hay, R.T. 2003. P300 transcriptional repression is mediated by SUMO modification. *Mol. Cell.* **11**: 1043–1054.
129. Nagata, S. 1997. Apoptosis by death factor. *Cell.* **88**: 355-365.
130. Kerr, J.F., Wyllie, A.H., and Currie, A.R. 1972. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. *Br. J. Cancer.* **26**: 239–257.
131. Thornberry, N.A., and Lazebnik, Y. 1998. Caspases: enemies within. *Science.* **281**: 1312–1316.
132. Baker, S., and Reddy, E.P. 1998. Modulation of life and death by the TNF receptor superfamily. *Oncogene.* **17**: 3261–3270.
133. Ashkenazi, A., and Dixit, V.M. 1998. Death receptors: signaling and modulation. *Science.* **281**: 1305-1308.
134. Chaudhary, P.M., Eby, M., Jasmin, A., Bookwalter, A., Murray, J., and Hood, L. 1997. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway. *Immunity.* **7**: 821-830.
135. Yang, X., Khosravi-Far, R., Chang, H.Y., and Baltimore, D. 1997. Daxx, a novel Fas-binding protein that activates JNK and apoptosis. *Cell.* **89**: 1067-1076.
136. Vaux, D.L. 2002. Apoptosis and toxicology-what relevance? *Toxicology.* **181**: 3-7.
137. Gross, A., McDonnell, J.M., and Korsmeyer, S.J. 1999. Bcl-2 family members and the mitochondria in apoptosis. *Genes Dev.* **13**: 1899-1911.
138. Kluck, R.M., Bossy-Wetzell, E., Green, D.R., and Newmeyer, D.D. 1997. The release of cytochrome c from mitochondria: a primary site or bcl-2 regulation of apoptosis. *Science.* **275**: 1132–1136.
139. Vander Heiden, M.G., Chandel, N.S., Williamson, E.K., Schumacher, P.T., and Thompson, C.B. 1997. Bcl-xL regulates the membrane potential and volume homeostasis of mitochondria. *Cell.* **91**: 627–637.

140. Shimizu, S., Narita, M., and Tsujimoto, Y. 1999. Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. *Nature*. **399**: 483-487.
141. Rosse, T., Olivier, R., Monney, L., Rager, M., Conus, S., Fellay, I., Jansen, B., and Borner, C. 1998. Bcl-2 prolongs cell survival after bax-induced release of cytochrome c. *Nature*. **391**: 496-499.
142. Li, P., Nijhawan, D., Budihardjo, I., Srinivasula, S.M., Ahmad, M., Alnemri, E.S., and Wang, X. 1997. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. *Cell*. **91**: 479-489.
143. Ackermann, E.J., Kempner, E.S., and Dennis, E.A. 1994. Ca<sup>2+</sup>-independent cytosolic phospholipase A<sub>2</sub> from macrophage-like P388D<sub>1</sub> cells: isolation and characterization. *J. Biol. Chem.* **269**: 9227-9233.
144. Dole, V.P. 1956. A relation between non-esterified fatty acids in plasma and the metabolism of glucose. *J. Clin. Invest.* **35**: 150-154.
145. Dignam, J.D., Lebovitz, R.M., and Roeder, R.G. 1983. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. *Nucleic Acids Res.* **11**: 1475-1489.
146. Winer, J., Jung, C.K., Shackel, I., and Williams, P.M. 1999. Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. *Anal. Biochem.* **270**: 41-49.
147. Chiocca, S., Kurtev, V., Colombo, R., Boggio, R., Scieurpi, M.T., Brosch, G., Seiser, C., Draetta, G.F., and Cotton, M. 2002. Histone deacetylase 1 inactivation by an adenovirus early gene product. *Curr. Biol.* **12**: 594-598.
148. Hauser, C., Schuettengruber, B., Bartl, S., Lagger, G., Seiser, C. 2002. Activation of the mouse histone deacetylase 1 gene by cooperative histone phosphorylation and acetylation. *Mol. Cell. Biol.* **22**: 7820-7830.
149. Boyd, K.E., and Farnham, P.J. 1999. Coexamination of site-specific transcription factor binding and promoter activity in living cells. *Mol. Cell. Biol.* **19**: 8393-8399.
150. Orlando, V. 2000. Mapping chromosomal proteins *in vivo* by formaldehyde-crosslinked-chromatin immunoprecipitation. *Trends Biochem. Sci.* **25**: 99-104.
151. Ghannoum, M.A. 1998. Extracellular phospholipases as universal virulence factor in pathogenic fungi. *Nippon Ishinkin Gakkai Zasshi.* **39**: 55-59.

152. Napoli, C., de Nigris, F., and Palinski, W. 2001. Multiple role of reactive oxygen species in the arterial wall. *J. Cell Biochem.* **82**: 674-682.
153. Ibata-Ombetta, S., Idziorek, T., Trinel, P.A., Poulain, D., Jouault, T. 2003. *Candida albicans* phospholipomannan promotes survival of phagocytosed yeasts through modulation of bad phosphorylation and macrophage apoptosis. *J. Biol. Chem.* **278**: 13086-13093.
154. Panagio, L.A., Felipe, I., Vidotto, M.C., and Gaziri, L.C. 2002. Early membrane exposure of phosphatidylserine followed by late necrosis in murine macrophages induced by *Candida albicans* from an HIV-infected individual. *J. Med. Microbiol.* **51**: 929-936.
155. Lemaitre, B., Nicolas, E., Michaut, L., Reichhart, J.M., and Hoffmann, J. A. 1996. The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in *Drosophila* adults. *Cell.* **86**: 973-983.
156. Sieling, P.A., and Modlin, R.L. 2002. Toll-like receptors: mammalian "taste receptors" for a smorgasbord of microbial invaders. *Curr. Opin. Microbiol.* **5**: 70-75.
157. Aliprantis, A.O., Yang, R.B., Weiss, D.S., Godowski, P., and Zychlinsky, A. 2000. The apoptotic signaling pathway activated by toll-like receptor2. *EMBO Journal.* **19**: 3325-3336.
158. Fuentes, L., Perez, R., Nieto, M.L., Balsinde, J., and Balboa, M.A. 2003. Bromoenol lactone promotes cell death by a mechanism involving phosphatidate phosphohydrolase-1 rather than calcium-independent phospholipase A<sub>2</sub>. *J. Biol. Chem.* **278**: 44683-44690.
159. Dore, M., Cote, L.C., Mitchell, A., and Sirois, J. 1998. Expression of prostaglandin G/H synthase type 1, but not type 2, in human ovarian adenocarcinomas. *J. Histochem. Cytochem.* **46**: 77-84.
160. Ryu, H.S., Chang, K.H., Yang, H.W., Kim, M.S., Kwon, H.C. and Oh, K.S. 2000. High cyclooxygenase-2 expression in stage IB cervical cancer with lymph node metastasis or parametrial invasion. *Gynecol. Oncol.* **76**: 320-325.
161. Jabbour, H.N., Milne, S.A., Williams, A.R.W., Anderson, R.A., and Boddy, S.C. 2001. Expression of COX-2 and PGE synthase and synthesis of PGE<sub>2</sub> in endometrial adenocarcinoma: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors. *Br. J. Cancer.* **85**: 1023-1031.

162. Schaller, M., Mailhammer, R., and Korting, H.C. 2002. Cytokine expressions induced by *Candida albicans* in a model of cutaneous candidiasis based on reconstructed human epidermis. *J. Med. Microbiol.* **51**: 672-676.
163. Hwang, D., Jang, B.C., Yu, G., and Boudreau, M. 1997. Expression of mitogen-inducible cyclooxygenase induced by lipopolysaccharide: mediation through both mitogen-activated protein kinase and NF- $\kappa$ B signaling pathways in macrophages. *Biochem. Pharmacol.* **54**: 87-96.
164. Inoue, H., Yokoyama, C., Hara, S., Tone, Y., and Tanabe, T. 1995. Transcriptional regulation of human prostaglandin-endoperoxide synthase-2 gene by lipopolysaccharide and phorbol ester in vascular endothelial cells: involvement of both nuclear factor for interleukin-6 expression site and cAMP response element. *J. Biol. Chem.* **270**: 24965-24971.
165. Sheppard, K.A., Rose, D.W., Haque, Z.A., Kurokawa, R., Mcinerney, E., Westin, S., Thanos, D., Rosenfeld, M.G., Glass, C.K., and Collins, T. 1999. Transcriptional activation by NF- $\kappa$ B requires multiple coactivators. *Mol. Cell. Biol.* **19**: 6367-6378.
166. Ashburner, B.P., Westerheide, S.D., and Baldwin A.S.Jr. 2001. The p65 (RelA) subunit of NF- $\kappa$ B interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2. To negatively regulate gene expression. *Mol. Cell. Biol.* **21**: 7065-7077.
167. Colditz, I.G. 1990. Effect of exogenous prostaglandin E<sub>2</sub> and actinomycin D on plasma leakage induced by neutrophil-activating peptide-1/interleukin-8. *Immunol Cell Biol.* **68**: 397-403.
168. Tong, X., Yin, L., Joshi, S., Rosenberg, D.W., and Giardina, C. 2005. Cyclooxygenase-2 regulation in colon cancer cells: Modulation of RNA polymerase II elongation by histone deacetylase inhibitors. *J. Biol. Chem.* **280**: 15503-15509.
169. Anthonsen, M.W., Stengel, D., Hourton, D., Ninio, E., and Johansen, B. 2000. Mildly oxidized LDL induces expression of group IIa secretory phospholipase A<sub>2</sub> in human monocyte-derived macrophages. *Arterioscler. Thromb. Vasc. Biol.* **20**: 1276-1282.
170. Kramer, R.M., Roberts, E.F., Manetta, J., and Putnam, J.E. 1991. The Ca<sup>2+</sup>-sensitive cytosolic phospholipase A<sub>2</sub> is a 100 kDa protein in human monoblast U937 cells. *J. Biol. Chem.* **266**: 5268-5272.

171. Rehfeldt, W., Resch, K., and Goppelt-Struebe, M. 1993. Cytosolic phospholipase A<sub>2</sub> from human monocytic cells: Characterization of substrate specificity and Ca<sup>2+</sup>-dependent membrane association. *Biochem. J.* **293**: 255–261.
172. Ushio-Fukai, M., Alexander, R.W., Akers, M., Griendling, K.K. 1998. P38 Mitogen-activated protein kinase is a critical component of the redox-sensitive signaling pathways activated by angiotensin II: role in vascular smooth muscle cell hypertrophy. *J. Biol. Chem.* **273**: 15022-15029.
173. Lee, J.C., Laydon, J.T., McDonnell, P.C., Gallagher, T.F., Kumar, S., Green, D., McNulty, D., Blumenthal, M.J., Heys, J.R., Landvatter, S.W. 1994. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. *Nature.* **372**: 739-746.
174. Murakami, M., Kambe, T., Shimbara, S., and Kudo, I. 1999. Functional coupling between various phospholipase A<sub>2</sub>s and cyclooxygenases in immediate and delayed prostanoid biosynthetic pathways. *J. Biol. Chem.* **274**: 3103-3115.
175. Hamilton, T.A., Major, J.A., Armstrong, D., and Tebo, J.M. 1998. Oxidized LDL modulates activation of NF-κB in mononuclear phagocyte by altering the degradation of IκBs. *J. Leukocyte Biol.* **64**: 667-674.
176. Xu, J., Yu, S., Sun, A.Y., and Sun, G.Y. 2003. Oxidant-mediated AA release from astrocytes involves cPLA<sub>2</sub> and iPLA<sub>2</sub>. *Free Radic. Biol. Med.* **34**: 1531-1543.
177. Kornfeld, H., Mancino, G., and Colizzi, V. 1999. The role of macrophage cell death in tuberculosis. *Cell Death Differ.* **6**: 71-78.
178. Luder, C.G., Gross, U., and Lopes, M.F. 2001. Intracellular protozoan parasites and apoptosis: diverse strategies to modulate parasite-host interactions. *Trends Parasitol.* **17**: 480-486.
179. Reynolds, J.E., Yang, T., Qian, L., Jenkinson, J.D., Zhou, P., Eastman, A., and Craig, R.W. 1994. Mcl-1, a member of the Bcl-2 family, delays apoptosis induced by c-Myc overexpression in Chinese hamster ovary cells. *Cancer Res.* **54**: 6348-6352.
180. Hsu, S.Y., Kaipia, A., McGee, E., Lomeli, M., and Hsueh, A.J. 1997. Bak is a pro-apoptotic Bcl-2 protein with restricted expression in reproductive tissues and heterodimerizes with selective anti-apoptotic Bcl-2 family members. *Proc. Natl. Acad. Sci USA.* **94**: 12401-12406.
181. Lin, M.T., Lee, R.C., Yang, P.C., Ho, F.M., and Kuo, M.L. 2001. Cyclooxygenase-2 inducing Mcl-1-dependent survival mechanism in human lung adenocarcinoma CL1.0

- cells. Involvement of phosphatidylinositol 3- kinase/Akt pathway. *J. Biol. Chem.* **276**: 48997-49002.
182. Ma, Z., Ramanadham, S., Corbett, J., Bohrer, A., Gross, R., McDaniel, M., and Turk, J. 1996. Interleukin-1 enhances pancreatic islet arachidonic acid 12-lipoxygenase product generation by increasing substrate availability through a nitric oxide-dependent mechanism. *J. Biol. Chem.* **271**: 1029-1042.
183. Ramanadham, S., Song, H., Bao, S., Hsu, F.F., Zhang, S., Ma, Z., Jin, C., and Turk, J. 2004. Islet Complex Lipids. Involvement in the actions of group VIA calcium-independent phospholipase A<sub>2</sub> in  $\beta$ -cells. *Diabetes*. **53**: S179-185.
184. Underhill, D.M., and Ozinsky, A. 2002. Toll-like receptors: key mediators of microbe detection. *Curr. Opin. Immunol.* **14**: 103-110.
185. Takeda K, and Akira, S. 2001. Roles of Toll-like receptors in innate immune responses. *Genes cells*. **6**: 733-742.
186. Jouault, T., Ibata-Ombetta, S., Takeuchi, O., Trinel, P.A., Sacchetti, P., Lefebvre, P., Akira, S., and Poulain, D. 2003. *Candida albicans* phospholipomannan is sensed through toll-like receptors. *J. Infect. Dis.* **188**: 165-172.
187. Wang T., Lafuse, W.P. and Zwilling, B.S. 2001. NF- $\kappa$ B and Sp1 elements are necessary for the maximal transcription of Toll-like receptor 2 induced by *Mycobacterium avium*. *J. Immunol.* **167**: 6924-6932.

**GANCHIMEG ISHDORJ**

My curriculum vitae is not published for privacy reasons in the electronic version of my thesis.

## 8. LIST OF PUBLICATIONS

- Nigam, S., Patabhraman, S., Ciccoli, R., Ishdorj, G., Schwarz, K., Petrucev, B., Kuhn, H., and Haeggstrom, J.Z. 2004. The rat leukocyte-type 12-lipoxygenase exhibits an intrinsic hepxilin A3 synthase activity. *J. Biol. Chem.* 279: 29023-29030.
- Ishdorj, G., Deva, R., Singh, S., Ciccoli, R., and Nigam, S. Calcium-independent PLA<sub>2</sub> as key regulator of toll-like receptor 2-mediated apoptosis in *C. albicans*-infected HeLa cells. Submitted.
- Ciccoli, R., Sahi, S., Singh, S., Prakash, H., Zafiriou, M.P., Ishdorj, G., Kock, J.L., and Nigam, S. 2005. Oxygenation by cyclooxygenase-2 (COX-2) of 3-Hydroxyeicosa-tetraenoic acid (3-HETE), a fungal mimetic of arachidonic acid, produces a cascade of novel bioactive 3-hydroxy-eicosanoids. *Biochem. J.* 390: 737-747. .
- Ishdorj, G., Singh, S., Deva, R., and Nigam, S. Transcriptional activation of TLR2 gene expression by *C.albicans* in HeLa cells is regulated by the interaction of p65 subunit of NF-κB and Histone Deacetylase. MS in preparation.
- Ishdorj, G., Urtnasan, D., and Badgaa, D. 1999. Breast milk fatty acid composition: a comparative study between breast milk and white goat milk. *Scientific Report Chemistry and Chemical Technology Institute.* 10: 72-75.

## POSTER PRESENTATION:

- Ishdorj, G., Rybak, A.M., Ciccoli, R., Köhler, G., Agabian, N., and Nigam, S. Activation of COX-2 gene in vulvovaginal candidosis is triggered by *Candida* PLA<sub>2</sub>: specific role of 14-3-3 protein. 2nd International Conference on Phospholipases A<sub>2</sub> and 8<sup>th</sup> International

Congress on Platelet-Activating Factor and Related Lipid Mediators. Berlin, Germany. 6-9 October, 2004. Abstract No: P-30.

- Nigam, S., Ishdorj, G., Deva, R., Rüter, H., Ciccoli, R., Agabian, N. Role of candidal PLA<sub>2</sub> on the activation of TLR2 and COX-2 genes in HeLa cells infected with *C.albicans*. 2nd International Conference on Phospholipases A<sub>2</sub> and 8<sup>th</sup> International Congress on Platelet-Activating Factor and Related Lipid Mediators. Berlin, Germany. 6-9 October, 2004. Abstract No: L-28.
- Theiss, S., Ishdorj, G., Ketschmar, M., Nichterlein, T., Murillo, L.A., and Nigam, S., Agabian, N., and Köhler, G.A. Ablation of PLB5 gene in *Candida albicans* reduces cell-associated phospholipase A<sub>2</sub> activity and attenuates pathogenicity. 2nd International Conference on Phospholipases A<sub>2</sub> and 8<sup>th</sup> International Congress on Platelet-Activating Factor and Related Lipid Mediators. Berlin, Germany. 6-9 October, 2004. Abstract No: P-08.
- Nigam, S., Deva, R., Ishdorj, G., Ciccoli, R., Singh, S., Zafiriou, M.P., Lui, S., Baran, A., Dewitz, J., Sahi, S., Kothekar, V., Ivanov, I., Groza, N., Venter, P., Bareetseng, A., Kock, L., Van der Merwe, R.R., Stapelton, E.H., and Agabian, N. 3-hydroxyoxylipins, novel fungal fatty acid metabolites, in the analysis of candidiasis: host-pathogen-interactions. 9<sup>th</sup> International Conference on Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Related Diseases. San Francisco, California, USA. 11-14 September, 2005. Abstract No: L-82.
- Ciccoli, R., Sahi, S., Singh, S., Deva, R., Zafiriou, M.P., Ishdorj, G., Kock, L., and Nigam, S. 3-hydroxyeicosanoids: novel bioactive compounds obtained from the interaction of 3-HETE, a fungal mimetic of AA, with COX-2. 9<sup>th</sup> International Conference on Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Related Diseases. San Francisco, California, USA. 11-14 September, 2005. Abstract No: P-149.